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Brought into the limelight many decades ago, Polycystic Ovary Syndrome (PCOS) 
is still, to date, surrounded by controversy and mystery. Much attention has been 
attracted to various topics associated with PCOS research and there has been a healthy 
advance towards bettering the understanding of the many implications of this complex 
syndrome. A variety of topics have been dealt with by a panel of authors and compiled 
in this book. They span methods of diagnosis, reproductive anomalies, metabolic 
consequences, psychological mindset and ameliorative effects of various lifestyle 
and medical management options. These books are designed to update all associated 
professionals on the recent developments in this fast-growing field and to encourage 
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“The beginning of knowledge is the discovery of something we do not understand.” 
Frank Herbert (1920-1986) 
Polycystic Ovary Syndrome (PCOS) is a common heterogenous disorder in women of 
reproductive age. It is a leading cause of anovulatory infertility all over the world. 
Having an early onset during pre-pubertal years, it has been associated with many 
reproductive complications. Over the years there has been a paradigm shift in thought; 
it is no longer just a gynecological concern but has a strong metabolic component too. 
Women with PCOS have a markedly increased risk of developing central obesity, 
Type 2 Diabetes and cardiovascular diseases. Research in this field has been 
progressing at an incredible rate, however even with staggering data available, 
researchers have not been able to fully understand this endocrine enigma. Questions 
regarding its pathophysiology and its possible long-term reproductive and metabolic 
outcomes are being tackled by rigorous research, but no definite conclusions have 
been reached yet. The focus in this book is drawn towards understanding the clinical 
and metabolic manifestations, as well as the impact that they have on the psychosocial 
well-being in women with PCOS. Some therapeutic options such as the use of insulin 
sensitizing agents and ovulation inducers to improve fertility, as well as impact of 
lifestyle and dietary modifications to reduce obesity and its associated consequences, 
have been highlighted in this text. Analysis of this ongoing research has incited the 
search for alternative and improved treatments to alleviate these health concerns with 
great zeal. This book aims to offer fellow researchers a comprehensive overview of the 
current knowledge of the developments in this expanding field. 
 
Srabani Mukherjee 
Department of Molecular Endocrinology, 




Management of Women with Clomifene Citrate 
Resistant Polycystic Ovary Syndrome –  
An Evidence Based Approach  
Hatem Abu Hashim 
Department of Obstetrics & Gynecology,  
 Faculty of Medicine, Mansoura University, Mansoura,  
Egypt 
1. Introduction 
World Health Organisation (WHO) type II anovulation is defined as normogonadotrophic 
normoestrogenic anovulation and occurs in approximately 85% of anovulatory patients. 
Polycystic ovary syndrome (PCOS) is the most common form of WHO type II anovulatory 
infertility and is associated with hyperandrogenemia (1,2). Moreover, PCOS is the most 
common endocrine abnormality in reproductive age women. The prevalence of PCOS is 
traditionally estimated at 4% to 8% from studies performed in Greece, Spain and the USA 
(3-6). The prevalence of PCOS has increased with the use of different diagnostic criteria and 
has recently been shown to be 11.9 ± 2.4% -17.8 ± 2.8 in the first community-based 
prevalence study based on the current Rotterdam diagnostic criteria compared with 10.2 ± 
2.2% -12.0 ± 2.4% and 8.7 ± 2.0% using National Institutes of Health criteria and Androgen 
Excess Society recommendations respectively (7). Importantly, 70% of women in this recent 
study were undiagnosed (7).  
Clomiphene citrate (CC) is still holding its place as the first-line therapy for ovulation 
induction in these patients (2,8,9). CC contains an unequal mixture of two isomers as their 
citrate salts, enclomiphene and zuclomiphene. Zuclomiphene is much the more potent of the 
two for induction of ovulation, accounts for 38% of the total drug content of one tablet and 
has a much longer half-life than enclomiphene, being detectable in plasma 1 month 
following its administration (10). CC is capable of inducing a discharge of FSH from the 
anterior pituitary and this is often enough to reset the cycle of events leading to ovulation 
into motion. This is achieved indirectly, through the action of CC, a non-steroidal compound 
closely resembling an estrogen, in blocking hypothalamic estrogen receptors, signalling a 
lack of circulating estrogen to the hypothalamus and inducing a change in the pattern of 
pulsatile release of GnRH(10). Standard practice is to administer CC for 5 days from the 
second or third day of the menstrual cycle, starting with 50mg/day and increasing to 
250mg/day (10). However managed care studies have shown that the most effective dosage 
is 100–150mg/day and over 75% of ovulations occur within these dosages (11). After six to 
nine cycles of treatment with CC cumulative pregnancy rates reach 70–75% (11). Life table 
analysis of the most reliable studies indicated a conception rate up to 22% per cycle in 
women ovulating on CC (8). In a large randomized trial, Legro et al., 2007 (12) compared the 
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effects of CC, metformin and combination therapy in 626 infertile women with PCOS. They 
reported an ovulation and clinical pregnancy rates per woman of 75.1% and 23.9% 
respectively, after CC treatment up to 150mg/day. 
Clomiphene resistance defined as failure to ovulate after receiving 150 mg of CC daily for 5 
days per cycle, for at least three cycles, is common and occurs in approximately 15 to 40% in 
women with PCOS (2, 13). Insulin resistance, hyperandrogenemia, and obesity represent the 
major factors involved in CC resistance; avert the ovaries from responding to raised 
endogenous FSH levels following CC therapy (14-16). Moreover, a genetic predisposition 
was suggested (17). 
The purpose of this chapter is to review the evidence based treatment strategies for 
ovulation induction in anovulatory PCOS patients with known CC resistance, both the 
traditional and new ones. The traditional options include gonadotrophins and surgery 
(laparoscopic ovarian drilling). New strategies as insulin-sensitizing drugs, aromatase 
Inhibitors, oral contraceptives, dexamethasone, N-acetyl-cysteine…etc. Moreover, 
optimizing the body mass index (BMI) firstly before commencing therapy is an important 
issue to improve the treatment outcome in obese anovulatory women with PCOS. In vitro 
fertilization (IVF) is the recommended line of treatment after failure of these strategies; 
however, it is outside the scope of this chapter. Finally an algorithm will be provided to 
facilitate management of this important clinical issue. 
2. Weight loss and lifestyle modifications 
Obesity is strongly associated with PCOS and may be present in up to 50% of cases (18-22). 
Obese women with PCOS are more likely than thin women with PCOS to suffer from 
anovulation (18). This effect on ovulation may be secondary to insulin resistance, which in 
turn results in hyperinsulinemia and stimulation of excess androgen production from the 
ovaries (22). Lifestyle modification is the first line treatment in an evidence based approach 
for the management of the majority of PCOS women who are overweight (8,9,13, 23-25). The 
NICE, 2004 (13) recommended weight loss for anovulatory PCOS women who have a BMI > 
29 kg/m2 before starting ovulation induction therapy. In these women, weight loss of even 
5% to 10% of body weight often restores ovulatory cycles (9, 19, 21). Studies also showed 
that overweight women are less likely to respond to pharmacologic ovulation induction 
methods. In a cohort of 270 women, with PCOS who received either CC or gonadotrophins 
for ovulation induction, almost 80% with a BMI of 18–24 kg/m2 ovulated at 6 months 
compared with only 12% of women with a BMI≥35 kg/m2 (18). Moreover, overweight 
women require higher doses of CC and gonadotrophins (19). 
The current recommendation is to reduce weight gradually to increase the chances of 
maintaining the weight loss (9). Preferential diet composition has been evaluated in 2 small 
studies (26, 27). These studies compared a high carbohydrate (55%), low protein (15%) 
hypocaloric diet with a low carbohydrate (40%), high protein (30%) hypocaloric diet and 
found similar weight loss and decrease in circulating androgen and insulin levels. Routine 
exercise is also very important in the reproductive health of PCOS women. Exercise 
increases insulin sensitivity and helps achieve and maintain weight loss (9, 25). 
Incorporating simple moderate physical activity including structured exercise (at least 30 
min/ day) and incidental exercise increases weight loss and improves clinical outcomes in 
PCOS, compared to diet alone (28). Also, a recent study reported that a 6-week intervention 
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of structured exercise training and a hypocaloric diet was effective in increasing the 
probability of ovulation under CC treatment in overweight and obese CC-resistant PCOS 
patients (29). Other lifestyle factors such as excessive caffeine intake, alcohol consumption, 
and smoking should also be addressed (13,20). 
Otta et al., 2010 (30) in a randomized, double-blind, and placebo control trial compared 
lifestyle modification and 1500 mg of metformin or placebo for 4 months in 30 women with 
insulin resistance PCOS. They reported that metformin has an additive effect to diet and 
exercise to improve parameters of hyperandrogenism and insulin resistance. However, a 
small decrease in body weight through lifestyle changes could be enough to improve 
menstrual cycles in these women. Karimzadeh & Javedani, 2010 (31)in another randomized 
double-blind study compared lifestyle modification with medical treatment plans such as 
CC, metformin, and CC with metformin in 343 overweight infertile women with PCOS. 
They showed that metformin or metformin with CC does not cause a significant weight loss 
or an improvement in the endocrine status of PCOS women. However, lifestyle modification 
to reduce waist circumference and body weight could improve their menstrual cycles, 
hormonal status and was an effective treatment for ovulation induction in those patients 
with an ovulation and pregnancy rates of 66.6% and 20% respectively. 
In morbidly obese women, the PCOS phenotype appears to be very frequent (32). 
Importantly, this disorder has been found to improve markedly after sustained weight loss 
following bariatric surgery (33). Anti-obesity pharmacological agents have been used in 
obese women with PCOS. Both orlistat, which blocks intestinal absorption of fat (34), and 
sibutramine, an appetite suppressant (35), have displayed a weight loss-independent effect 
on androgens and insulin resistance. It should be noted that these treatments should not be 
considered as first-line therapy for obesity in women with PCOS (8). 
3. Gonadotrophins 
Ovulation induction for women with anovulatory PCOS using gonadotrophin therapy is 
based on the physiological concept that initiation and maintenance of follicle growth may be 
achieved by a transient increase in FSH above a threshold dose for sufficient duration to 
generate a limited number of developing follicles (8). Traditionally, Ovulation induction 
with gonadotrophins has been used as a second line treatment for CC-resistant PCOS 
women, however it is expensive, requires extensive monitoring and associated with 
significantly increased risk for ovarian hyperstimulation syndrome (OHSS) and multiple 
pregnancy (8, 9, 13, 36-38). Furthermore, a significant and consistent relationship between 
PCOS and OHSS was reported in a systematic review (39). The high sensitivity of the PCOS 
to gonadotrophic stimulation is probably related to the fact that they contain twice the 
number of available follicle-stimulating hormone (FSH)-sensitive antral follicles in their 
cohort than the normal ovary (40). A meta-analysis concluded that the outcomes of 
treatment achieved with hMG and with FSH alone in infertile patients with PCOS were 
similar except for a reduction in the risk of OHSS with the urinary FSH (uFSH) (41). A low-
dose, step-up gonadotrophin therapy should be preferred to the now outdated conventional 
protocol for patients with PCOS and the strong justification seems to be; the achievement of 
high rate of mono-follicular development which is ~69% (54–88%) (36,42) with nearly 
complete elimination of OHSS (0–2.4%) and a multiple pregnancy rate of ~6% (36,43). The 
recommended approach is to begin with a low dose of gonadotrophin, typically 37.5– 75 
 
Polycystic Ovary Syndrome 
 
2 
effects of CC, metformin and combination therapy in 626 infertile women with PCOS. They 
reported an ovulation and clinical pregnancy rates per woman of 75.1% and 23.9% 
respectively, after CC treatment up to 150mg/day. 
Clomiphene resistance defined as failure to ovulate after receiving 150 mg of CC daily for 5 
days per cycle, for at least three cycles, is common and occurs in approximately 15 to 40% in 
women with PCOS (2, 13). Insulin resistance, hyperandrogenemia, and obesity represent the 
major factors involved in CC resistance; avert the ovaries from responding to raised 
endogenous FSH levels following CC therapy (14-16). Moreover, a genetic predisposition 
was suggested (17). 
The purpose of this chapter is to review the evidence based treatment strategies for 
ovulation induction in anovulatory PCOS patients with known CC resistance, both the 
traditional and new ones. The traditional options include gonadotrophins and surgery 
(laparoscopic ovarian drilling). New strategies as insulin-sensitizing drugs, aromatase 
Inhibitors, oral contraceptives, dexamethasone, N-acetyl-cysteine…etc. Moreover, 
optimizing the body mass index (BMI) firstly before commencing therapy is an important 
issue to improve the treatment outcome in obese anovulatory women with PCOS. In vitro 
fertilization (IVF) is the recommended line of treatment after failure of these strategies; 
however, it is outside the scope of this chapter. Finally an algorithm will be provided to 
facilitate management of this important clinical issue. 
2. Weight loss and lifestyle modifications 
Obesity is strongly associated with PCOS and may be present in up to 50% of cases (18-22). 
Obese women with PCOS are more likely than thin women with PCOS to suffer from 
anovulation (18). This effect on ovulation may be secondary to insulin resistance, which in 
turn results in hyperinsulinemia and stimulation of excess androgen production from the 
ovaries (22). Lifestyle modification is the first line treatment in an evidence based approach 
for the management of the majority of PCOS women who are overweight (8,9,13, 23-25). The 
NICE, 2004 (13) recommended weight loss for anovulatory PCOS women who have a BMI > 
29 kg/m2 before starting ovulation induction therapy. In these women, weight loss of even 
5% to 10% of body weight often restores ovulatory cycles (9, 19, 21). Studies also showed 
that overweight women are less likely to respond to pharmacologic ovulation induction 
methods. In a cohort of 270 women, with PCOS who received either CC or gonadotrophins 
for ovulation induction, almost 80% with a BMI of 18–24 kg/m2 ovulated at 6 months 
compared with only 12% of women with a BMI≥35 kg/m2 (18). Moreover, overweight 
women require higher doses of CC and gonadotrophins (19). 
The current recommendation is to reduce weight gradually to increase the chances of 
maintaining the weight loss (9). Preferential diet composition has been evaluated in 2 small 
studies (26, 27). These studies compared a high carbohydrate (55%), low protein (15%) 
hypocaloric diet with a low carbohydrate (40%), high protein (30%) hypocaloric diet and 
found similar weight loss and decrease in circulating androgen and insulin levels. Routine 
exercise is also very important in the reproductive health of PCOS women. Exercise 
increases insulin sensitivity and helps achieve and maintain weight loss (9, 25). 
Incorporating simple moderate physical activity including structured exercise (at least 30 
min/ day) and incidental exercise increases weight loss and improves clinical outcomes in 
PCOS, compared to diet alone (28). Also, a recent study reported that a 6-week intervention 
Management of Women with Clomifene Citrate  
Resistant Polycystic Ovary Syndrome – An Evidence Based Approach 
 
3 
of structured exercise training and a hypocaloric diet was effective in increasing the 
probability of ovulation under CC treatment in overweight and obese CC-resistant PCOS 
patients (29). Other lifestyle factors such as excessive caffeine intake, alcohol consumption, 
and smoking should also be addressed (13,20). 
Otta et al., 2010 (30) in a randomized, double-blind, and placebo control trial compared 
lifestyle modification and 1500 mg of metformin or placebo for 4 months in 30 women with 
insulin resistance PCOS. They reported that metformin has an additive effect to diet and 
exercise to improve parameters of hyperandrogenism and insulin resistance. However, a 
small decrease in body weight through lifestyle changes could be enough to improve 
menstrual cycles in these women. Karimzadeh & Javedani, 2010 (31)in another randomized 
double-blind study compared lifestyle modification with medical treatment plans such as 
CC, metformin, and CC with metformin in 343 overweight infertile women with PCOS. 
They showed that metformin or metformin with CC does not cause a significant weight loss 
or an improvement in the endocrine status of PCOS women. However, lifestyle modification 
to reduce waist circumference and body weight could improve their menstrual cycles, 
hormonal status and was an effective treatment for ovulation induction in those patients 
with an ovulation and pregnancy rates of 66.6% and 20% respectively. 
In morbidly obese women, the PCOS phenotype appears to be very frequent (32). 
Importantly, this disorder has been found to improve markedly after sustained weight loss 
following bariatric surgery (33). Anti-obesity pharmacological agents have been used in 
obese women with PCOS. Both orlistat, which blocks intestinal absorption of fat (34), and 
sibutramine, an appetite suppressant (35), have displayed a weight loss-independent effect 
on androgens and insulin resistance. It should be noted that these treatments should not be 
considered as first-line therapy for obesity in women with PCOS (8). 
3. Gonadotrophins 
Ovulation induction for women with anovulatory PCOS using gonadotrophin therapy is 
based on the physiological concept that initiation and maintenance of follicle growth may be 
achieved by a transient increase in FSH above a threshold dose for sufficient duration to 
generate a limited number of developing follicles (8). Traditionally, Ovulation induction 
with gonadotrophins has been used as a second line treatment for CC-resistant PCOS 
women, however it is expensive, requires extensive monitoring and associated with 
significantly increased risk for ovarian hyperstimulation syndrome (OHSS) and multiple 
pregnancy (8, 9, 13, 36-38). Furthermore, a significant and consistent relationship between 
PCOS and OHSS was reported in a systematic review (39). The high sensitivity of the PCOS 
to gonadotrophic stimulation is probably related to the fact that they contain twice the 
number of available follicle-stimulating hormone (FSH)-sensitive antral follicles in their 
cohort than the normal ovary (40). A meta-analysis concluded that the outcomes of 
treatment achieved with hMG and with FSH alone in infertile patients with PCOS were 
similar except for a reduction in the risk of OHSS with the urinary FSH (uFSH) (41). A low-
dose, step-up gonadotrophin therapy should be preferred to the now outdated conventional 
protocol for patients with PCOS and the strong justification seems to be; the achievement of 
high rate of mono-follicular development which is ~69% (54–88%) (36,42) with nearly 
complete elimination of OHSS (0–2.4%) and a multiple pregnancy rate of ~6% (36,43). The 
recommended approach is to begin with a low dose of gonadotrophin, typically 37.5– 75 
 
Polycystic Ovary Syndrome 
 
4 
IU/day, increasing after 7 days or more if no follicle >10 mm has yet emerged, in small 
increments, at intervals, until evidence of progressive follicular development is observed. 
The maximum required daily dose of FSH/hMG seldom exceeds 225 IU/day (38, 44). There 
is no evidence of a difference between recombinant FSH (rFSH) and uFSH for ovulation 
induction in CC- resistant PCOS women (45,46). In addition, a randomised trial (RCT) of 
highly purified uFSH (HP-uFSH) versus rFSH found that the former was non-inferior 
compared with the latter with respect to ovulation rate (85.2% versus 90.9%) in anovulatory 
WHO Group II women who failed to ovulate or conceive on CC (47) . 
4. Laparoscopic Ovarian Diathermy (LOD) 
Laparoscopic ovarian diathermy (LOD) is currently accepted as a successful second line 
treatment for ovulation induction in CC-resistant PCOS being as effective as gonadotrophin 
treatment and is not associated with an increased risk of multiple pregnancy or OHSS (8, 
9,13, 48-51). Bayram et al., 2004 (50) in a RCT compared LOD with rFSH in 168 CC-resistant 
PCOS women. They reported an ovulation rate of 70% and 69% per cycle and pregnancy 
and live-birth rates 37%, 75% and 34%, 60% of patients respectively following LOD and FSH 
therapy. In patients remaining anovulatory 8 weeks after LOD or those who subsequently 
became anovulatory, adjuvant therapy with CC or gonadotrophins was required to achieve 
equivalent pregnancy and live-birth rates (50). A Cochrane review found no difference in 
the rates of miscarriage, ongoing pregnancy or live birth between LOD and gonadotrophins. 
Multiple pregnancy rates were significantly lower with LOD than with gonadotrophins (1% 
versus 16%; OR 0.13, 95% CI 0.03 to 0.52) (49). A recent study concluded that LOD for 
women with CC-resistant PCOS is as effective as ovulation induction with rFSH treatment 
in terms of live births, but reduces the need for ovulation induction or ART in a significantly 
higher proportion of women and increases the chance for a second child (52). 
The main shortcomings of LOD are the need for general anesthesia and the risk of 
postoperative adhesions (53, 54). The claim that it might affect the ovarian reserve is not 
more than a theoretical concern since a recent report concluded that LOD, when applied 
properly, does not seem to compromise the ovarian reserve in PCOS women (55). Moreover, 
an economic evaluation has shown that the cost of a live birth after LOD is approximately 
one-third lower than the equivalent cost of gonadotrophin treatment (56). The most 
commonly used energy for LOD is electrocautery. It has been reported that the clinical and 
endocrine response to LOD is governed by a dose response relationship. Four punctures per 
ovary using a power setting of 30 W applied for 5s per puncture (i.e. 600 J per ovary) are 
sufficient to produce an optimal response (67% spontaneous ovulation rate and 67% 
conception rate). Reducing the thermal energy below that level reduces the chances of 
spontaneous ovulation and conception (57). Also, different studies argued for unilateral 
LOD being equally efficacious as bilateral drilling in inducing ovulation and achieving 
pregnancy in CC resistant PCOS patients and may be regarded as a suitable option with the 
potential advantage of decreasing the chances of adhesion formation (58-60). 
Although it remains unclear as to how LOD induces ovulation, a potential mechanism is 
that LOD drains the ovarian follicles containing a high concentration of androgens and 
inhibin, which causes the reduction of blood androgens and blood inhibin resulting in an 
increase of FSH and recovery of the ovulation function (51,53, 61,62). Surgery may also 
provoke an increased blood flow to the ovary, allowing increased delivery of 
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gonadotrophins (53, 62). Women with marked obesity (BMI >35 kg/m2), marked 
hyperandrogenism (serum testosterone concentration >4.5 nmol/l, free androgen index 
(FAI) >15) and/or long duration of infertility (>3 years) seem to be poor responders to LOD. 
On the other hand, high LH levels >10 IU/l in LOD responders appear to predict higher 
probability of pregnancy (63). van Wely et al., 2005 (64) reported that women who had an 
age at menarche < 13years, an LH/FSH ratio < 2 and a glucose level < 4.5 mmol/l, were 
more likely to remain anovulatory following LOD. 
Restoration of consecutive spontaneous ovulations after LOD in some CC-resistant PCOS 
patients is one of the most important advantages of this approach (65). Another potential 
advantage is the increased responsiveness of the ovary to oral ovulation induction agents 
following the procedure. In a recent study, we evaluated whether LOD in CC-resistant 
PCOS patients led to the restoration of CC-sensitivity. LOD was performed in 234 CC-
resistant PCOS patients. In 150 patients ovulation occurred. The remaining 84 aonvulatory 
patients were again treated with CC. Ovulation occurred in 30 /84 patients (35.7%), 
meanwhile, pregnancy occurred in 13/ 84 patients (15.5%). Hyperandrogenism and insulin 
resistance were negative predictors (66). 
5. Insulin-sensitizing drugs 
Approximately 50%-70% of all women with PCOS have some degree of insulin resistance 
(67). Hyperinsulinemia probably contributes to the hyperandrogenism which is responsible 
for the signs and symptoms of PCOS (67). Metformin, a biguanide, is now the most widely 
insulin sensitizer used for ovulation induction in women with PCOS. In these women, it 
appears to affect ovarian function in a dual mode, through the alleviation of insulin excess 
acting upon the ovary and through direct ovarian effects. Being an insulin sensitizer, it 
reduces insulin secretion and, consequently, lowers circulating total and free androgen 
levels with a resulting improvement of the clinical sequelae of hyperandrogenism. 
Importantly, it also seems to have a direct action on ovarian theca cells to decrease androgen 
production (68). A recent meta-analysis of RCTs showd no significant difference in 
effectiveness of metformin versus CC as a first-line treatment for ovulation induction in 
non-obese women with anovulatory PCOS (69). Also a recent Cochrane review reported that 
metformin is still of benefit in improving clinical pregnancy and ovulation rates. However, 
there is no evidence that it improves live birth rates whether it is used alone or in 
combination with CC, or when compared with CC. Therefore, the use of metformin as a 
first-line treatment in improving reproductive outcomes in women with PCOS appears to be 
limited (70). 
Many investigators have demonstrated an improvement in insulin sensitivity and a 
significant decrease in serum insulin and free testosterone levels after long term treatment 
with metformin for 5–8 weeks (71-73). Creanga et al., 2008 (74) in a meta-analysis, confirmed 
that metformin in combination with CC increased the likelihood of ovulation [OR 4.39, 95% 
CI 1.94–9.96, number - needed- to-treat (NNT) 3.7] and pregnancy (OR 2.67, 95% CI 1.45–
4.94, NNT 4.6) in comparison with CC alone, especially in CC-resistant and obese PCOS 
patients. Actually, different mechanisms explaining why metformin therapy would facilitate 
ovulation induction by CC in CC- resistant PCOS patients have been proposed entailing; an 
intrinsic alteration of follicle steroidogenesis through the IGF-I pathway in granulosa cells 
(73); direct inhibition of androgen production in ovarian thecal cells (75); reduction in the 
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adrenal steroidogenesis response to ACTH (76) and recently its central action on the 
pituitary gland with an LH lowering and prolactin effects in the PCOS women (77). There 
are unpleasant gastrointestinal side effects including nausea, vomiting, bloating, cramps and 
diarrhoea. Rare complication includes lactic acidosis. Metformin has been used in increasing 
doses from 500 to 1500 mg daily for the induction of ovulation in women with PCOS (9).  
Recently, the efficacy of the combination of metformin and CC versus other traditional 
options including gonadotrophins and LOD for treatment of CC-resistant infertile PCOS 
patients has been reported. Two RCTs compared the combination of metformin and CC 
with LOD, showing that both are effective approaches to treat CC- resistant infertile PCOS 
patients (78, 79). In fifty primary infertile patients with CC- resistant PCOS, Palombo et al., 
2010 (78) found no significant difference between the 2 groups in pregnancy and live-birth 
rates per cycle (13.1% vs.16.3% and 11.2% vs. 14.1% respectively). However, the ovulation 
rate per cycle was significantly lower in LOD group than in Metformin/CC group (56.5% vs. 
72.0%). On the other hand, in a well designed adequately powered RCT comprised of 282 
anovulatory women with CC-resistant PCOS, we reported no significant difference between 
the 2 groups in ovulation and pregnancy rates per cycle (67% vs. 68.2% and 15.4% vs. 17% 
respectively). However, a significant difference regarding midcycle endometrial thickness 
was found (9.2 ± 1.2 mm vs. 7.6 ± 1.1 mm, in Metformin/CC and LOD groups respectively) 
(79). George et al., 2003 (80) in a small trial of limited power compared sequential treatment 
of metformin and CC with conventional hMG protocol in 60 CC-resistant PCOS patients. In 
this trial, metformin alone was given as a single pretreatment for 6 months, followed by 
ovulation induction with CC. There was no significant difference in pregnancy rates 
between the two groups (16.7 vs. 23.3%). However, in the metformin group, significant 
improvements in menstrual function and ovulation rate of 46.7% with a significant decrease 
in fasting insulin levels were reported. The ovulation rate in hMG group was 43.3%, with a 
high drop-out rate. Recently, in a well designed adequately powered RCT we compared the 
effects of combined metformin–CC with HP-uFSH using low-dose, step-up regimen for 
three cycles in 153 anovulatory women with CC-resistant PCOS (81). Actually, combined 
metformin-CC therapy was not expected to be more effective than gonadotrophins, 
however, it did result in modest ovulation and pregnancy rates. Ovulation and pregnancy 
rates per cycle were 62% vs. 83.8% and 11.2% vs. 21.5% in combined metformin- CC group 
and HP-uFSH groups respectively. HP-uFSH administration had good results, but, the low-
dose, step-up regimen requires extensive monitoring and expertise, and has high costs. 
Accordingly, it is logical to offer combined metformin- CC therapy first in the step-wise 
treatment protocol for CC-resistant PCOS patients before resorting to more expensive 
alternatives especially in developing communities where economic aspects of therapy are 
important (81). 
The safety of metformin has sparked a heated debate. Recent evidence that metformin is 
probably safe during the first trimester of pregnancy and beyond is accumulating (82-85). 
Moreover, a recent meta-analysis found no effect of pregestational metformin 
administration on abortion risk in PCOS patients (86). Other insulin sensitizers from the 
thiazolidenediones family, namely rosiglitazone, have been used effectively in CC-resistant 
PCOS patients. In a RCT, the combination of rosiglitazone and CC was reported to be more 
effective than metformin and CC in terms of ovulation rate (64.3 vs. 36.4%, respectively); 
whereas no statistical significance was observed in pregnancy rate (50 vs. 38.5%) (87). Also, 
a recent RCT reported no significant difference between combined treatment with 
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rosiglitazone and CC vs. LOD in 43 CC-resistant PCOS patients in terms of biochemical 
response, ovulation rate (80.8 vs. 81.5%) and pregnancy rate (50 vs. 42.8%) (88). A 
retrospective analysis investigated various clinical, biochemical, and ultrasonographic 
factors that determine clinical response to rosiglitazone as a first-line therapy in a series of 
PCOS women with newly diagnosed CC-resistance. It showed that marked obesity, marked 
hyperandrogenism, and long duration of infertility were predictors of resistance to 
rosiglitazone therapy (89). 
6. Third-generation aromatase inhibitors 
Third-generation aromatase inhibitors (anastrozole, letrozole, exemestane) are approved 
adjuvants for treatment of estrogen-receptor–positive breast cancer (90) that were first used 
in ovulation induction in anovulatory women in 2001 (91). Evidence suggests that 
nonsteroidal aromatase inhibitors (AIs), specifically letrozole and anastrozole, have 
ovulation-inducing effects by inhibiting androgen-to-estrogen conversion. Centrally, this 
effect releases the hypothalamic/pituitary axis from estrogenic negative feedback, increases 
gonadotrophin secretion, and results in stimulation of ovarian follicle maturity. Moreover, 
peripherally, AIs may increase follicular sensitivity to FSH (92). AIs have relatively short 
half-lives (~2 days) compared with CC (~2 weeks) so estrogen target tissues (e.g., 
endometrium and cervix ) are spared adverse effects. Because of these mechanisms, it was 
postulated that AIs may have superior ovulation induction properties in terms of follicular 
growth and endometrium development, which is important for embryo implantation (92). 
Recent studies showed that letrozole has better ovulation and pregnancy rates in 
comparison to CC and placebo in patients with CC- resistant PCOS (93-96). There are 2 
prospective studies in the literature comparing the two commercially available third 
generation AIs, letrozole and anastrozole in CC-resistant infertile women with PCOS. Al-
Omari et al., 2004 (97) studied 40 cases who were considered CC- resistant if failed ovulation 
after 200 mg CC daily for 5 days or were ovulatory with an endometrium thickness less than 
5 mm. Ovulation and pregnancy rates per cycle were significantly higher with letrozole 
compared with anastrozole (84.4% vs. 60% and 18.8% vs. 9.7%, respectively). Endometrium 
thickness was significantly greater for letrozole compared with anastrozole (8.16 ± 1.32 vs. 
6.53 ± 1.55 mm). Multiple pregnancies did not occur. In this small trial, PCOS diagnostic 
criteria were not stated. Additionally, the dose of CC used to define resistance was very 
high, possibly suggesting an extremely refractory population. Importantly, a larger RCT 
compared the efficacy of letrozole and anastrozole in 220 CC–resistant women with PCOS 
diagnosed with Rotterdam criteria. More growing and mature follicles and greater 
endometrial thickness in patients receiving anastrozole were demonstrated; however, no 
significant advantage for anastrozole over letrozole with regard to ovulation, pregnancy or 
miscarriage rates was observed (63.4 vs.62% and 15.1vs. 12.2% and 9.5vs. 11.1% 
respectively). Two twin pregnancies occurred with letrozole, while none occurred with 
anastrozole (98). In the above mentioned 2 studies, a short course (5 days) of letrozole was 
used. However, a long letrozole protocol (10 days) was also proposed, with proved 
advantages in terms of more mature follicles and subsequently more pregnancies (99).  
One small trial of limited power compared combined metformin–letrozole vs. metformin–
CC in 60 CC-resistant PCOS patients reported that combined metformin–letrozole was 
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associated with significantly more endometrial thickness, E2 levels and full-term pregnancy 
rate. However, no statistically significant difference was found between the two groups as 
regards the mean number of mature follicles, ovulation and pregnancy rates. The authors 
admitted that combined metformin– letrozole is better than letrozole alone, particularly in 
overweight women and asked for further studies to confirm their hypothesis (100). Recently, 
in a well designed adequately powered RCT, we compared the effects of letrozole 
monotherapy (2.5 mg daily for 5 days from D3-7 of the cycle) with combined metformin–CC 
in 250 anovulatory women (582 cycles) with CC resistant PCOS. Our findings suggested that 
letrozole monotherapy and combined metformin-CC were equally effective for inducing 
ovulation and achieving pregnancy in patients with CC-resistant PCOS (64.9% vs.69.6% and 
14.7% vs. 14.4% respectively). The total number of follicles was significantly more in the 
combined metformin–CC group (4.4 ± 0.4 vs. 6.8 ± 0.3). A non significant increase in 
endometrial thickness on the day of hCG administration was observed in the letrozole 
group (9.5 ± 0.2 mm vs. 9.1 ± 0.1 mm). Since letrozole was well tolerated, it is considered as 
an acceptable alternative if CC-resistant PCOS patients cannot tolerate long-term metformin 
pretreatment (101).  
More recently, the efficacy of the AIs vs. other traditional options including gonadotrophins 
and LOD for treatment of CC-resistant infertile PCOS patients has been reported. 2 RCTs 
compared the effect of letrozole (2.5mg and 5 mg respectively from day 3 to day 7 of menses 
for 6 consecutive cycles) with LOD for ovulation induction in CC resistant women with 
PCOS. Both trials reported that letrozole and LOD are equally effective for inducing 
ovulation and achieving pregnancy in these patients. Moreover, women in the letrozole 
group had a significantly thicker endometrium than those in the LOD group. In view of the 
invasiveness and cost of surgery, it seems plausible that letrozole therapy should be tried 
first for most of those women before shifting to LOD (102,103). A recent large randomized 
trial by Ganesh et al., 2009 (104) compared the efficacy of letrozole with that of rFSH and 
CC/rFSH for ovarian stimulation in IUI cycles in 1387 PCOS women after CC failure. They 
reported an ovulation rate of 79.30% in letrozole group vs. 56.95% and 89.89% in other 
groups respectively and pregnancy rate of 23.39% in letrozole group vs. 14.35% and 17.92% 
in other groups respectively. However, they included not only CC-resistant PCOS patients 
but also those who failed to conceive with100 mg/day CC for 6 cycles despite ovulating and 
those who showed poor endometrial development i.e. endometrial thickness < 7 mm on the 
day of hCG administration. 
Letrozole was evaluated in 44 women with CC–resistant PCOS and both responders and 
nonresponders were characterized. PCOS was diagnosed by Rotterdam criteria; CC- 
resistance was defined as failure to ovulate after 6 cycles of 150 mg CC /day for 5 days. 
Whereas response to CC is less likely with elevated BMI, amenorrhea, and increased age, 
significant differences between letrozole responders and nonresponders were not noted for 
any evaluated measure. This apparent lack of predictive factors for letrozole suggests utility 
in CC–resistant patients since its efficacy is not limited to specific patient characteristics 
(105). The safety of letrozole has elaborated a vivid discussion. Preliminary data by Biljan et 
al., 2005 (106) suggested an increased risk of congenital anomalies in letrozole treated 
babies, whereas recent data from retrospective and prospective trials (107,108) have 
contested these initial findings and supported the safety of letrozole compared to traditional 
ovulation induction treatment. 
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7. Oral contraceptives 
Branigan & Estes., 2003 (109) in a RCT showed that the suppression of the hypothalamic 
pituitary- ovarian axis for 2 months with combined oral contraceptives (COC) (0.03 mg of 
ethinyl estradiol and 0.15 mg of desogestrel) followed by CC, at dosage of 100 mg/day on 
days fifth to ninth of the cycle, improved ovulation and pregnancy rates in CC resistant 
women in comparison with repeated cycles of CC alone. Oral contraceptive administration 
showed to reduce serum LH, estradiol and androgen levels. These hormonal changes, 
especially the reduced androgenic milieu, could act improving the ovarian 
microenvironment, and thus the ovarian response to CC. Kriplani et al., 2010 (110) in a RCT 
reported that in women with PCOS, a drospirenone containing COC has better outcome in 
terms of persistent regular cycles, antiandrogenic effect,fall in BMI and BP, better lipid 
profile, favorable glycemic and hormonal profile than desogestrel-containing COC. 
8. N-acetyl-cysteine 
N-acetyl-cysteine (NAC) is a mucolytic drug. Fulghesu et al., 2002 (111) demonstrated that 
long term NAC treatment (1.8 g/d for 5–6 weeks) was associated with significant increase in 
insulin sensitivity and reduction in insulin levels, testosterone and FAI in hyperinsulinemic 
PCOS. Rizk et al., 2005 (112) showed that the combination of NAC (1.2 g/d) with CC (100 
mg/d) for only 5 days significantly increased both ovulation and pregnancy rates in obese 
women with CC-resistant PCOS compared with placebo (49.3% vs. 1.3% and 21.3% vs. 0, 
respectively). Actually, these results supporting the shorter duration (5 days only) of NAC 
administration in CC- resistant PCOS women have not been replicated by other trials. 
Recently, in a well designed adequately powered RCT, we reported that the efficacy of 
metformin–CC combination therapy is higher than that of NAC – CC for inducing ovulation 
and achieving pregnancy among CC-resistant PCOS patients (113). In our study, the dose 
and duration of NAC were chosen based on that published by Fulghesu et al., 2002(111). 
Over a 3-month follow-up period, women in metformin-CC group had significantly higher 
ovulation and pregnancy rates compared with women in NAC-CC group (69.1% vs. 20.0% 
and 22.7% vs. 5.3%, respectively). Moreover, the level of serum estrogen, the endometrial 
thickness on the day of hCG administration and the midluteal serum progesterone level 
were all significantly higher for women in metformin-CC group than other group. 
Additionally, a lower miscarriage rate was observed among women in metformin-CC group 
(113). 
9. Dexamethasone therapy 
Dexamethasone therapy during the follicular phase has been described without any side 
effects or serious events (114). Parsanezhad et al., 2002 (115) in a double-blind RCT, showed 
the safety and the efficacy of a high-dose short course of dexamethasone for inducing 
ovulation in 230 CC-resistant patients with PCOS and normal DHEAS levels. They reported 
significantly higher ovulation and pregnancy rates in those who received 200mg of CC 
(days 5–9) and 2mg of dexamethasone (days 5–14) compared with CC alone (88% vs. 20% 
and 40.5 vs. 4.2% respectively). In these patients, dexamethasone reduced circulating 
DHEAS, T, and LH levels and the LH/FSH ratio after 2 weeks of treatment (115). These 
results were further confirmed in another RCT (116).  
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Currently, evidence suggests that PCOS and hyperprolactinaemia are two distinct entities 
without a patho-physiological link (117-119). Bromocriptine administration provided no 
benefit in CC-resistant PCOS patients with normal prolactin levels, receiving 150mg CC 
(days 5–9) and bromocriptin continuously administrated at a dosage of 7.5 mg daily (120). 
On the contrary, the use of cabergoline, a long-acting ergoline D2 agonist derivative, has 
been proved to improve ovarian response in hyperprolactinemic patients with PCOS 
candidates for treatment with gonadaotrophins (121). These data suggested the presence of 
a dopaminergic component in the control of LH release in PCOS patients (121). 
11. Conclusion 
Ovulation induction in women with PCOS who present with CC-resistant anovulatory 
infertility remains a major challenge in gynecologic endocrinology. Traditional alternatives 
for CC-resistant patients include gonadotrophin therapy and laparoscopic ovarian 
diathermy. However, because of the cost and risk inherent in these therapies, alternative 
treatments are attractive. Obese PCOS women should try to attain BMI<30kg/m2 prior to 
commencing ovulation induction therapy. In view of our experience, combined metformin-
CC therapy did result in modest ovulation and pregnancy rates. Accordingly, it is logical to 
offer combined metformin- CC therapy for CC-resistant PCOS patients before resorting to 
more expensive alternatives especially in developing communities where economic aspects 
of therapy are important. Third generation aromatase inhibitors are promising agents for 
treatment in these patients. Figure 1 shows an algorithm for ovulation induction treatment 
in anovulatory infertile women with CC-resistant PCOS. 
CC- resistant PCOS
Optimize lifestyle
= Weight loss (Diet + exercise)
if BMI >29 Kg/m2
• Metformin+ CC (3-6 cycles)
• 3rd generation AIs (Letrozole




Obese women Non Obese women
FailureCC: Clomiphene Citrate
AIs: Aromatase inhibitors
LOD: laparoscopic ovarian drilling
 
Fig. 1. Algorithm for ovulation induction treatment in anovulatory infertile women with 
CC-resistant PCOS. 
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1. Introduction 
The polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women 
of reproductive age [1]. PCOS is not only accompanied with negative physical 
consequences, but this syndrome also affects psycho-social and sexual well-being. 
Characteristics of PCOS include enlarged ovaries with a polycystic appearance along with 
menstrual irregularities such as amenorrhoea or oligoamenorrhoea, excessive growth of 
body hair (hirsutism) or biochemical hyperandrogenism, and to a lesser extent acne. In 
addition, PCOS is associated with anovulatory infertility, obesity, insulin resistance, and 
lipid disorders [2, 3]. 
In clinical scenarios, the treatment of women with PCOS is mainly focused on correcting 
menstrual disturbances and physical consequences. Besides the physical consequences, the 
negative implications of PCOS in daily life such as impaired social contacts and sexual 
satisfaction and depression seem to be rarely discussed with PCOS women during 
treatment. The scientific interest in the psycho-social and sexual consequences of PCOS has 
grown in the past years and has increased our knowledge on these topics. For example, 
recent studies indicated that PCOS is associated with depression [4-6], body dissatisfaction 
[5, 6], decreased quality of life [7], a decreased feeling of sexual attractiveness and self-
esteem as well as sexual dissatisfaction [4, 7]. 
First, an extensive overview is provided in this chapter on what is known about psycho-
social and sexual well-being in women with PCOS (Part I). Second, we studied the 
association between on the one hand common physical features of PCOS (polycystic ovaries, 
hirsutism, acne, menstrual irregularities, and Body Mass Index) and endocrine variables 
(e.g. testosterone, progesterone, and estradiol) and sexual well-being on the other hand (Part 
II). In addition, we evaluated whether there is an association between aspects of psycho-
social well-being (self-esteem, body satisfaction, and self-perceived fear of negative 
appearance evaluation) and sexual well-being (Part II). 
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treatment. The scientific interest in the psycho-social and sexual consequences of PCOS has 
grown in the past years and has increased our knowledge on these topics. For example, 
recent studies indicated that PCOS is associated with depression [4-6], body dissatisfaction 
[5, 6], decreased quality of life [7], a decreased feeling of sexual attractiveness and self-
esteem as well as sexual dissatisfaction [4, 7]. 
First, an extensive overview is provided in this chapter on what is known about psycho-
social and sexual well-being in women with PCOS (Part I). Second, we studied the 
association between on the one hand common physical features of PCOS (polycystic ovaries, 
hirsutism, acne, menstrual irregularities, and Body Mass Index) and endocrine variables 
(e.g. testosterone, progesterone, and estradiol) and sexual well-being on the other hand (Part 
II). In addition, we evaluated whether there is an association between aspects of psycho-
social well-being (self-esteem, body satisfaction, and self-perceived fear of negative 
appearance evaluation) and sexual well-being (Part II). 
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2. Part I: Psycho-social well-being in women with PCOS 
In some women, the appearance of PCOS might be characterized by an excess growth of body 
hair on various body areas such as the chin, lip, abdomen, and arms as well as by acne. It is 
imaginable that these outer appearances, together with non-visible characteristics (e.g. 
menstrual irregularities) influence psycho-social well-being. Moreover, PCOS causes infertility 
and involuntary childlessness. It has in fact been shown that women with PCOS report more 
psychological distress than controls [7, 8]. With respect to the diagnosis of PCOS itself, one 
study measuring patient’s perception of the diagnosis of PCOS found that the emotions 
associated with the diagnosis included frustration (67%), anxiety (16%), and sadness (10%) [9].  
It has been shown that hirsutism, menstrual irregularities, and infertility are the PCOS 
symptoms experienced as most bothersome by affected women [10]. Lipton and colleagues 
[11] demonstrated that women with facial hair spend a considerable time on the 
management of their facial hair (104 min/week). Besides, two thirds reported continually 
checking their facial hair in mirrors and 76% by touch. In addition, more than half of the 
women tried at least four methods for hair removal in the past. Furthermore, it is 
conceivable that infertility increases a woman’s emotional distress. Indeed, many PCOS 
women seem to worry about remaining without children in the future and report a current 
wish to conceive; however, infertility does not appear to be a determinant for psychological 
problems [12]. Together, it is imaginable that the symptoms of PCOS might cause a woman 
to experience issues with their femininity and might therefore not only affect psychological 
well-being, but more in particular sexual well-being. Studies have indicated that women 
with PCOS experience more psychological problems such as depression and anxiety than 
non-PCOS controls with infertility problems [13], indicating that mood swings might be 
caused by the distressing symptoms of the syndrome. The emotional distress related to 
symptoms and consequences of PCOS might affect various domains of their lives, including 
romantic relationships, friendships, social contacts, and their working life. It could be that 
women find it difficult to share their experiences with other people and feel uncomfortable 
when conversations about motherhood are started. Also, about 50% of all women with 
PCOS are overweight, compared to 30% of women in the general population [2]. A higher 
Body Mass Index (BMI) in women with PCOS is not only related to negative physical [2, 3, 
14, 15], but also to negative psychological consequences [4].  
Altogether, a greater incidence of psychological problems have been found in women with 
PCOS [8]. In the sections below we will describe what is known about psycho-social well-
being in women with PCOS as well as the association with features of PCOS. The results 
will not be discussed in detail as this is beyond the scope of this chapter.  
2.1 Quality of Life 
It is widely recognized that QoL is significantly reduced in women with PCOS [6, 16-18]. 
Generic QoL (focuses on domains of well-being in general) [19, 20] as well as specific QoL 
(focuses on domains of well-being related to a specific disease/syndrome) measurements 
[21] are used in research. Several studies investigated mechanisms that might be responsible 
for a reduced QoL in PCOS women. Being overweight has been found to be one of the most 
important contributors reducing QOL in women with PCOS [7, 22, 23]. In addition, there is 
converging evidence suggesting that hirsutism is one of the most important predictors of 
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impaired QoL besides obesity [4, 23, 24]. In addition, it is demonstrated that acne, diabetes 
mellitus [21], menstrual irregularities [7], and concerns about infertility [4, 25, 26] are related 
to a reduced QoL in women with PCOS. Nevertheless, Hahn et al. [23] failed to find an 
association between QoL and androgens and insulin resistance.  
With respect to psychological mechanisms, a reduced psychological QoL in PCOS women 
has been indicated to be associated with a passive coping style (a maladaptive coping 
strategy) [16] as well as with anxiety and depression [27].  
2.2 Depression 
Women with PCOS report higher levels of depressive symptoms than the general 
population [8]. The prevalence of depressive symptoms is not only higher but also more 
variable (25-64%) [12, 28-31] than for women in the general population. In addition, it has 
been found that women with PCOS report higher depression scores than non-PCOS controls 
with fertility problems [13]. PCOS features, endocrine imbalance (e.g. testosterone levels), 
and psychological mechanisms seem to have an impact on mood in women with PCOS and 
have therefore been studied as mediators of depression. For example, infertility [12] and an 
unfulfilled wish to conceive [27] do not appear to contribute to higher depression scores; 
however, infertile PCOS women seem to have higher depression scores compared to 
infertile women in whom infertility is related to other causes than PCOS [5]. Hence, other 
characteristics of PCOS seem to play a mediating role. Several studies have shown that BMI 
is related to depressive symptoms [22, 32, 33] as well as hirsutism and acne [11, 27]. 
Moreover, higher depression scores have been demonstrated in PCOS women with 
hirsutism compared to women with newly diagnosed gynaecological cancer [34].  
PCOS is associated with high testosterone levels. Lower testosterone levels seem to be 
related to depression in women with PCOS [35]. Also, testosterone was found to be lower in 
depressive PCOS women compared to PCOS women without depressive symptoms, 
whereas the researchers found no significant relation between BMI and hirsutism [36]. 
Conversely, Barry and colleagues [13] failed to find an association between testosterone and 
mood disturbances in women with PCOS. Accordingly, others failed to find an association 
between depression and hormonal and metabolic profile [36, 37]. 
With respect to psychological mechanisms, it has been shown that depression in PCOS 
women is predicted by a poorer perception of self-worth and body image [29, 38], fitness 
orientation, appearance evaluation, lower QoL [29], and passive coping style (a maladaptive 
coping strategy) [16]. 
2.3 Anxiety and fears 
Recently, researchers showed an increased level of anxiety [27, 29] and social anxiety [8] in 
PCOS women compared to controls. The finding of reduced sleep in women with PCOS 
might be explained by a higher prevalence of sleep apnea in obese women with PCOS [39].  
An interesting issue is determining which characteristics of PCOS are related to anxiety. It 
has been shown that not only visual features of PCOS such as a higher body weight and an 
excessive growth of bodily hair were related to an increased experience of fear of what other 
people thought about their appearance, but also the absence of their cycle (amenorrhoea) 
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was negatively associated with fear of appearance evaluation [40]. The association between 
fear of negative appearance evaluation and non-visual characteristics might be explained by 
a reduced feeling of femininity [10]. The experience of women with PCOS feeling less 
feminine seem to be related to menstrual irregularities and hirsutism [10]. Contrasting 
findings have been found with respect to the relation between anxiety and hirsutism. Some 
studies reported women with hirsutism showing greater anxiety levels [7, 11] and social 
fears [41]. Moreover, one study found that higher anxiety scores were indicated in PCOS 
women with hirsutism than in women with newly diagnosed gynaecological cancer [34]. 
Furthermore, both acne and an unfulfilled wish to conceive seem to be a risk factor for 
clinically relevant anxiety in women with PCOS [27]; however, this study failed to find a 
relationship for BMI and hirsutism. This is in the same line with other study results not 
finding a relationship between anxiety, acne, hirsutism, and BMI [36, 42]. Contrasting 
findings might be explained by the use of different questionnaires. 
Livadas et al. [36] studied whether anxiety was associated with hormonal and metabolic 
profile. PCOS women with higher anxiety scores showed significantly elevated HOMA-IR 
(insulin resistance) and FAI (free androgen excess) values than PCOS women with lower 
anxiety scores, independently of BMI; however, no relation was found with hormonal values 
such as testosterone, androstenedione, sex hormone-binding globulin levels, 
dehydroepiandrosterone sulphate, and estradiol. In the same line, the relation between greater 
FAI values and greater levels of anxiety was previously reported by Mansson et al. [8]. 
Moreover, Deeks and colleagues [29] indicated in a cross-sectional study in PCOS women 
and controls that poor perception of self-worth and body image as well as health evaluation 
predicted higher anxiety levels. It has also been found that anxiety in PCOS women is 
associated with having a passive coping style [16].  
2.4 Self-esteem and body satisfaction 
A recent study demonstrated a more negative body image in women with PCOS 
compared to healthy controls [29]. It has been indicated that women with facial hair and 
decreased self-esteem have higher depression and anxiety scores as well as poorer QoL 
[11], although poorer self-esteem compared to the general population was not confirmed. 
In a previous study, we showed that women with PCOS and a higher BMI in addition to 
hirsutism reported having poorer self-esteem and greater body dissatisfaction than 
women without hirsutism and lower BMI scores. In addition, amenorrhoea was 
associated with poorer self-esteem whereas hyperandrogenism and acne were found to be 
associated with body dissatisfaction. In line with our previous findings, it has been shown 
that women with PCOS and clinical symptoms of hirsutism and acne have greater body 
dissatisfaction than healthy controls with regular cycles, even after adjustment for BMI [5, 
35]. Furthermore, poorer self-esteem in PCOS women has been linked to higher levels of 
depression and anxiety [29, 38]. 
2.5 Other domains of psycho-social well-being 
2.5.1 Eating disorders 
A higher prevalence of eating disorders such as bulimia has been reported in women with 
PCOS compared to controls [8]. One study found that 12.6% of PCOS women had an eating 
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disorder compared to 1.6% in controls [32]. No association between PCOS characteristics 
(such as hirsutism and acne) and eating disorders has been found [43]. Further, Livadas and 
colleagues [36] failed to find an association between eating disorders and hormonal and 
metabolic profile in women with PCOS. 
2.5.2 Suicide 
Mansson et al. [8] were the first who studied suicide attempts in women with PCOS: they 
found that suicide attempts were seven times more common in women with PCOS 
compared to controls [8]. This finding might be explained by the increased risk for 
psychological disturbances such as depression and anxiety. 
2.5.3 Neuroticism and stress responses 
Furthermore, a recent study reported that women with PCOS were more neurotic, meaning 
that they had difficulties coping with stress, exhibited more anger symptoms, and were 
more likely to withhold feelings of anger compared to non-PCOS women with fertility 
problems [44]; however, these findings disappeared with using multiple regression 
analyses, indicating that they might be related to distressing symptoms of the syndrome. In 
addition, disturbed stress responses were indicated in PCOS women [45]. This finding 
might be linked to the elevated risks for depression, overweight, and the cardiovascular and 
diabetes risks associated with the diagnosis 
3. Sexual well-being in women with PCOS 
Hormones play a major role in various aspects of sexuality. As PCOS is an endocrine 
disorder, it seems plausible that the endocrine changes associated with PCOS influence 
sexuality. Sexuality is an important aspect of an individual’s well-being, highlighting the 
importance of our understanding of sexuality in women with PCOS. Existing studies with 
respect to PCOS and sexuality have been mainly focussing on sexual satisfaction in women 
with PCOS, whereas for example sexual functioning has not been given much attention. 
Sexual satisfaction is defined as the balance between costs and rewards concerning sexuality 
[46], for example: A woman without problems in the domain of sexual desire but who 
experiences painful intercourse has lowered sexual satisfaction because the costs (pain) are 
too high. Sexual functioning refers to the ability to experience the phases of the sexual 
response cycle (desire, arousal, lubrication, orgasm), for example: A woman who is able to 
feel sexually aroused but who is not able to experience an orgasm has poorer sexual 
functioning. Sexual satisfaction is part of sexual functioning [47] given that a person without 
problems in the domain of sexual functioning might experience a decreased sexual 
satisfaction, for example caused by negative feelings such as guilt. On the contrary, not 
being able to function sexual fully does not necessarily mean that one has low sexual 
satisfaction; one might not experience this as a problem. It is imaginable that clinicians and 
researchers find it more comfortable talking about sexual satisfaction than sexual 
functioning, with the latter being more detailed and intimate. Clinicians might not be 
trained in discussing sexual problems with their patients or it is unknown as to where to 
refer patients to with sexual problems.  
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was negatively associated with fear of appearance evaluation [40]. The association between 
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disorder compared to 1.6% in controls [32]. No association between PCOS characteristics 
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sexuality. Sexuality is an important aspect of an individual’s well-being, highlighting the 
importance of our understanding of sexuality in women with PCOS. Existing studies with 
respect to PCOS and sexuality have been mainly focussing on sexual satisfaction in women 
with PCOS, whereas for example sexual functioning has not been given much attention. 
Sexual satisfaction is defined as the balance between costs and rewards concerning sexuality 
[46], for example: A woman without problems in the domain of sexual desire but who 
experiences painful intercourse has lowered sexual satisfaction because the costs (pain) are 
too high. Sexual functioning refers to the ability to experience the phases of the sexual 
response cycle (desire, arousal, lubrication, orgasm), for example: A woman who is able to 
feel sexually aroused but who is not able to experience an orgasm has poorer sexual 
functioning. Sexual satisfaction is part of sexual functioning [47] given that a person without 
problems in the domain of sexual functioning might experience a decreased sexual 
satisfaction, for example caused by negative feelings such as guilt. On the contrary, not 
being able to function sexual fully does not necessarily mean that one has low sexual 
satisfaction; one might not experience this as a problem. It is imaginable that clinicians and 
researchers find it more comfortable talking about sexual satisfaction than sexual 
functioning, with the latter being more detailed and intimate. Clinicians might not be 
trained in discussing sexual problems with their patients or it is unknown as to where to 
refer patients to with sexual problems.  
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3.1 Sexual functioning in women in general: The role of hormones 
Androgens and estrogens play an important role in female sexual functioning. The sex 
steroids testosterone and estradiol play a role in all structures and organs related to female 
sexual functioning. For example, changes in sexual desire are noticed during changes in the 
menstrual cycle [48]. Sexual desire refers to a subjective feeling that is triggered by both 
internal and external cues, which may or may not result in overt sexual behaviour [49]. 
Sexual arousal has physiological and subjective aspects: the physiological part is related to 
an increased autonomic activation that prepares the body for sexual activity and increases 
the amount of sexual stimulation necessary to induce orgasm. The subjective part is related 
to an emotional state of arousal, including sexual thoughts and fantasies[50].  
3.2 Estrogens 
Estrogens play an important role in making the brain susceptible for the influence of 
testosterone. In addition, estrogens influence mood and physical signs of sexual 
attractiveness (e.g. breast development). An estrogen deficiency can cause various 
complaints such as mood disturbances and might indirectly influence sexuality negatively 
[51, 52]. It has been demonstrated in healthy pre-menopausal women without PCOS that 
menstrual cycle changes can influence sexual behaviour by changes in psychological well-
being: improved sexual activity (frequency of partner sex, masturbation and orgasm) was 
related to an increased well-being (mood and pre-menstrual symptoms) [48]. 
Furthermore, atrophic changes (thinning of the vaginal walls) are influenced by reduced 
estrogen levels [53, 54]; however, sexual reactions, sexual arousal, lubrication and genital 
vasocongestion do not seem to be estrogen dependent. Even though estrogen levels were 
significantly different, studies failed to find a difference in sexual functioning between pre-
menopausal and post-menopausal women [51, 52]. Likewise, no evidence has been found 
for a significant effect of estrogen on sexual interest, arousal, and orgasmic response [48, 53]. 
The best predictor for post-menopausal sexual functioning seems to pre-menopausal sexual 
functioning [53]. Estrogen levels are in general within the normal range in women with 
PCOS [55]. 
3.3 Androgens 
Androgens have been indicated to play an important role in female sexual functioning [56] 
and seem to influence sexual desire and arousal (either alone or in combination with estrogen), 
sexual thoughts, sexual fantasies, and nocturnal genital responses [54, 57]. Androgens prepare 
the female sexual system to be susceptible for sexual stimuli and sexual arousal [54, 56]. Sexual 
arousal through non-cognitive processes (audiovisual stimulation, ‘quick and dirty’) has not 
been found to be androgen dependent, whereas sexual arousal through cognitive processes 
(thoughts, fantasies, ‘neat and slow’) has been shown to be androgen dependent [56]. 
Androgen levels are often increased in women with PCOS which in turn might influence 
sexual thoughts and desire [55]. Bancroft et al. [48] failed to find an association between 
testosterone levels and sexual activity with their partner; however, a positive relation was 
found with respect to the frequency of masturbation. Finally, testosterone and DHEAS were 
not found to be related with Hypoactive Sexual Desire Disorder (HSDD: a deficiency or 
absence of desire for sexual activity) in community based studies in women [53, 58, 59].  
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3.4 Hyperandrogenism and sexuality  
A recent publication [60] found that not only acne and hirsutism improved by oral 
contraception as a result of reduced androgen levels, a positive influence on social contacts, 
QoL, sexual self-esteem, and feelings of sexually attractiveness has also been found. In 
addition, sex life in general (sexual pleasure in particular) and orgasm by intercourse 
improved as well as that dyspareunia (painful sexual intercourse) declined. Moreover, the 
frequency of intercourse increased as opposed to the frequency of masturbation. Sexual 
functioning seems to be improved by the mediation of improved QoL, whereas sexual self-
esteem and sexual attractiveness as a result of decreasing hirsutism and acne [60]. 
Furthermore, Wierman and colleagues [53] found a minor influence of hyperandrogenism 
or its treatment on sexual functioning in women with PCOS. The researchers speculate that 
psycho-social factors such as decreased levels of self-esteem might have a greater impact on 
sexuality. 
Abovementioned studies indicate that hormonal influences play a minimal role in 
predicting sexual functioning in women with PCOS. Lowered sexual satisfaction and sexual 
functioning might be mediated by psychosocial factors or by a variety in responsiveness to 
testosterone [61]. Finally, contextual influences (e.g. partner relationship) combined with the 
appropriate stimuli can cause sexual arousal resulting in sexual desire [57, 62-64].  
4. Sexual functioning  
4.1 Sexarche and sexual intercourse 
It has been found that adolescents and women with PCOS become sexually active later in 
life than controls. In addition, it seems that PCOS women are less likely to have had 
intercourse compared to their healthy peers [7, 26, 65]. Furthermore, De Niet et al. [40] 
found that sexarche (the first sexual intercourse) is related to amenorrhoea; women with 
PCOS and amenorrhoea had an earlier sexarche than women with PCOS and 
oligomenorrhoea.  
Although it has been indicated that PCOS women experience lower sexual satisfaction and 
feel less attractive than controls, the frequency of sexual intercourse [7, 66] and the number 
of sexual partners [66] was not found to be different compared to controls. Moreover, it has 
been found that the frequency of sexual intercourse increased as a result of improved QoL, 
sexual self-esteem, feelings of sexual attractiveness, and sexual pleasure when using oral 
contraceptive [60].  
Pagidas et al. [67] found that intercourse compliance (2-3 times a week) was related to 
having an ovulatory cycle in women undergoing fertility treatment. An ovulatory cycle 
increased intercourse compliance, especially in women with a BMI over 35. 
Painful sexual intercourse has also been studied [7, 23, 60, 66]. Two studies have found that 
pain during sexual intercourse is increased in women with PCOS compared to controls [23, 
66]. The incidence of painful intercourse seems to be negatively influenced by BMI [23]. 
Painful intercourse seem to decrease with the use of oral contraceptives [60] or metformin 
[65], probably due to mediating factors of overall increased sexual functioning (in particular 
sexual pleasure).  
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QoL, sexual self-esteem, and feelings of sexually attractiveness has also been found. In 
addition, sex life in general (sexual pleasure in particular) and orgasm by intercourse 
improved as well as that dyspareunia (painful sexual intercourse) declined. Moreover, the 
frequency of intercourse increased as opposed to the frequency of masturbation. Sexual 
functioning seems to be improved by the mediation of improved QoL, whereas sexual self-
esteem and sexual attractiveness as a result of decreasing hirsutism and acne [60]. 
Furthermore, Wierman and colleagues [53] found a minor influence of hyperandrogenism 
or its treatment on sexual functioning in women with PCOS. The researchers speculate that 
psycho-social factors such as decreased levels of self-esteem might have a greater impact on 
sexuality. 
Abovementioned studies indicate that hormonal influences play a minimal role in 
predicting sexual functioning in women with PCOS. Lowered sexual satisfaction and sexual 
functioning might be mediated by psychosocial factors or by a variety in responsiveness to 
testosterone [61]. Finally, contextual influences (e.g. partner relationship) combined with the 
appropriate stimuli can cause sexual arousal resulting in sexual desire [57, 62-64].  
4. Sexual functioning  
4.1 Sexarche and sexual intercourse 
It has been found that adolescents and women with PCOS become sexually active later in 
life than controls. In addition, it seems that PCOS women are less likely to have had 
intercourse compared to their healthy peers [7, 26, 65]. Furthermore, De Niet et al. [40] 
found that sexarche (the first sexual intercourse) is related to amenorrhoea; women with 
PCOS and amenorrhoea had an earlier sexarche than women with PCOS and 
oligomenorrhoea.  
Although it has been indicated that PCOS women experience lower sexual satisfaction and 
feel less attractive than controls, the frequency of sexual intercourse [7, 66] and the number 
of sexual partners [66] was not found to be different compared to controls. Moreover, it has 
been found that the frequency of sexual intercourse increased as a result of improved QoL, 
sexual self-esteem, feelings of sexual attractiveness, and sexual pleasure when using oral 
contraceptive [60].  
Pagidas et al. [67] found that intercourse compliance (2-3 times a week) was related to 
having an ovulatory cycle in women undergoing fertility treatment. An ovulatory cycle 
increased intercourse compliance, especially in women with a BMI over 35. 
Painful sexual intercourse has also been studied [7, 23, 60, 66]. Two studies have found that 
pain during sexual intercourse is increased in women with PCOS compared to controls [23, 
66]. The incidence of painful intercourse seems to be negatively influenced by BMI [23]. 
Painful intercourse seem to decrease with the use of oral contraceptives [60] or metformin 
[65], probably due to mediating factors of overall increased sexual functioning (in particular 
sexual pleasure).  
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4.2 Sexual desire  
Conaglen & Conaglen [68] compared women with PCOS or idiopathic hirsutism (IH) and 
healthy controls on psychosocial functioning and various aspects of sexuality including 
sexual desire. Sexual desire was found to be significantly lower in PCOS women than in 
controls. After anti-androgen medication, the treatment group reported a significantly 
further decline in sexual desire despite a significantly increase in self-esteem and a decrease 
in hirsutism. This indicates that anti-androgen therapy can improve self-esteem and 
hirsutism, but negatively influences sexual desire. This could be due to decreasing androgen 
levels causing the brain to be less susceptible to sexual stimuli resulting in decreased sexual 
desire [54]. In line with these findings, studies failed to find a relation between sexual desire 
and androgen levels [57, 58, 67] in non PCOS women; however, an impaired sexual interest 
and desire (e.g., arousal, orgasm, pain, initiation, receptiveness, affection, relationship) was 
shown in with women with HSDD compared to controls [58]. In contrast, two studies 
indicated that women with PCOS seem to take more sexual initiative and to have greater 
sexual desire than controls [66, 69]. Interestingly, one study found PCOS women reporting 
less interest in physical contact with their partner compared to controls. These contrasting 
findings might be explained by psychological factors [61]. 
4.3 Sexual arousal, orgasm 
As mentioned before, androgens influence sexual arousal; however, free or total testosterone 
has not been found to be related to arousal. Furthermore, it has been shown that women 
with PCOS are less satisfied with their sex life, had more problems with getting aroused, 
and showed more often no interest in physical contact with their partner compared with 
healthy controls [66]. In addition, insufficient lubrication was significantly higher in PCOS 
women [11]. This finding seems to explain the higher incidence of painful sexual 
intercourse.  
The incidence of sexual thoughts and fantasies (part of subjective arousal) seems to be 
negatively correlated to BMI [23]; however, orgasm frequency was not found to differ 
between PCOS women and controls [66]. In addition, total serum testosterone but not FAI 
was positively related to higher scores in aspects of sexual functioning (such as satisfaction 
sex life, frequency of orgasm during intercourse, and vaginal lubrication) in PCOS women 
[66]. A hypothesis is that levels of testosterone above average improve sexual functioning; 
however, this is not in line with other findings [12, 23, 66, 68]. 
Using oral contraceptives seem to improve the frequency of orgasm during intercourse in 
women with PCOS [60], probably due to mediating factors as improved sexual pleasure, 
sexual self-esteem, and BMI. One study [70] failed to find a difference in sexual functioning 
or in genital anatomy between lean PCOS women and lean controls. Despite differences in 
androgen levels, no difference was found in clitoral volume and vascularisation. 
4.4 Sexual satisfaction, attractiveness, and self-worth 
It is widely recognized that women with PCOS report a decreased sexual satisfaction than 
healthy controls [7, 12, 26, 65, 66]. Sexual satisfaction seems to be influenced by both 
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endocrine and psycho-social factors. For example, both BMI and hirsutism seem to 
negatively influence sexual satisfaction, sexual attractiveness [23], and body esteem [68]. 
PCOS women also thought that their partners found them less sexually attractive [12]. Using 
an oral contraceptive improved hirsutism and acne [60, 68] which led to an improved feeling 
of sexual attractiveness and sexual self-esteem [60].  
Sexual self-worth seems to be lower in PCOS women [12, 17]. This finding might be related 
to infertility; however, this association could not be established. No other studies were 
found using the term self-worth. Self-esteem was reported [60, 68] and seem to be related to 
hirsutism and acne [68, 71]. 
Furthermore, it seems that BMI, hirsutism, and acne negatively influence making social 
contacts [12, 23] in women with PCOS. This finding might be explained by lower levels of 
self-esteem and other psychosocial factors [70].  
Finally, poorer body-image has been found to be associated with sexual avoidance [38] in 
women with PCOS compared to controls. Likewise, depression as a consequence of BMI 
was also found to have a negative association with sexual functioning in pre-menopausal 
women [72]. A similar relation might be expected in women with PCOS. In the same line, 
psychosocial aspects seem to negatively influence sexuality in women with PCOS: impaired 
psychological well-being [7, 60, 68], partner relationship [47], general health [65], social 
influences [59], and quality of the sexual stimuli [47]. 
4.5 Sex-typed behaviour and sexual orientation in PCOS women 
Last, there is evidence that sex typed behaviour and sexual orientations are related to 
hormonal levels. One study measured sex-typed behaviour online as well as self-reported 
PCOS diagnosis [73]. The results indicated that PCOS women reported significantly less 
typical feminine behaviour as a child (e.g., experimenting with make-up). In addition, PCOS 
women reported to have lower rates of dating boys and being part of a sports team.  
The results of studies examining the prevalence of PCOS in lesbian women and heterosexual 
women are contrasting. For example, Smith et al. [74] did not find a difference in the 
prevalence of PCOS and associated factors (e.g. hirsutism and testosterone level) in a 
general population of lesbian and heterosexual women. In contrast, another study 
conducted in a clinical population found a significant higher prevalence of PCOS and 
associated factors in lesbian than in heterosexual women [75].  
Finally, one study found that higher testosterone levels and a higher incidence of hirsutism, 
acne, menstrual irregularities as well as a higher prevalence of PCOS in female-to-male 
transsexuals (FMT) [76].  
5. Part II 
The objective of Part II was to evaluate the association between PCOS characteristics 
(polycystic ovaries, hirsutism, acne, menstrual irregularities (amenorrhea and 
oligomenorrhea), and BMI) and endocrine variables (e.g., testosterone and estradiol) on the 
one hand and sexual well-being on the other hand. In addition, we studied whether there is 
an association between aspects of psycho-social well-being (self-esteem, body satisfaction, 
and self-perceived fear of negative appearance evaluation) and sexual well-being. 
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[66]. A hypothesis is that levels of testosterone above average improve sexual functioning; 
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endocrine and psycho-social factors. For example, both BMI and hirsutism seem to 
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6.1 Participants and procedure 
Women with normogonadotropic anovulation (WHO II) who attended our fertility clinic at 
the Erasmus MC University Medical Centre between 1991 and 2006 were included in this 
cross-sectional study. In this group of WHO II women, we determined if the diagnosis of 
PCOS could be established on the basis of the revised Rotterdam criteria [77]. To establish 
the diagnosis of PCOS, all patients underwent a standardized evaluation including: 
assessing cycle history, the presence or absence of acne, transvaginal ultrasonography (to 
assess ovarian volume and follicle count for both ovaries), and anthropomorphometric 
measurements (height and weight, Ferriman-Gallwey score). Exclusion criteria included the 
presence of related disorders with similar clinical presentation, such as congenital adrenal 
hyperplasia and Cushing’s syndrome. The study protocol was approved by the Medical 
Ethics Committee of the Erasmus MC University Medical Centre, Rotterdam the 
Netherlands. All patients gave informed consent prior to their inclusion in the present 
study. In 2007, all women with WHO II received a letter with information about the current 
study and a seventy-two item questionnaire. Two months after mailing this questionnaire, 
non-respondents were sent a reminder together with a copy of the questionnaire. 
6.2 Study outcomes 
6.2.1 Independent variables: PCOS characteristics and endocrine variables 
In the period of 1991 to 2006, all women who were referred to the fertility clinic underwent a 
standard fertility test including evaluation of the following aspects:  
1. Menstrual irregularities: oligomenorrhoea was defined as an interval between 
menstrual periods 35 days and amenorrhoea as the absence of vaginal bleeding for at 
least 6 months, i.e. >199 days;  
2. Biochemical and clinical hyperandrogenism: in accordance with the revised Rotterdam 
criteria, hyperandrogenism was defined as having either biochemical or clinical signs of 
androgen excess. Biochemical hyperandrogenism was defined by a free androgen index 
(FAI)>4.5. Clinical hyperandrogenism (hirsutism) was assessed by the Ferriman-
Gallwey score where patients estimated their hair growth on nine different body parts 
from 0 (no terminal hair) to 4 (maximal growth) with a maximum score of 36. A score of 
8 or more indicates the presence of hirsutism [78];  
3. Acne: the presence or absence of acne was evaluated by the physician;  
4. Polycystic ovaries (PCO): the presence of PCO was examined by vaginal ultrasound 
examination. PCO were defined as the presence of 12 follicles or more in one or both 
ovaries and/or increased ovarian volume (>10 ml); and 
5. Endocrine evaluation: blood samples were obtained by venipuncture. Serum levels of 
gonadotropic hormones (luteinizing hormone (LH) and follicle-stimulating hormone 
(FSH)), estradiol (E2), androgens (testosterone (T), androstenedione (AD), 
dehydroepiandrosterone (DHEA), and dehydroepiandrosterone sulphate (DHEAS)), 
progesterone, sex hormone-binding globulin levels (SHBG), fasting glucose and insulin, 
thyroid-stimulating hormone (TSH), and prolactin were obtained. Serum was isolated 
after centrifugation at 3000 rpm for 10 min at 20°C and subsequently stored at -20°C. 
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Immunofluorometric assays were used for the LH, FSH, TSH, prolactin and insulin, 
whereas serum E2, T, AD, and SHBG were measured by RIA provided by Diagnostic 
Products Corp. (Los Angelas, CA). Intraassay and interassay coefficients of variation 
were <5% and <15% for LH, <3% and <5% for T, <8% and <11% for AD, <5% and <7% 
for E2, <4% and <5% for SHBG, respectively [3]. 
6.2.2 Independent variables: Psycho-social well-being 
6.2.2.1 Rosenberg Self-Esteem Scale (RSES) 
The RSES was administered to measure the level of self-esteem. On a 4-point-Likert scale 
from ‘strongly disagree’ to ‘strongly agree’, responses on 5 positively worded and 5 
negatively worded questions were assessed. Higher scores reflect a higher level of self-
esteem. The Dutch version of the RSES was shown to have good internal reliability 
(Chronbach’s alpha = .87) [79].  
6.2.2.2 Body Cathexis Scale (BCS) 
The BCS is a self-report questionnaire assessing body satisfaction [80]. The questionnaire 
consists of 52 items about a person’s satisfaction with their body parts and body 
functions, such as hips and respiration. Body satisfaction is measured on a 5-point Likert 
scale from the most negative attitude towards a body part or function to the most positive 
attitude towards the body part or function. The Dutch version of the questionnaire was 
shown to have good test-retest reliability (Pearson product-moment correlation coefficient 
= .91) [81].  
6.2.2.3 Fear of Negative Appearance Evaluation Scale (FNAES) 
The brief version of the FNAES was used to assess apprehension related to a negative 
appearance evaluative experience. The items are answered on 5-point Likert scales from ‘not 
at all’ to ‘enormously’. The higher the score, the more fear of negative appearance 
evaluation by others is experienced. This six-item questionnaire was shown to be valid and 
reliable with a high internal consistency (Chronbach’s α=0.87) [82] 
6.2.3 Dependent variables: Sexual well-being 
6.2.3.1 Sexual well-being 
Subjects completed questions that were part of a Dutch questionnaire measuring sexual 
health in youth and young adults between the age of 12 and 25 years [83]. The questions that 
we used in the current study included the following: (1) ‘How old were you when you had your 
first intercourse?’; (2) ‘Have you ever had a romantic relationship?’; (3) ‘How old were you when you 
had your first romantic relationship?’; (4) ‘Have you ever been in love?’; and (5) Are you in a 
romantic relationship at this moment?’  
6.2.3.2 Confounders: Demographics 
Information on women’s demographic characteristics such as age and ethnicity were 
collected. Ethnicity was divided into two categories: (0) non-Caucasian (another ethnicity 
than Dutch) and (1) Caucasian (Dutch). 
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7. Statistical analyses 
Data are presented for women with PCOS only. As measures for central tendency the means 
(for continuous data) and medians (for ordinal data) were estimated, while as measure for 
dispersion standard deviation was used. The observed score range was also presented. To 
explore the association between sexual well-being variables (dependent variables) on the one 
hand and the PCOS characteristics and endocrine variables or psycho-social well-being 
(independent variables) on the other hand, multiple linear regression analysis was applied on 
continuous dependent variables. The PCOS characteristics and endocrine variables were 
entered into the regression analysis together with confounding variables (age and ethnicity). 
Psychological variables were analyzed separately. For dichotomous dependent variables, 
adjusted odds ratios (Ors) and 99% confidence intervals (CI) were derived from logistic 
regression analyses. PCOS characteristics were entered as dichotomous variables: 
oligoamenorrhoea (0) versus amenorrhoea (1); no or doubtful hirsutism (0) versus hirsutism 
(1); few or no acne (0) versus acne (1); no PCO (0) versus PCO (1). In analyzing the relationship 
between sexuality and PCOS characteristics, we adjusted for the time interval between the 
date of the clinical evaluation and the sexuality measures, age of the participant, and ethnicity. 
As sexarche was prior to the clinical investigation for most women, we entered years between 
sexarche and the clinical evaluation as a confounding variable in the analyses. Ethnicity was 
entered as a confounding variable because non-Caucasian women appeared to have sexarche 
later in life and higher clinical scores such as hirsutism than Caucasian women. Statistical 
analyses were performed using the Statistical Package for the Social Sciences (SPSS version 
15.0) and testing took place at a 0.05 level of significance (two tailed).  
8. Imputation 
Multiple imputation was performed using the SPSS software in the Missing Value Analysis 
module in SPSS (version 17.0) to impute missing values under missing-at-random 
assumptions and the reasons for the missing data are unrelated to the outcome [84]. 
Multiple imputed data sets of the data were created and replaced by imputed values based 
on estimated underlying distributions using the Expectation Maximization method [85]. 
Eight variables were imputed, of which six variables had ≤ than 1.5% imputed data. The 
variable acne (68%) and hirsutism (35%) had a high percentage of imputed data, numbers of 
missings that are controversy to impute.  
9. Results 
9.1 Participants 
In the period between 1991 and 2006, 1148 WHO II patients attended the fertility clinic of the 
Erasmus MC University Medical Centre and underwent standard clinical and endocrine 
evaluation. Of the 1148 women with WHO II, 480 women with PCOS returned the 
questionnaire. The overall participation rate was 51% of whom 42% had PCOS. Table I 
shows the demographical, clinical, endocrine, psychological, and sexual characteristics of 
the responders with PCOS in our study. It has been indicated that a higher percentage of 
non-responders with PCOS were overweight or obese and had hyperandrogenism 
compared to the responders [40]. In addition, we showed that PCOS women had lower self-
esteem and poorer body satisfaction compared to norm scores. Of the women that 
completed the sexuality questions, 2.1% responded that they had their first sexual 
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intercourse when they were of the age of 13 years or younger and 4.0% had their first 
relationship when they were13 years or younger. 
 PCOS responders (n=480) 
Demographical characteristics
Age in years at date of clinical evaluation 28.8 (4.3), 14.2-40.0 (480) 
Caucasian 72.1% (346/480) 
Clinical 
Oligoamenorrhoea 71.7% (344/480) 
Amenorrea 28.3% (136/480) 






Body Mass Index (BMI kg/m²) 26.4 (6.0) [16.8-50.6] (479) 
BMI ≥ 25 (kg/m²) 48.6% (233/479) 
Endocrine 
Hyperandrogenism (FAI>4.5) 53.1% (255/480) 
LH 7.2 (5.6) [1.0-37.9] (480) 
FSH 4.9 (1.9) [1.1-10.5] (480) 
Progesterone 5.1 (10.1) [0.1 – 73.0] (479) 
SHBG 49.2 (33.3) [7.7 – 342] (480) 
T 2.2 (1.0) [0.3 – 6.7] (480) 
E2 275.8 (159.9) [51.0 – 1141.0] 
AD 13.0 (5.7) [2.6 – 40.7] 
DHEAS 6.0 (3.2) [0.2 – 21.3] 
Psycho-social well-being
RSES 31.0 (5.4) [14.0-40.0] (477) 
BCS 188.6 (30.3) [72.0 – 260.0] (435) 
FNAES 13.8 (5.9) [6.0 – 30.0] (473) 
Sexual well-being
‘Are you in a romantic relationship at this moment?’ %yes 92.7% (443/478) 
‘Have you ever been in love?’
% Never or 1 time 14.4% (69/473) 
% More than 1 time 84.2% (404/473) 
‘Have you ever had a romantic relationship?’ 
% Never or 1 time 41.6% (198/478) 
% More than 1 time 58.3% (280/478) 
‘How old were you when you had your first intercourse?’ 18.4 (3.3) [5.0 – 30.0] (467) 
‘How old were you when you had your first romantic 
relationship?’ 17.7 (3.2) [10.0 – 30.0] (471) 
PCO= Polycystic ovaries; LH= luteinizing hormone; FSH= follicle-stimulating hormone; SHBG= sex 
hormone-binding globulin levels; DHEAS= dehydroepiandrosterone sulphate; T= Testosterone; E2= 
Estradiol; AD= Androstenedione; RSES= Rosenberg Self-esteem Scale; BCS= Body Cathexis Scale; 
FNAES= Fear of Negative Appearance Evaluation Scale. 
¹Values are mean (SD), range, N or (N/total N), or number (%) of participants. 
Table 1. Demographical and (bio)clinical characteristics of PCOS responders¹ 
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9.2 PCOS characteristics and endocrine variables and the association with sexual 
well-being  
Table II shows the regression coefficients (B’s) and corresponding P-values derived by the 
logistic and linear multivariate regression analyses studying the association between the 
dependent sexual well-being variables and independent PCOS symptoms and endocrine 
variables. 
Relationship at the moment 
Results indicated that oligomenorrhoea was positively associated with having a relationship 
at the moment. In addition, the confounder ethnicity was also significant. These results 
indicated that PCOS women with oligomenorrhoea were more likely than women with 
amenorrhea to have a relationship at the moment. In addition, Caucasian PCOS women 
were more likely to have a relationship at the time of questionnaire completion than non-
Caucasian PCOS women.  
In love 
Older PCOS women, Caucasian women, and women without or doubtful hirsutism were 
more likely to have been in love multiple times as compared to younger PCOS women. 
Relationship in the past 
The results showed that the confounders ethnicity, age, and the years between measuring 
the clinical/endocrine variables and sexuality variables were significant in logistic analysis: 
Caucasian women and older women were more likely to have had more than one 
relationship in the past. 
Age at first intercourse 
Non-Caucasian women and older women have had their first intercourse at an older age 
than younger and Caucasian PCOS women.  
Age at first relationship 
With respect to the age of the first relationship, we found women with PCOS and hirsutism 
and older women with PCOS were comparatively older when they had their first 
relationship. In addition, non-Caucasian women had their first relationship at an older age 
compared to Caucasian women.  
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PCO= Polycystic ovaries; BMI= Body Mass Index; T= Testosterone; E2= Estradiol; AD= 
Androstenedione; SHBG= sex hormone-binding globulin levels; DHEAS= dehydroepiandrosterone 
sulphate. 
*Significant at a 0.05 level of significance 
Table 2. The association between the dependent sexual well-being variables and 
independent PCOS symptoms and endocrine variables 
9.3 Psycho-social well-being and the association with sexual well-being 
Table III shows the regression coefficients (B’s) with corresponding P-values derived by the 
logistic and linear multivariate regression analyses analyzing the association between the 
dependent sexual well-being variables and independent psycho-social well-being variables. 
Relationship at the moment 
In logistic regression analysis studying the association between having a relationship at the 
moment and psycho-social variables, we found that older PCOS women and Caucasian 
women were more likely to have a relationship at the moment than younger and non-
Caucasian PCOS women.  
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women were more likely to have a relationship at the moment than younger and non-
Caucasian PCOS women.  
 




PCOS women with higher self-esteem and Caucasian women were more likely to have been 
in love multiple times.  
Relationship in the past 
Being Caucasian, having higher self-esteem and lower body satisfaction scores were 
associated with having had multiples relationship in the past. 
Age at first intercourse 
Being older and non-Caucasian were both associated with having experienced the first 
intercourse at an older age. 
Age at first relationship 
Finally, PCOS women with lower levels of self-esteem as well as women with greater body 
satisfaction had their first relationship at an older age. Also, both older women with PCOS 
and non-Caucasian PCOS women were more likely to be comparatively older when they 
had their first relationship. 
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1.75; 0.000* 1.57; 0.000* 
RSES= Rosenberg Self-esteem Scale; BCS= Body Cathexis Scale; FNAES= Fear of Negative Appearance 
Evaluation Scale. 
*Significant at a 0.05 level of significance 
Table 3. The association between the dependent sexual well-being variables and 
independent psycho-social well-being variables 
10. Discussion 
A higher incidence of psycho-social disturbances [8] and impaired sexual well-being [7, 26, 
65] in women with PCOS highlight the clinical relevance of these topics. To improve overall 
well-being in women with PCOS, we need to have a better understanding to what extent the 
features of the syndrome affect psycho-social and sexual well-being.  
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The current study examined the association of PCOS characteristics and endocrine variables 
with sexual well-being. In addition, we studied whether psycho-social well-being was 
associated with sexual health. First, we found that several PCOS characteristics and 
endocrine parameters predicted sexual well-being. PCOS women with amenorrhoea seem to 
be less likely to have had a relationship at the time of completing the questionnaire. It is 
imaginable that an irregular cycle causes distress in women, which might have withheld 
them from starting a romantic relationship. In the same line, it has been found that 
menstrual irregularities decrease QoL [7] and are linked to fear of negative appearance 
evaluation [40]. An association between menstrual irregularities and any aspect of sexual 
health has not been confirmed previously [7].  
Furthermore, we found that women with PCOS and hirsutism were less likely to have been 
in love more than once and were older when they had their first relationship. It is widely 
recognized that hirsutism is one of the many factors that has a considerable negative impact 
on QoL [21], self-esteem, body satisfaction [5, 35, 40], and sexual health [23]. Hirsutism is 
considered as one of the most stressful characteristics of PCOS [10]. As women with PCOS 
and hirsutism also experience greater fear of negative appearance evaluation [40] and 
excessive body hair seem to withhold PCOS women from making social contacts [7], it 
seems plausible to assume that this negatively affects starting a romantic relationship.  
With respect to the studied endocrine variables, we did not find that hormonal and 
endocrine variables are associated with sexual health. In contrast, other studies showed that 
higher levels of T and androgens are associated with higher levels of sexual arousal and 
sexual desire [54, 66, 86], although an association with DHEAS was not confirmed in a 
previous study [58]. However, we measured different aspects of sexual well-being. Other 
studies showed decreased lubrication [66], lower levels of arousal, and improvement of 
orgasm frequency by using oral contraceptives [60]. Furthermore, lower levels of T seem to 
be associated with depression [42], which might also have indirectly influenced sexual well-
being. Contrasting results have been found with respect to sexual desire in PCOS women 
[66, 69, 87]. Anti-androgen therapy seems to further lower sexual desire, even though it 
improved psychological well-being [68]. Contrasting results with respect to the association 
between androgens and sexual desire [66, 69, 87] indicate that androgen levels are as yet 
unreliable predictors of sexual functioning, specifically for sexual desire. It is hypothesized 
that contradicting findings concerning the role of androgens in female sexual functioning 
may be due to, among other factors, a greater variety in responsiveness to testosterone in 
women and mediation of psychological mechanisms [61]. 
With respect to the significant result of the confounder age, it is imaginable that older 
women have different norms and values concerning sexuality and romantic relationships. 
For example, it is not inconceivable that the age of having first sexual intercourse or a 
relationship is younger in the present time than in previous generations. In addition, the 
confounder ethnicity is also associated with sexual well-being. Possible differences in sexual 
morality and cultural backgrounds might have caused non-Caucasian women to have their 
first intercourse at an older age.  
Surprisingly, BMI and acne were not found to predict any of our measured sexual well-
being variables. We might have failed to find an effect for acne since this variable had much 
missing data. Imputing high percentages of missing data is controversial; however, when 
we analyzed the data again on non-imputed data. The results still indicated a non-
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significant effect of acne. Also, Progesterone, SHBG, and E2 were not related to sexual health 
in the current study.  
Second, we studied the association between psycho-social variables and sexual health. 
Women with PCOS seem to have poorer self-esteem and poorer body satisfaction compared 
to the general population [40]. In addition, it is indicated that PCOS characteristics such as 
hirsutism, menstrual irregularities, and BMI are related to impaired psychological 
functioning [40]. In the current study, we demonstrated that self-esteem plays a significant 
role in sexual health. We showed that PCOS women with greater self-esteem are more likely 
have been in love multiple times, to have had more than one relationship in the past, and to 
have their first relationship at a younger age compared to PCOS women with poorer self-
esteem. Decreased sexual satisfaction has been reported in PCOS women [7, 26, 65, 66], 
which is negatively correlated to BMI and hirsutism. Improving hirsutism and acne, for 
instance by using an oral contraceptive, seem to improve sexual satisfaction, sexual 
attractiveness, and self-esteem [60, 68, 71]. Furthermore, an improvement in QoL seems to 
be related to an increase in the frequency of sexual intercourse and satisfaction with sex life 
in women with PCOS [7, 65]. Also, it has been shown that BMI, hirsutism, acne negatively 
influences making social contacts in women with PCOS [61], probably due to low self-
esteem. Therefore, it seems conceivable that women with higher levels of self-esteem feel 
more confident to make social contact and specifically start romantic relationships. 
Surprisingly, we found that women with greater body satisfaction were older when they 
had their first relationship. Likewise, it is indicated that body dissatisfaction increased the 
probability of coitus onset in adolescent girls [88]. Future research should further investigate 
this relationship. Fear of negative appearance evaluation was not related to any of the sexual 
variables. This is surprising as it would be plausible to assume that if a person fears what 
others think of their appearance, they are less likely to be involved in romantic relationships. 
A recent study indicated that increased anxiety predicted lifelong female sexual 
dysfunctioning in a sample of the general population [89]. Future research should focus on 
the relation of anxiety and sexual health in women with PCOS.  
Pitfalls of studies conducting research on psycho-social and sexual well-being in women 
with PCOS include the use of self-reported measures. Self-reported questionnaires measure 
mostly mental symptoms but not clinical syndromes. Mansson et al. [8] did use clinical 
structured interviews to assess DSM-IV diagnoses and did show psychiatric disorders such 
as depression and anxiety to be more common in women with PCOS compared to controls. 
Other drawbacks of our study include that the PCOS women completed the questionnaires 
later in time than the laboratory and clinical tests were performed. Patients reasonably 
would have scored the psychological questionnaires different at the time when laboratory 
and clinical parameters were measured and reported to them. Therefore, we also adjusted 
for the time interval in years between the endocrine evaluation and the psychological 
measures. Furthermore, we did not include a matched control group. The current results 
therefore particularly apply to differences within the PCOS population. Finally, the non-
responding rate in our study was high [40]. This might be due to a high percentage of non-
Caucasian patients in the non-responding group. A possible explanation is that the 
Caucasian non-responders had trouble filling out the questionnaires due to insufficient 
command of the Dutch language. Therefore the results could not be generalized to all 
women with PCOS. Furthermore, it might be that those women returning the questionnaire 
were those PCOS women whose psycho-social and sexual well-being were the least affected 
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by their syndrome. In the latter case, the impact of PCOS on psycho-social and sexual well-
being might even be underestimated. The impact of symptoms of PCOS on sexual well-
being established in the current study might also be underestimated because the non-
responders harboured the more pronounced phenotypes.  
In conclusion, this study stresses that the treatment of women with PCOS should notably 
focus not only on physical but also on psycho-social and sexual well-being. Future research 
should study various aspects of sexuality, e.g. sexual satisfaction, sexual motivation, and 
sexual self-esteem in randomized control trials with validated questionnaires as well as the 
influence of PCOS features. To fully understand the correlation between PCOS and 
sexuality, future studies should take all confounders (endocrine, psychological, and 
interpersonal) into account. 
11. Clinical management  
The overview provided in this chapter demonstrates the considerable impact of PCOS and 
its symptoms on psycho-social and sexual health. As women with PCOS are four times more 
likely to have abnormal depression scores compared to controls [90] This risk was 
independent of BMI, therefore it seems necessary to screen all women with PCOS for 
depression using validated measurements. Moreover, the literature shows an impairment of 
a variety of psycho-social and sexual health domains in women with PCOS and associations 
with features of PCOS characteristics. Therefore, we recommend assessing psycho-social 
and sexual domains by validated measurements.  
An important finding is that treatment of associated PCOS characteristics seems to improve 
psychological and sexual outcomes. For example, metformin or oral contraceptive pill 
treatment in women with PCOS seems to be related to a reduction of clinical symptoms as 
well as to an improved psychological and sexual well-being [65]. In addition, using an oral 
contraceptive [60] or metformin [65] seems to decrease the frequency of painful intercourse. 
A reduction in body weight and normalized menstrual cycle seems to have mediated these 
findings. Various oral contraceptives seem to have a different effect on sexuality and 
psychosocial factors [60, 68, 91]. This should be taken into account when prescribing these 
medications. 
Furthermore, the presence of obesity in PCOS women is associated with various physical 
consequences and psychological impairments. Lifestyle modification should be the first step 
before treating PCOS women for their infertility. Various studies have investigated the 
effects of weight loss and weight loss interventions in women with PCOS, indicating the 
beneficial effects of weight loss on the clinical and biochemical manifestations of PCOS [92, 
93], insulin sensitivity [94], and menstrual cyclicality and fertility outcomes during 
treatment [95, 96]. Moreover, self-esteem [95] and quality of life [97] have found to be 
improved by modest weight loss of 5% to 10% of the initial body weight. We also discussed 
the considerable impact of hirsutism on several psychosocial and sexual domains. It has 
been shown that laser treatment aimed at reducing the severity of facial hirsutism has not 
only a positive effect on the severity of facial hair, but also seems to improve self-esteem and 
QoL [98] and alleviate depression and anxiety [99]. Therefore, treatment of related PCOS 
symptoms should be considered. 
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A recent paper of Farrell and colleagues [37] demonstrated the benefits of psychological and 
behavioural approaches in addition to medical management of PCOS. Likewise, Rofey et al. 
[38] found decreased depression scores as well as weight loss after a behavioural program in 
adolescents with PCOS. The intervention consisted of phone calls and face to face meetings 
addressing coping mechanisms, scheduling behaviourally activating events, and engaging 
in positive thinking and cognitive restructuring. Furthermore, another study showed that a 
nurse-led peer support group providing socio-emotional and informational support reduced 
isolation and women reported feeling empowered [100].  
Bitzer et al. [101] developed a tool for sexual counselling that can be used by physicians. It 
contains 3 dimensions (pre-existing person related factors, disease specific factors, and the 
individual’s and partners reaction to the disease) that can be addressed when discussing 
sexuality with the patient. Remembering these dimensions is fairly easy and gives a good 
direction in discussing sexuality aspects with patients. A treatment plan might depend on 
the outcome of the conversation. Another easy-to-use tool is the PLISSIT model [102]. This is 
a stepped care model providing guidance in counselling and treating sexual problems.  
Aforementioned treatments and their positive effect on psycho-social and sexual well-being 
indicate that physicians should work interdisciplinary to also address consequences other 
than physical consequences and discuss treatment options aimed at reducing PCOS 
characteristics and improving psycho-social and sexual well-being.  
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individual’s and partners reaction to the disease) that can be addressed when discussing 
sexuality with the patient. Remembering these dimensions is fairly easy and gives a good 
direction in discussing sexuality aspects with patients. A treatment plan might depend on 
the outcome of the conversation. Another easy-to-use tool is the PLISSIT model [102]. This is 
a stepped care model providing guidance in counselling and treating sexual problems.  
Aforementioned treatments and their positive effect on psycho-social and sexual well-being 
indicate that physicians should work interdisciplinary to also address consequences other 
than physical consequences and discuss treatment options aimed at reducing PCOS 
characteristics and improving psycho-social and sexual well-being.  
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1. Introduction 
Polycystic Ovary-Syndrome (PCOS) is a complex endocrine disorder which affects 
approximately 5-10% of females of reproductive age (Asunción et al, 2000, Diamanti-
Kandarakis et al, 1999, Dunaif A, 1997). The syndrome is characterized by abnormal 
menstrual cyclicity, ovulatory dysfunction, hyperandrogenism and hirsutism (Goodarzi et 
al, 2011, Hatch et al, 1981). Functional ovarian hyperandrogenism is due to 
hyperinsulinemia, insulin resistance and hyperlipidemia. The acute problems of the patient, 
namely ovarian abnormalities and ovulation induction for subfertility, have shifted toward 
the prevention of long-term health consequences (Cupisti et al, 2007). Insulin resistance is a 
key feature of females with PCOS, especially, when they are overweight or obese. This has 
important effects in favouring androgen excess and oligo-anovulation. It is evident, that 
females with PCOS, especially the overweight ones, have a higher risk for developing type 2 
diabetes. It is suggested, that insulin resistance is even more common in overweight patients 
with PCOS that in lean females. There is a continuum of decrease in insulin sensitivity with 
increasing abdominal fat accumulation (Zelzer et al, 2011). Hyperandrogenism is associated 
with fat accumulation at the body trunk. This android, “apple”-like fat pattern is a risk for 
metabolic disturbances like cardiovascular diseases and type 2 diabetes (Cupisti et al, 2007, 
Nathan & Moran, 2008). 
Early symptoms of PCOS such as growing precociously pubic hair, height growth and 
overweight, do already appear during childhood and adolescence, but the problems are not 
diagnosed seriously (Bronstein et al, 2011, Oliveira et al, 2010). Obesity in childhood is 
widely spread worldwide. Lower physical activity and a general availability of high caloric 
food may cause high proportions of overweight and obese juveniles for higher risks for 
females to develop PCOS. 
Females with PCOS need medical care for different reasons: the pediatrician may be 
contacted because of childhood obesity or abnormal menstrual bleeding. The dermatologist 
may be approached for hirsutism. The gynecologist may be consulted for menstrual cycle 
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abnormalities, unfulfilled wish for pregnancy, or complications during pregnancy. The 
physician of internal medicine may be consulted for obesity or type 2 diabetes. The cause of 
a first contact of the patient with a physician is often a rapid weight gain. The consulted 
physician will measure BMI or waist circumference. The suggestion of metabolic terms, 
however, should focus the interest on the distribution of body fat, not only on body weight. 
A rapid, non-invasive and precise measurement of the thickness of adipose tissue might 
render important information of metabolic risks even in juveniles and in young females. 
Advanced statistic methods could support the detection of a PCOS - like fat distribution and 
confirm the risk for metabolic disturbances (Tafeit et al, 2000; Tafeit et al, 2000a, Tafeit et al, 
1999). 
2. The lipometer 
Measuring body fat has increasing priority in medical care, but also in sports and human 
biology. The standard methods are caliper, computed tomography, underwater weighing, 
nuclear magnetic resonance, bio-impedance or dual energy X-ray absoptiometry (DEXA). 
These methods have several disadvantages like high costs, stress for the subject, radiological 
burden or lack of precision. 
The newly certificated optical device Lipometer is a computerized optical system for precise 
measurement of the absolute thicknesses of subcutaneous adipose tissue in mm (Tafeit et al, 
2000b). 
 
Fig. 1. The Lipometer, an optical device to measure the thickness of subcutaneous adipose 
tissue layers 
2.1 Design of the lipometer 
The sensor head of the Lipometer consists of five light-emitting diodes as light sources 
(wavelength 660 nm, light intensity 3000 mcd) and a photodetector. The diodes illuminate 
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the body site to be measured, forming geometrical patterns that vary in succession. The light 
intensities from the adipose tissue are back-scattered, amplified, digitized and render fat 
thickness of the named body site in mm (Moeller at al, 2000). Calibration and evaluation was 
done by computed tomography as reference method.  
2.2 Procedere of measuring Subcutaneous Adipose Tissue Topography (SAT-Top) 
Fifteen anatomically well defined body sites from 1-neck to 15-calf give the information of 
individual body fat distribution (Subcutaneous adipose tissue topography, SAT-Top) (Tafeit 
et al, 2007). The coefficient of variation of these 15 body sites was published previously 
(Sudi et al, 2000). 
 
Fig. 2. The set of fifteen anatomically well- defined body sites from 1-neck to 15-calf on the 
right side oft the human body 
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Fig. 3. SAT-Top protocols: Female pear profile (left) and female apple profile (right) with the 
same age, weight and BMI 
SAT-Top of the measured person is like an individual “fingerprint”, defined by genetics, 
sex, nutritional status, hormonal and metabolic disorders and modified by age and life style.  
2.3 Comparing an individually measured SAT-Top with the data of healthy or diseased 
subjects of the same sex and age 
SAT-Tops of more than 3000 men, women and children are included in the Lipometer data 
base, healthy subjects as well as patients with type 2 diabetes, coronary heart disease, 
obesity and fertility disorders (Moeller et al, 2000a). 
Both, male and female children develop about the same SAT-Top between birth and the age 
before the onset of puberty. At the age of about eleven years the adipose tissue layers on the 
extremities increase in girls. The maximum of the adipose tissue layers on the legs is reached 
at the age of 22 years. Boys, however, decrease the thicknesses of the subcutaneous adipose 
tissue layers at the extremities. The minimum of the thickness of adipose tissue layers at the 
extremities is reached at the age of 17 years.  
At the age of 20 years men and women increase adipose tissue layers at their trunks until 
they are about 60 years old. Men have skinny extremities, women have not. 
In later life man and women stop increasing the thicknesses of adipose tissue layers at the 
trunks and turn back to thinner layers at their trunks. 
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Patients with obesity, type 2 diabetes, coronary heart disease, PCOS and anorexia nervosa 
have significantly different SAT-Tops compared to age-matched healthy controls. Anorectic 
patients have not the typical patterns of a male or female body fat distribution, but all over 
the body extremely thin adipose tissue layers of somewhat less than one mm. Overweight 
patients increase adipose tissue layers on neck, trunk, abdomen, hip and back and 
accumulate visceral fat, the “apple”-like body fat distribution. An even more pronounced 
“super- apple”- like body silhouette can also be found in overweight PCOS women and 
patients with type 2 diabetes and coronary heart disease (Moeller et al, 2000). 
3. Polycystic Ovary Syndrome and body fat distribution 
The diagnosis of PCOS is based on the Rotterdam criteria (The Rotterdam ESHRE-ASRM-
Sponsored consensus workshop group, 2004). Two out of three of the following are required 
for the diagnosis: oligo- and/or anovulation, clinical and/or biochemical signs of 
hyperandrogenism, polycystic ovaries by ultrasound. Disorders with a similar clinical 
presentation have to be excluded. 
About half of the females with PCOS are overweight or obese. The body fat distribution and 
SAT-Top is a better indicator of metabolic changes than waist circumference or BMI. 
Hyperandrogenism can be attributed to a fat accumulation at the trunk (Enea et al, 2011). 
Females with an android body silhouette have a higher risk for developing cardiovascular 
diseases, or type 2 diabetes (Goodarzi et al, 2011).  
3.1 SAT-Top comparison of adult females 
SAT-Top was measured in healthy females, overweight and lean females with PCOS. 
Diagnosis was performed by the Division of Reproductive Endocrinology of the Medical 
University Graz because of unfulfilled wish of pregnancy. Polycystic ovaries were 
diagnosed by ultrasound. Oligo- and anovulation, acne or alopecia and /or elevated 
androgen levels were identified (Hatch et al, 1981). 
 
healthy 
controls obese PCOS lean PCOS 
N 87 18 15 
Age (years) 28,1+4,1 27,3+4,9 25,6+4,1 
Height (cm) 165,5+6,6 164,5+6,5 165,8+8,3 
Weight (kg) 60+9,4 83,9+13,6 56,8+7,6 
BMI (kg/m2) 21,9+2,9 31,0+4,7 20,7+2,3 
Table 1. Personal data of adult females 
The green area in figure 4 shows the body fat distribution of healthy females, a typical “pear”-
like body fat distribution with thicker adipose tissue layers at the extremities: triceps and legs. 
Lean young females with PCOS (orange bars in figure 4) have thinner adipose tissue layers 
over the whole body and relatively thin layers at the extremities, but the profile is still more 
“pear”-like. 
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SAT-Top is a better indicator of metabolic changes than waist circumference or BMI. 
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3.1 SAT-Top comparison of adult females 
SAT-Top was measured in healthy females, overweight and lean females with PCOS. 
Diagnosis was performed by the Division of Reproductive Endocrinology of the Medical 
University Graz because of unfulfilled wish of pregnancy. Polycystic ovaries were 
diagnosed by ultrasound. Oligo- and anovulation, acne or alopecia and /or elevated 
androgen levels were identified (Hatch et al, 1981). 
 
healthy 
controls obese PCOS lean PCOS 
N 87 18 15 
Age (years) 28,1+4,1 27,3+4,9 25,6+4,1 
Height (cm) 165,5+6,6 164,5+6,5 165,8+8,3 
Weight (kg) 60+9,4 83,9+13,6 56,8+7,6 
BMI (kg/m2) 21,9+2,9 31,0+4,7 20,7+2,3 
Table 1. Personal data of adult females 
The green area in figure 4 shows the body fat distribution of healthy females, a typical “pear”-
like body fat distribution with thicker adipose tissue layers at the extremities: triceps and legs. 
Lean young females with PCOS (orange bars in figure 4) have thinner adipose tissue layers 
over the whole body and relatively thin layers at the extremities, but the profile is still more 
“pear”-like. 
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Overweight and obese females with PCOS (red bars in the figure) have a remarkable 
different body fat distribution with significantly thicker fat layers at all body sites from neck 
to hip and thinner layers at their legs, a typical “apple”- like body fat distribution (Tafeit et 
al, 2003). 
 
Fig. 4. SAT-Tops of healthy control females (green area), obese women with PCOS (red bars) 
and lean women with PCOS (orange bars) 
3.2 Body fat distribution of women with type 2 diabetes 
SAT-Top of 20 women with type 2 diabetes was published previously and the subcutaneous 
body fat pattern has strong similarities to obese women with PCOS. 
The personal data are shown in table 2: 
 healthy women type 2 diabetes 
N 122 20 
Age (years) 58,1+6,2 62,4+6,6 
Height (cm) 161,9+5,9 160,9+5,4 
Weight (kg) 72,1+11,6 75,4+13,1 
BMI (kg/m2) 27,5+4,5 29,1+4,9 
Table 2. Personal data of elderly females 
Figure 5 shows SAT-Tops of healthy controls (green area) compared to those with type 2 
diabetes (violet bars): 
The healthy elderly controls have increased thicknesses of adipose tissue layers located at 
the trunk during the postmenopausal aging processes. Overthere females with type 2 
diabetes develop thicker fat layers at their trunks, while the extremities are thinner than that 
of healthy elderly controls (Tafeit et al, 2000). 
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Fig. 5. SAT-Tops of healthy elderly controls (green area) and elderly females with type 2 
diabetes (violet bars). 
3.3 Body fat distribution of normal weight and overweight young girls 
SAT-Top was measured in 25 overweight, female juveniles and age-matched controls.  
The table shows the personal data: 
 healthy controls overweight girls 
N 301 25 
Age (years) 12,6+1,3 13,1+0,3 
Height (cm) 156+9,2 160+6,1 
Weight (kg) 46,8+10,8 78,8+12,3 
BMI (kg/m2) 19,3+3,0 30,8+4,7 
Table 3. Personal data of adolescent females 
Figure 6 shows the SAT-profiles of healthy (green area) and overweight (pink bars) female 
juveniles at the age of 13 years: 
Healthy girls begin to develop a gynoid body silhouette with thicker fat layers at the 
extremities. The overweight girls have thicker adipose tissue layers at all measured body 
sites, including also at the extremities. The body sites at the trunk are significantly thicker 
than those of the healthy controls. The body fat distribution of those juveniles is comparable 
to 60-years–old females with type 2 diabetes and adult females with PCOS (Tafeit et al, 2000, 
Moeller et al, 2007). 
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Fig. 6. SAT-Tops of healthy young girls (green area) and overweight girls (pink bars) 
3.4 Comparison of the three groups of patients 
The presented groups of patients (obese young females with PCOS, elderly females with 
type 2 diabetes and obese young girls) have an “apple”-like body fat distribution. Insulin 
resistance is suggested and consistently high risk for meatabolic diseases. The comparison of 
their SAT-Top plots is shown in figure 7: 
 
Fig. 7. SAT-Tops of obese females with PCOS (red line), females with type 2 diabetes (violet 
line) and overweight girls (pink line) 
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The “apple”- like body fat distribution is nearly congruent in females at the age of 13 years 
(overweight girls), 27 years (females with PCOS) and 62 years (females with type 2 
diabetes). 
Factor analysis condenses the 15-dimensional information of SAT-Top data in a two- 
dimensional diagram. Factor 1, the x-axis, represents the combined measured data of the 
trunk, Factor 2, the y-axis, represents the data of the extremities. The blue line in the figure is 
the development healthy male controls from 9 (m09) to 80 years (m80). A 9 years old boy 
has thin fat layers at the trunk. To the age of 17 years the young male decreases the thickness 
of adipose tissue layers at the extremities. Between the age of 17 years to 40 years the young 
male increases fat layers on the trunk (m17, m22, m30, m40). Between 40 and 60 years male 
individuals turn back to thinner trunk layers (m40, m50, m60).  
The red line shows the development of SAT-Top in females from 9 (f09) to 80 (f80) years. A 9 
years-old girl has lean extremities and thin fat layers at the trunk. The thickness of adipose 
tissue layers at the extremities increases till the age of 22 (f22). Between 22 years and 60 
years female persons increase their fat layers at their trunks and decrease it in older age 
between 60 and 80 years (f60 –f80). 
 
Fig. 8. Factor analysis condenses the SAT-Top information at the trunk and the body sites at 
the extremities into a two-dimensional plot, where the position of each subject can be 
shown. 
The gynoid body silhouette seen in fertile young females is a signal reproductive potential. 
Regarding SAT-Top of females with PCOS, a high divergence of the typical femal body 
silhouette is evident. 
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All SAT-Top plots shown in this chapter indicate, that almost all SAT layers of the upper 
body were significantly thicker in obese adolescents, obese females with PCOS and elderly 
females with type 2 diabetes, whereas SAT-layers at the legs were thinner compared to 
healthy controls of the same age group. 
The patients described in this chapter, namely overweight females with PCOS, females with 
type 2 diabetes and overweight female adolescents are positioned at higher values of Factor 
1, indicating significantly thicker adipose tissue layers at the trunk. Factor 2, the condensed 
body sites at the extremities show lower values in females with PCOS and type 2 diabetes 
compared to the age matched control group. 
4. Conclusion 
PCOS is a common disorder, representing an early indication of future metabolic risks 
(Barber & Franks, 2010, Sloboda et al, 2011). Obese females with PCOS have more severe 
clinical features than normal weight females with PCOS (lean PCOS) (Pandey & 
Bhattacharya, 2010). Because of the world-wide epidemic increase of obesity the prevalence 
of PCOS appears to be rising, too. Overweight and obesity have a profound effect on the 
clinical manifestation of insulin resistance, PCOS, and type 2 diabetes. Females and 
adolescents with PCOS suffer also from psychicals burdens such as feeling less attractive 
than peers, they have less sexual contacts also because of obesity and hirsutism. 
Insulin resistance is a condition of PCOS. Insulin resistance promotes fat storage because 
glucose is not taken by the cells. Increased levels of insulin in the blood stream cause wide-
ranging consequences that can lead to a variety of other serious health conditions, such as 
coronary heart disease, hypertension, diabetes, as well as infertility, abnormal hair growth, 
cysts on the ovaries. These high insulin levels in the blood even in young girls are correlated 
to abdominal fat accumulation, which is highly difficult to demolish. Recent studies confirm 
that caloric intake and energy expenditure is at a comparable range in healthy and insulin 
resistant subjects. Therefore loosing weight and decreasing abdominal fat is a long-term and 
often frustrating process. Otherwise - it is highly important for females with PCOS and 
overweight adolescent girls to induce weight loss and fat loss in the abdominal area; more 
than in the general population (Hrzystek-Korpacka et al, 2011). Body weight loss is 
associated with beneficial effects on the clinical features. Insulin-sensitizing agents might 
support weight reduction programs (Grover & Yialamas, 2011). The named patients 
(juvenile females, overweight young women with PCOS and elderly women with type 2 
diabetes) should receive any support for weight loss (fat loss) by their practitioner. 
Especially the early intervention combating obesity in juveniles regarding growth and 
development stages must become the challenge of health services. Lifestyle modification is a 
key factor for enhancing quality of life for overweight and anovulatory females. Prior to 
ovulation induction treatments weight loss should be encouraged. The lower life quality is 
more attributed to obesity and hirsutism than to psychosocial status and social adjustment 
(Swallen et al, 2005). Any interventions in PCOS women that reduce trunk fat also 
influences hirsutism, acne, infertility and overall psychological and emotional condition 
(Elsenbruch et al, 2003). An individually adapted diet and physical activity should be the 
first steps in intervention strategies for overweight juveniles and women with PCOS. Early 
lifestyle interventions cause significantly reduced body fat and androgen levels, and 
improved insulin sensitivity and menstrual cycles (Norman et al, 2004). 
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The process of an effective weight-loss management by diet and exercise can be monitored 
by SAT-Top measurement. The decrease of the thickness of adipose tissue layers might be a 
motivation factor for the patient to continue and maintain weight loss intervention 
programs.  
 
Fig. 9. Expectation of a successfull intervention program: the movement of an” apple”-like 
SAT-Top to a more “pear”- position in the factor plot (green arrow).  
Furthermore, factor analysis of the SAT-Top data can immediately demonstrate, where the 
position of the patient in the factor plot is located. An effective trunk fat reduction program 
should move the position of the subject towards the area of healthy controls of the same age.  
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1. Introduction 
1.1 Definition of infertility and habitual abortion 
Infertility is defined as an inability of a woman to carry a pregnancy to a viable foetus. From 
the perspective of differential diagnosis, infertility differs from sterility, i.e. an inability of a 
woman to get pregnant. If a woman miscarries on at least three consecutive occasions, this is 
termed habitual abortion (or habitual pregnancy loss, HPL). Habitual abortion is a stand-
alone nosological unit rather than an accumulation of circumstantial factors, as is confirmed 
by the lower incidence of foetal chromosomal aberrations in repeatedly miscarrying women 
compared to spontaneous abortions and a greater involvement of peristatic factors. A loss of 
all consecutive pregnancies in the first or second trimester is termed primary recurrent 
miscarriage. Secondary recurrent miscarriage is a situation when repeated miscarriages are 
preceded by a pregnancy leading to childbirth or an induced abortion. The term dysfertility 
is used if a woman miscarries on two consecutive occasions only (Zwinger, 2004). 
1.2 Epidemiology and etiology of habitual abortion 
Habitual abortion occurs in 1% of women in reproductive age and 15–38% of pregnancies 
result in spontaneous abortion. This number is, nevertheless, likely to be much higher as 
more than 40% of conceptions end before pregnancy is diagnosed (Madar, 2002). The 
frequency of spontaneous abortions increases with mother’s age. Up to 90% of the first 
spontaneous abortions result from, usually de novo, chromosomal aneuploidy, whereas the 
risk of recurrence of the same abnormality is minimal (Roztočil, 2001). Causes of habitual 
abortion include age, anatomy factors, genetic factors, haematology factors, endocrine 
factors, infections, immunology factors, environmental factors, psychological factors, 
idiopathic factors.  
1.3 Prerequisites of successful treatment of habitual abortion 
Successful therapy of infertile women is subject to a careful and individualised differential 
diagnosis of habitual abortions. Comprehensive evaluation aimed at identification of the 
specific cause of infertility should be performed in the pregnant women who have 
previously repeatedly lost their pregnancy. Rigorous approach to diagnose the causes of 
repeated miscarriage is essential when an effective therapy is to be selected. Causal therapy 
 
Polycystic Ovary Syndrome 
 
60
Zelzer, S., Fuchs, N., Almer, G.,Raggam, R.,Prueller, F., Truschnig-Wilders, M., Schnedl, W. 
Horejsi, R., Moeller, R.,Weghuber, D., Ille, R. & Mangge, H. (2011) High density 
lipoprotein cholesterol level is a robust predictor of lipid peroxidation irrespective 
of gender, age, obesity, and inflammatory or metabolic biomarkers. Clinica Chimica 
Acta , in press. 
4 
Embryoprotective Therapy of Infertile 
 Women with Polycystic Ovary Syndrome 
Robert Hudeček and Renata Krajčovičová 
Dept. Obstetrics and Gynecology, Masaryk University and University Hospital, Brno 
Czech Republic 
1. Introduction 
1.1 Definition of infertility and habitual abortion 
Infertility is defined as an inability of a woman to carry a pregnancy to a viable foetus. From 
the perspective of differential diagnosis, infertility differs from sterility, i.e. an inability of a 
woman to get pregnant. If a woman miscarries on at least three consecutive occasions, this is 
termed habitual abortion (or habitual pregnancy loss, HPL). Habitual abortion is a stand-
alone nosological unit rather than an accumulation of circumstantial factors, as is confirmed 
by the lower incidence of foetal chromosomal aberrations in repeatedly miscarrying women 
compared to spontaneous abortions and a greater involvement of peristatic factors. A loss of 
all consecutive pregnancies in the first or second trimester is termed primary recurrent 
miscarriage. Secondary recurrent miscarriage is a situation when repeated miscarriages are 
preceded by a pregnancy leading to childbirth or an induced abortion. The term dysfertility 
is used if a woman miscarries on two consecutive occasions only (Zwinger, 2004). 
1.2 Epidemiology and etiology of habitual abortion 
Habitual abortion occurs in 1% of women in reproductive age and 15–38% of pregnancies 
result in spontaneous abortion. This number is, nevertheless, likely to be much higher as 
more than 40% of conceptions end before pregnancy is diagnosed (Madar, 2002). The 
frequency of spontaneous abortions increases with mother’s age. Up to 90% of the first 
spontaneous abortions result from, usually de novo, chromosomal aneuploidy, whereas the 
risk of recurrence of the same abnormality is minimal (Roztočil, 2001). Causes of habitual 
abortion include age, anatomy factors, genetic factors, haematology factors, endocrine 
factors, infections, immunology factors, environmental factors, psychological factors, 
idiopathic factors.  
1.3 Prerequisites of successful treatment of habitual abortion 
Successful therapy of infertile women is subject to a careful and individualised differential 
diagnosis of habitual abortions. Comprehensive evaluation aimed at identification of the 
specific cause of infertility should be performed in the pregnant women who have 
previously repeatedly lost their pregnancy. Rigorous approach to diagnose the causes of 
repeated miscarriage is essential when an effective therapy is to be selected. Causal therapy 
 
Polycystic Ovary Syndrome 
 
62
of habitual pregnancy loss includes conservative pharmacological treatment, surgery and 
lifestyle changes. 
2. Endocrine causes of recurrent pregnancy losses 
An endocrinopathy is a common and severe cause of infertility. These are either 
gynaecology-related endocrinopathies and gynaecology-unrelated endocrinopathies. 
Gynaecology-related endocrinopathies results from ovarian hypofunction. Abnormal follicle 
stimulating/luteinizing hormone (FSH/LH) ratio and hyperandrogenism in the polycystic 
ovary syndrome are also considered as factors associated with an increased risk of habitual 
abortions. The proportion of first trimester miscarriages in women with the polycystic ovary 
syndrome is about 30–50% higher than in healthy women (Kauffman, 2003) 
Gynaecology-unrelated endocrinopathies with unequivocal impact on fertility include 
thyreotoxicosis, hypothyreosis, diabetes mellitus, hyperprolactinaemia and obesity 
(Krajčovičová, 2007).  
2.1 Gynaecology-related endocrinopathies 
Epidemiologically, polycystic ovary syndrome is a highly prevalent gynaecology-related 
endocrinopathy. However, it is not solely a gynaecological condition but rather a disease 
with a range of metabolic and endocrine findings, including diabetes (Moller, 1993, Toscano, 
1998). Ovarian hypofunction as a cause of habitual miscarriages represents another separate 
nosological unit of endocrinopathies with an impact on female reproductive function. 
2.1.1 Polycystic ovary syndrome 
It is estimated that polycystic ovary syndrome affects 5 – 10% of women of childbearing 
potential, with 35 – 45% of polycystic ovary syndrome patients being obese (Svačina, 2001). 
The real incidence of this syndrome in the population depends on the diagnostic criteria 
used and is probably higher than that published in the literature. Complications of 
pregnancy associated with maternal PCOS include increased prevalence of early pregnancy 
loss (EPL), gestational diabetes (GDM), pregnancy-induced hypertensive disorders 
(PET/PIH), and the birth of small-for-gestational-age (SGA) babies. Increased risk of EPL 
has been attributed to obesity, hyperinsulinaemia, elevated luteinizing hormone 
concentrations, and endometrial dysfunction. Avoiding obesity before pregnancy and 
treatment with metformin are therapeutic options, also for the increased prevalence of GDM 
(Homburg, 2006). Administration of metformin throughout pregnancy is a contentious 
issue. Screening pregnant women with PCOS for GDM and PET/PIH-especially if they are 
obese-is recommended, although data for a firm association between PCOS and PET/PIH is 
weak. Impaired insulin-mediated growth and foetal programming are possible explanations 
for a higher prevalence of SGA infants in mothers with PCOS (Homburg, 2006). 
2.1.1.1 Polycystic ovary syndrome - pathophysiology  
The mechanism behind metabolic and hormonal disposition for polycystic ovary syndrome, 
or what the primary disorder is, is rather unclear. Over the recent years, large groups of 
researchers have been involved in polycystic ovary syndrome research but the results are 
often controversial and confusing. Insulin resistance and the status of insulin receptors have 
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frequently been investigated. Page: 3 Higher insulin independent autophosphorylation of 
insulin receptor at serine residue was observed. The role of IRS substrate disorders is also 
discussed as is the role of TNF-a, e.g. IRS-1 phosphorylation induced by TNF-a (Svačina, 
2001). Defects of the glycoprotein PC-1 are being considered as another potential factor. 
Insulin resistance in male relatives has recently been shown. Phosphorylation of serine is a 
process that explains hyperanadrogenism as well as insulin resistance. This is a key process 
of androgen secretion in an ovary and adrenal glands and there also is important serine 
phosphorylation on insulin receptors (Svačina, 2001). 
A number of studies focused on the clear association with abdominal obesity (even though 
some of the patients are not particularly obese) and it seems that it is only the women with 
higher abdominal fat that are insulin resistant and hyperandrogenemic. SHBG reduction is 
typical, particularly in obese patients. Sex hormone-binding globulin (SHBG) is the primary 
plasma transport protein for sex steroid hormones and regulates the bioavailability of these 
hormones to target tissues. The gene encoding SHBG is complex and any of several 
polymorphisms in SHBG have been associated with alterations in circulating SHBG levels 
(Chen, 2010). Epidemiological studies have revealed that low plasma SHBG levels are an early 
indicator of insulin resistance and predict the development of type 2 diabetes mellitus (T2DM) 
in both men and women. Although association between low SHBG levels and risk of diabetes 
could be explained by the observation that elevations in insulin suppress hepatic SHBG 
production. Recent studies documenting that the SHBG-altering polymorphisms are 
associated with risk of T2DM suggest that SHBG may have a more direct physiologic role in 
glucose homeostasis (Chen, 2010). However, the exact mechanism(s) underlying this 
association is not known (Chen, 2010). Non-diabetic women with the polycystic ovary 
syndrome (PCOS), a common endocrine disorder that is associated with insulin resistance, 
similarly demonstrate lower levels of SHBG. In light of studies investigating polymorphisms 
in SHBG and T2DM, our group and others have hypothesized that SHBG may represent a 
candidate gene for PCOS. In this manuscript, we review studies investigating the association 
between SHBG polymorphisms and PCOS. In summary, multiple studies in women with 
PCOS confirm that certain genetic polymorphisms are associated with circulating SHBG levels, 
but they are not consistently associated with PCOS per se. (Chen, 2010) 
According to some authors, insulin resistance can be found in women with anovulation 
cycles only. Women with polycystic ovary syndrome have lower basal energy expenditure 
as well as postprandial termogenesis. This is an analogy with android obesity, metabolic 
syndrome and diabetes. A relative lack of gestagens and, consequently, dominance of 
cortisol on receptors in abdominal fat may also contribute to the pathogenesis. This results 
in higher level of free fatty acids and insulin resistance. 
To assess the diabetes risk score in polycystic ovary syndrome (PCOS) and in different 
phenotypes of PCOS and controls was observed and evaluated by overweight 
premenopausal women with PCOS, non PCOS or controls folowing factors: Finnish 
Diabetes Risk Score, anthropometrics, oral glucose tolerance test (OGTT), glucose, insulin, 
and reproductive hormone levels. The women with PCOS had higher adiposity, abdominal 
adiposity and 120-minute OGTT glucose. The women with PCOS and non-PCOS had 
elevated 120-minute OGTT insulin compared with controls. The women with PCOS and 
non-PCOS had similar diabetes risk scores, but both had higher diabetes risk score 
compared with controls after matching age and BMI. The women with PCOS (4%) and non-
PCOS (12%) had a lower prevalence of low risk of diabetes scores compared with controls 
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(50%) and they have similar Finnish Diabetes Risk Scores and elevated scores relative to 
controls independent of age and adiposity. Similar clinical screening and treatment practices 
for type 2 diabetes are warranted for both phenotypes of PCOS (Moran, 2011) 
Another research study compared pregnancy outcome, specifically the prevalence of 
gestational diabetes mellitus (GDM), in a group of patients with polycystic ovary syndrome 
(PCOS) to a group of healthy weight-matched women. Pregnancies of women with PCOS, 
who had been treated for infertility were compared with a group of age- and weight-
matched controls. There were no significant differences in the prevalence of pregnancy 
complications such as gestational diabetes mellitus, pregnancy-induced hypertension (PIH) 
and premature deliveries between the group of PCOS patients and the controls. When 
differences in age and weight between PCOS patients and controls are negligible, PCOS is 
not associated with a higher risk of pregnancy complications. (Hašková, 2003) 
2.1.1.2 Polycystic ovary syndrome - diagnosis  
The international conference in Bethesda in 1990 have recommended three diagnostic 
criteria: hyperandrogenism, chronic anovulation (enzyme deficits at a level of adrenal 
glands, e.g. 21-hydroxylase deficit as well as hyperprolactinaemia and androgen-producing 
tumours should be excluded) and hyperinsulinmia (Svačina, 2001). Frequent, although not 
exclusive, symptoms include hirsutism, alopecia and acne. There may be no morphological 
changes on the ovaries. An older definition assumed the presence of at least eight 
subcapsular cysts in the ovaries of 10 cm in diameter. Higher LH/FSH ratio (usually above 
2,0), previous important endocrine diagnostic criterion, is not anymore required for the 
diagnosis (Toscano, 1998). 
2.1.1.3 Polycystic ovary syndrome – treatment  
Management of polycystic ovary syndrome (PCOS) usually spans woman's reproductive 
years. While treatment of androgenic symptoms is often a primary concern, periodically, the 
regimen has to be modified because of a desire for pregnancy. At this time the couple should 
be evaluated for factors that may contribute to infertility and this should include semen 
analysis. However, for many, anovulation is likely to be the cause of infertility and ovulation 
induction is generally required. The premise on which ovulation induction in PCOS is based is 
two-fold: increasing ovarian exposure to follicle stimulating hormone (FSH) and/or correcting 
hormonal derangements. Potential differences in pathogenesis, evidenced clinically by 
phenotypic diversity, would suggest that treatment should be individualized. These options 
include the use of clomiphene citrate, insulin sensitizers, and the combination. Protocols for 
ovulation induction with FSH injections are outlined and the relative risks of multiple 
gestation and severe ovarian hyperstimulation syndrome. The use of aromatase inhibitors and 
the occasional use of glucocorticoids are briefly reviewed, and indications for in vitro 
fertilization and laparoscopic ovarian diathermy outlined (Nader, 2010). 
2.1.1.3.1 Clomiphene citrate and insulin sensitizers 
The knowledge on the role of insulin resistance in the pathogenesis of PCOS has led to the use 
of insulin sensitizers in PCOS treatment. Metformin was the first to be used in 1994. 
Administration of metformin results in decreased androgen and LH levels, improvement in 
insulin sensitivity and normalization of menstrual cycle (Legro, 2007). Metformin decreases 
liver gluconeogenesis and reduces oxidation of free fatty acids. It increases uptake of glucose 
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by skeletal muscles and fat tissue, improves dyslipidemia and it has other specific effects in the 
ovaries (Mansfield, 2003). Metformin impacts on ovarian steroidogenesis by reducing 
androgen production, improving the adverse environment of the endometrium and improves 
ovarian function. It seems so far that metformin (and glitazones) has no or insignificantly 
positive effect on hirsutism (Šarapatková, 2008). A meta-analysis of metformin studies showed 
that, compared to placebo, metformin significantly increases the occurrence of ovulation (Lord, 
2003). However, it is not clear yet whether treating women with PCOS and with normal BMI 
and insulin sensitivity with metformin is beneficial. Also, there is a question whether 
clomiphene should be used alone or in combination with metformin or whether metformin 
monotherapy should be used to enable infertile women with PCOS to become pregnant and 
deliver a healthy baby. In a 6-month study comparing all three approaches, clomiphene led to 
the highest pregnancy and live birth rates. Addition of metformin to therapy in this study did 
not show a significant advantage over clomiphene monotherapy. However, possible positive 
effect of this combination cannot be excluded. Induction of ovulation itself does not mean 
higher likelihood of conceiving and giving birth to a healthy child. Metformin provided, in line 
with previous findings, an improvement in parameters of insulin sensitivity, BMI, insulin and 
proinsulin levels, while insulin resistance and testosterone levels declined. Nevertheless, these 
effects may not be associated with higher rate of live births (Legro, 2007). 
Recently, glitazones, other insulin resistance modifying agents, have been tested in women 
with PCOS. They improve the effects of insulin in the liver, skeletal muscles and fat tissue. 
Similar to metformin, they also directly impact on ovarian steroidogenesis (Mansfield, 2003). 
Decrease in insulin levels results in decline in the levels of circulating androgens. Glitazones 
also reduce the levels of plasminogen activator inhibitor-1. Glitazones are not widely used 
in clinical practice and they are contraindicated in pregnancy (Šarapatková, 2008). The use 
of metformin in patients diagnosed with hyperinsulinaemia and in women with the 
polycystic ovary syndrome represents a therapeutic use of an insulin sensitizer with 
promising effects in anovulation sterility and dysfertility. 
2.1.1.3.2 Protocols for ovulation induction with FSH and in vitro fertilisation  
Women with PCOS and a history of habitual abortions or a history of sterility due to 
anovulation frequently undergo IVF cycles requiring ovarian stimulation with follicle-
stimulating hormone (FSH). In his retrospective study, Kdous compared standard long GnRH 
agonist protocol (Triptolerin) and GnRH antagonist regimens (Cetrorelix) in polycystic ovary 
syndrome (PCOS) patients undergoing controlled ovarian stimulation (COS) for ICSI cycles. 
He found that GnRH antagonist protocol is a short and simple protocol with a significant 
reduction in the incidence of OHSS and gonadotropin levels. However, GnRH antagonist 
protocol provides a lower live birth rate and an increased risk of early pregnancy loss 
compared to the GnRH agonist long protocol (Kdous 2009). Well-established 
micromanipulation techniques, the ICSI and PICSI methods, are successfully used for IVF in 
women with PCOS. Ovarian hyperstimulation syndrome (OHSS) is a feared complication of 
IVF. Women with PCOS are at a greater risk of developing OHSS because of the higher 
number of follicles produced in the ovaries following FSH stimulation (Moosová, 2011). 
2.1.1.3.3 Aromatase inhibitors  
Aromatase inhibitors block the final step in the enzymatic estrogen production: 
aromatization of the A-cycle of aromatizable androgens, specifically androstendione and 
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(50%) and they have similar Finnish Diabetes Risk Scores and elevated scores relative to 
controls independent of age and adiposity. Similar clinical screening and treatment practices 
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matched controls. There were no significant differences in the prevalence of pregnancy 
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differences in age and weight between PCOS patients and controls are negligible, PCOS is 
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liver gluconeogenesis and reduces oxidation of free fatty acids. It increases uptake of glucose 
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by skeletal muscles and fat tissue, improves dyslipidemia and it has other specific effects in the 
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deliver a healthy baby. In a 6-month study comparing all three approaches, clomiphene led to 
the highest pregnancy and live birth rates. Addition of metformin to therapy in this study did 
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effects may not be associated with higher rate of live births (Legro, 2007). 
Recently, glitazones, other insulin resistance modifying agents, have been tested in women 
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anovulation frequently undergo IVF cycles requiring ovarian stimulation with follicle-
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testosteron. Substances interfering with aromatase activity have been available for many 
years. However, the substances used during the aminoglutethimide era were non-specific 
and had a poor safety profile. The third generations of aromatase inhibitors are highly 
specific and virtually free of adverse events. These substances are licensed for treatment of 
breast cancer in postmenopausal women with advanced disease or as adjuvant treatment. 
Temporary inhibition of estradiol production in women with active ovaries leads to 
increased gonadotropin concentrations and, consequently, stimulation of follicle growth. 
This is undesirable in patients with ovarian cancer and thus aromatase inhibitors are not 
used in premenopausal women unless the production of gonadotropins is blocked. On the 
other hand, this effect is highly desirable in infertile women. Aromatase inhibitors may be 
used in women who do not ovulate but their no meaning (PCOS-type oligo-ovulation) or in 
ovulating women in whom higher number of follicles are required (idiopathic infertility, age 
factor, or prior to IVF). Preliminary studies published thus far show rather convincingly that 
aromatase inhibitors are effective in inducing ovulation in infertile women (Mitwally, 2006). 
Letrozole (one of aromatase inhibitors), though reported to be an effective ovulation 
inducing agent, warrants larger randomized trials. The purpose of this study is to compare 
the efficacy of letrozole with that of rFSH and clomiphene citrate (CC)/rFSH for ovarian 
stimulation in IUI cycles. In randomized, prospective, single-blinded clinical trial. 1387 
PCOS women after CC failure were randomized into three groups: Group A received 
letrozole, Group B received CC with two doses rFSH and Group C received continuous 
rFSH day 2 onwards until hCG injection. RESULTS: Group A, B and C had an ovulation rate 
of 79.30%, 56.95% and 89.89% and cycle cancellation rate of 20.70%, 43.05% and 10.11%, 
respectively. Pregnancy rates in Group A, B and C were 23.39%, 14.35% and 17.92%, while 
the miscarriage rates were 13.80%, 16.67% and 14.52%, respectively. CONCLUSION: 
Letrozole appears to be a suitable ovulation inducing agent in PCOS women with CC failure 
and is found to be most effective when baseline estradiol level >60 pg/ml. (Ganesh, 2009). 
2.1.1.3.4 Glucocorticoids  
In recurrently miscarrying women with PCOS, the presence of high titres of antizonal and 
antisperm antibodies should be excluded and potential insufficiency of sperm cell head’s 
enzymatic status considered. Patients in whom implantation is a problem, the presence of 
antizonal and antiendometrial antibodies has to be excluded. High levels of 
antiphospholipid antibodies and other mechanisms aimed at immunological mother-semi-
allogeneic graft tolerance might adversely affect the entire IVF process. Therapy is often 
carefully selected with respect to a patient’s age, character and type of antibodies and the 
number of IVF cycles. Most frequently, micromanipulation is combined with temporary 
immunosuppression (short-term administration of glucocorticoids, e.g. Prednison 5mg 
dosed 1-1/2-0 daily) and long-term antioxidant treatment (Ulčová-Gallová, 2001). 
2.1.1.3.5 Treatment by laparoscopic ovarian diathermy 
Laparoscopic ovarian drilling is used as one of the options for surgical management of 
infertility in patients with polycystic ovary syndrome. This method is performed as 
laparoscopic electrocautery with monopolar needle. Ovarian surface is systematically 
perforated with a needle and the surgery is frequently combined with a test of tubal patency 
or hysteroscopy as part of a comprehensive diagnostic laparoscopy. The effect of drilling on 
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reproductive function was evaluated by a number of studies. Kong compared the effects of 
laparoscopic ovarian drilling in treating infertile polycystic ovarian syndrome in patients 
with and without metabolic syndrome. A total of 89 infertile anovulatory polycystic ovarian 
syndrome patients, who underwent laparoscopic ovarian drilling with completed metabolic 
screening and seen over a 5-year period. The main outcome measures were clinical, 
hormonal and metabolic characteristics, as well as spontaneous ovulation rates, 
reproductive outcomes, and a risk of gestational diabetes after laparoscopic ovarian drilling. 
Approximately one fifth (21%) of polycystic ovary syndrome patients had metabolic 
syndrome. There were no differences in spontaneous ovulation rates (68% vs 61%, P=0.76), 
cumulative pregnancy rates (68% vs 61%, P=0.77), and a risk of gestational diabetes (64% vs 
42%, P=0.13) between patients with and without metabolic syndrome. Laparoscopic ovarian 
drilling was equally effective in inducing ovulation in polycystic ovary syndrome patients 
with metabolic syndrome. Thus, patients with metabolic syndrome should not be excluded 
from laparoscopic ovarian drilling, which has an additional advantage of enabling 
concurrent full tubo-peritoneal assessment (Kong, 2010). 
In randomized double-blind placebo-controlled pilot study Nasr evaluated N-acetyl-
cysteine (NAC) as an adjunctive therapy following unilateral laparoscopic ovarian drilling 
(LOD) for clomiphene citrate-resistant women with polycystic ovary syndrome (PCOS). 
Patients with clomiphene citrate-resistant PCOS who underwent unilateral LOD were 
assigned randomly to receive either NAC 1.2 g/d or placebo for 5 days starting at day 3 of 
the cycle for 12 consecutive cycles. The primary outcome was pregnancy rate; secondary 
outcomes were ovulation rates, endometrial thickness and pregnancy outcome. Baseline 
clinical, endocrine, and sonographic characteristics were similar in the two groups. A 
significant increase in both ovulation and pregnancy rates was observed in the NAC group, 
compared with placebo [87% versus 67% (RR 1.3; 95% CI 1.2-2.7) and 77% versus 57% (RR 
1.4; 95% CI 1.1-2.7), respectively, P<0.01]. Moreover, miscarriage rates were significantly 
lower and live birth rates were significantly higher in the NAC group [8.7% versus 23.5% 
(RR 0.4; 95% CI 0.1-3.7) and 67% versus 40% (RR 1.7; 95% CI 0.3-3.5), respectively, P<0.01]. 
NAC, a novel adjuvant therapy to be used following unilateral LOD, might improve overall 
reproductive outcome (Nasr, 2010). 
2.1.2 Ovarian hypofunction 
The main therapeutic aim of ovarian hypofunction management is to treat fertility disorders 
and to substitute the lacking hormones. Treatment of ovarian hypofunction-related 
dysfertility by assisted reproduction methods represents a complex issue. This group of 
patients (“low responders”) typically presents with low ovarian response to stimulation of 
foliculogenesis in in vitro fertilization cycles. 
2.1.2.1 Ovarian hypofunction – pathophysiology 
When discussing causes of recurrent miscarriages, experts differ in their opinion on the role 
of luteal insufficiency, the so called implantation factor. This is when a discrepancy occurs 
between adequate endometrial secretion and high nutritional needs of the fertilized egg, 
either during its free transport through the uterus before implantation or during 
histiotrophic nutrition. This discrepancy may lead to a suppression of embryonic 
development and the pregnancy ends in miscarriage in the first trimester (Erlebacher, 2004). 
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reproductive function was evaluated by a number of studies. Kong compared the effects of 
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with and without metabolic syndrome. A total of 89 infertile anovulatory polycystic ovarian 
syndrome patients, who underwent laparoscopic ovarian drilling with completed metabolic 
screening and seen over a 5-year period. The main outcome measures were clinical, 
hormonal and metabolic characteristics, as well as spontaneous ovulation rates, 
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with metabolic syndrome. Thus, patients with metabolic syndrome should not be excluded 
from laparoscopic ovarian drilling, which has an additional advantage of enabling 
concurrent full tubo-peritoneal assessment (Kong, 2010). 
In randomized double-blind placebo-controlled pilot study Nasr evaluated N-acetyl-
cysteine (NAC) as an adjunctive therapy following unilateral laparoscopic ovarian drilling 
(LOD) for clomiphene citrate-resistant women with polycystic ovary syndrome (PCOS). 
Patients with clomiphene citrate-resistant PCOS who underwent unilateral LOD were 
assigned randomly to receive either NAC 1.2 g/d or placebo for 5 days starting at day 3 of 
the cycle for 12 consecutive cycles. The primary outcome was pregnancy rate; secondary 
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significant increase in both ovulation and pregnancy rates was observed in the NAC group, 
compared with placebo [87% versus 67% (RR 1.3; 95% CI 1.2-2.7) and 77% versus 57% (RR 
1.4; 95% CI 1.1-2.7), respectively, P<0.01]. Moreover, miscarriage rates were significantly 
lower and live birth rates were significantly higher in the NAC group [8.7% versus 23.5% 
(RR 0.4; 95% CI 0.1-3.7) and 67% versus 40% (RR 1.7; 95% CI 0.3-3.5), respectively, P<0.01]. 
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2.1.2.2 Ovarian hypofunction - diagnosis 
During a pre-conception assessment, luteal insufficiency should be considered in patients 
with very short secretory phase by basal temperature readings, recurrent severe retardation 
of secretory transformation of the endometrium by microabrasion, or a significant reduction 
in serum progesterone in the secretory phase of the menstrual cycle (Zwinger, 2004). 
2.1.2.3 Ovarian hypofunction - treatmen 
No optimal, universal and adequately effective IVF stimulation protocol can be found in the 
literature (Mardesic, 1995). In these stimulation cycles, higher doses of gonadotropic 
hormones are usually used and a lower number of oocytes are obtained. Whilst fertilization 
rate is within the norm, there is significantly lower percentage of obtained clinical 
pregnancies. With higher incidence of early pregnancy losses (mainly in women above 40 
years of age), the percentage of pregnancies ending in a delivery of a healthy foetus in 
women with reduced ovarian reserve is significantly lower than in dysfertile couples with 
other than ovarian factors of infertility. 
Stimulation protocols in this group of patients should use higher doses of rFSH (max. 300 
IU/D), in combination with GnRH antagonists (from 6th DC). Follicular phase of the cycle 
should not be prolonged because of the risk of premature ovulation and ovulation should be 
induced by an administration of 10 000 IU hCG when a minimum of 3 follicles ≥ 17mm are 
visible by UZ folliculometry. Oocytes should be withdrawn no later than 16th day of a 
menstrual cycle. Embryos obtained through prolonged cultivation and assisted hatching 
should be transferred under gestagen facilitation of luteal phase no longer than 20th DC. The 
most reliable and most successful method of achieving pregnancy in POF women is in vitro 
fertilization using a donated oocyte together with oestrogen-gestagen preparation of the 
endometrium (Hudeček, 2004). Stimulation of ovulation with gonadotropins in women with 
POF is ineffective. Centres of assisted reproduction report pregnancy rate in women with 
POF around 40 – 50% per cycle. Even though the child is genetically related to the father 
only, not to the mother, this method of infertility treatment in women with POF is generally 
acceptable, especially because the woman has a chance to carry the pregnancy to term 
herself and is able to breast feed the child (Žáková, 2006). There is about 5% chance in 
women who do not accept donated oocytes that they are able to get spontaneously pregnant 
despite the diagnosis of POF. The likelihood of this depends mainly on aetiology of POF 
(Altchek, 2003). 
There are discussions in the literature on utilization of native IVF cycles, protocols with 
minimum stimulation, including a possibility to convert a stimulation cycle into intrauterine 
insemination (Shahine, 2009, Schimberni, 2009). Even though these techniques of assisted 
reproduction show significantly lower efficacy, they may be considered as a treatment 
option in individual specific cases. 
A long-term hormonal therapy leading to pseudopregnancy followed by an administration 
of gestagens during a subsequent pregnancy (usually during the first trimester) is indicated 
in patients with luteal insufficiency. Decrease in estrogen receptors as progesterone receptor 
promoters can be modulated by the means of gestagen substitution (supra-physiological 
doses of progesterone – 150 mg per day) (Hudeček, 2004). 
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2.2 Gynaecology-unrelated endocrinopathies 
2.2.1 Thyrotoxicosis 
Thyrotoxicosis (hyperthyreosis) is a clinical syndrome caused by an overproduction of 
thyroid hormones. The main signs and symptoms of thyrotoxicosis result from 
hypermetabolism due to intensified oxidative processes in the body caused by excessive 
concentrations of these hormones. Graves-Basedow disease is the most frequent form of 
hyperthyreosis (60-85% of thyrotoxicoses) with a production of anti-thyroid peroxidase 
autoantibodies and anti-thyrotropin receptor antibodies. Approximately 10 – 30% of 
hyperthyreoses involve toxic multinodular goitre with autoimmune production of thyroid 
hormones (T3, T4). Inflammations also frequently cause hyperthyreosis by provoking T3 
and T4 secretion (Ďuriš, 2001). 
Clinical signs of thyrotoxicosis include nervousness, hand tremor, weight loss with 
increased appetite, palpitations, heat intolerance and hyperhidrosis. Other subjective 
symptoms include emotional lability, muscle weakness and diarrhoea. 
Objective symptoms include tachycardia or atrial fibrillation, high pulse pressure (the 
difference between systolic and diastolic pressure), precordial pulsation, and accentuated 
first sound above the apex of the heart. Gynaecological symptoms include polymenorrhoea, 
metrorrhagia, sometimes amenorrhoea or sterility. Warm, soft skin, goitre and increased 
psychomotor reactivity or restlessness may all contribute to the complete clinical picture of 
hyperthyreosis. 
2.2.1.1 Pathophysiology of thyrotoxicosis 
Hyperthyreosis might be accompanied by an increased level of gonadotropins, SHBG, 
estrogens and androgens (although the free fraction of these steroids is lowered due to the 
increased SHBG levels). A change to the concentration of free steroids and direct effect of 
thyroid hormones frequently causes anovulation and luteal insufficiency. Hyperthyreosis 
might be associated with polymenorrhoea and metrorrhagia as well as amenorrhoea and 
sterility. Some studies have shown that the autoimmune thyroiditis (AT) itself, without 
obvious or subclinical thyroid gland dysfunction, diagnosed before conception, is associated 
with infertility, recurring miscarriages and more frequent failure of assisted reproduction 
methods (Stagnaro-Green , 2004, Poppe 2003). 
One theory uses immunological mechanisms to explain the association between infertility 
and AT without thyroid gland dysfunction (Poppe, 2003). Some published papers identified 
concurrent occurrence of anti-thyroid and anti-ovarian antibodies; this may contribute to 
explain the association between AT and ovarian dysfunction (Sterlz, 1997). However, cell 
immunity is more likely to be responsible for recurring miscarriages. According to this 
theory, AT is one of the symptoms of a systemic autoimmune disease and represents an 
indicator of an alteration of the woman’s immune system responsible for recurring 
miscarriages. Elevated levels of CD 5/20 lymphocytes identified in women with AT and an 
increased risk of miscarriage supports this theory (Roberts, 1996). 
2.2.1.2 Diagnosis of thyrotoxicosis  
Thyrotoxicosis is diagnosed from the patient’s medical history and an assessment of the 
clinical picture and laboratory parameters. Thyrotoxicosis is characterised by decreased and 
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2.2 Gynaecology-unrelated endocrinopathies 
2.2.1 Thyrotoxicosis 
Thyrotoxicosis (hyperthyreosis) is a clinical syndrome caused by an overproduction of 
thyroid hormones. The main signs and symptoms of thyrotoxicosis result from 
hypermetabolism due to intensified oxidative processes in the body caused by excessive 
concentrations of these hormones. Graves-Basedow disease is the most frequent form of 
hyperthyreosis (60-85% of thyrotoxicoses) with a production of anti-thyroid peroxidase 
autoantibodies and anti-thyrotropin receptor antibodies. Approximately 10 – 30% of 
hyperthyreoses involve toxic multinodular goitre with autoimmune production of thyroid 
hormones (T3, T4). Inflammations also frequently cause hyperthyreosis by provoking T3 
and T4 secretion (Ďuriš, 2001). 
Clinical signs of thyrotoxicosis include nervousness, hand tremor, weight loss with 
increased appetite, palpitations, heat intolerance and hyperhidrosis. Other subjective 
symptoms include emotional lability, muscle weakness and diarrhoea. 
Objective symptoms include tachycardia or atrial fibrillation, high pulse pressure (the 
difference between systolic and diastolic pressure), precordial pulsation, and accentuated 
first sound above the apex of the heart. Gynaecological symptoms include polymenorrhoea, 
metrorrhagia, sometimes amenorrhoea or sterility. Warm, soft skin, goitre and increased 
psychomotor reactivity or restlessness may all contribute to the complete clinical picture of 
hyperthyreosis. 
2.2.1.1 Pathophysiology of thyrotoxicosis 
Hyperthyreosis might be accompanied by an increased level of gonadotropins, SHBG, 
estrogens and androgens (although the free fraction of these steroids is lowered due to the 
increased SHBG levels). A change to the concentration of free steroids and direct effect of 
thyroid hormones frequently causes anovulation and luteal insufficiency. Hyperthyreosis 
might be associated with polymenorrhoea and metrorrhagia as well as amenorrhoea and 
sterility. Some studies have shown that the autoimmune thyroiditis (AT) itself, without 
obvious or subclinical thyroid gland dysfunction, diagnosed before conception, is associated 
with infertility, recurring miscarriages and more frequent failure of assisted reproduction 
methods (Stagnaro-Green , 2004, Poppe 2003). 
One theory uses immunological mechanisms to explain the association between infertility 
and AT without thyroid gland dysfunction (Poppe, 2003). Some published papers identified 
concurrent occurrence of anti-thyroid and anti-ovarian antibodies; this may contribute to 
explain the association between AT and ovarian dysfunction (Sterlz, 1997). However, cell 
immunity is more likely to be responsible for recurring miscarriages. According to this 
theory, AT is one of the symptoms of a systemic autoimmune disease and represents an 
indicator of an alteration of the woman’s immune system responsible for recurring 
miscarriages. Elevated levels of CD 5/20 lymphocytes identified in women with AT and an 
increased risk of miscarriage supports this theory (Roberts, 1996). 
2.2.1.2 Diagnosis of thyrotoxicosis  
Thyrotoxicosis is diagnosed from the patient’s medical history and an assessment of the 
clinical picture and laboratory parameters. Thyrotoxicosis is characterised by decreased and 
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even undetectable TSH level and hyperthyroxinemia. TSH levels above 0.1 mU/L exclude a 
significant form of thyrotoxicosis. An optimal way of treatment should be decided from 
serum autoantibody levels (anti-thyroid peroxidase autoantibodies, anti-thyrotropin 
receptor antibodies). Imaging methods and gammagraphy of the thyroid gland are also 
important (Ďuriš, 2001). 
2.2.1.3 Treatment of thyrotoxicosis 
Treatment of hyperthyreosis includes lifestyle changes (regular, substantial food intake, 
avoiding extreme temperatures and excessive physical activity), thyreostatic treatment, 
subtotal strumectomy and treatment with radioiodine. Pharmacological thyreostatic 
treatment suppresses the overproduction of thyroid hormones by the thyroid gland. The 
thiouracil derivatives and carbimazole represent the first line treatment. A surgical 
treatment, subtotal strumectomy, can be applied when remission was achieved using a 
thyrostatic agent (florid thyrotoxicosis is a contraindication to any surgery as the patient is 
at risk of developing thyrotoxic crisis). An administration of a therapeutic dose of 
radioiodine is indicated when thyrotoxicosis is a co-morbidity to cardiopathy and when 
thyrotoxicosis recurred following strumectomy (Ďuriš, 2001). 
2.2.2 Hypothyreosis 
Hypothyreosis is a disorder characterized by decreased thyroid hormone levels. The 
prevalence of hypothyreosis in the population is about 5-8%, higher in women than men 
(8:1) and increases with age. Hypothyreosis should always be thought of in older women 
(prevalence 15 – 20%), not only if the patient presents with specific symptoms but also if 
they report general complaints such as fatigue, depression and myalgia. Autoimmune 
thyroid gland disease as well as, understandably, post-thyroidectomy states or treatment 
with radioiodine are among the most frequent causes. The clinical picture is diverse and 
includes fatigue, inefficiency, somnolence, depression, poor cold tolerance, weight gain, 
feeling of pressure on the neck (may also occur if the thyroid gland is not enlarged during 
AIT), dry skin, myalgia and arthralgia. 
The thyroid gland may be enlarged, nodular as well as reduced, thinking and motor 
functions are slowed down, hypomimia, oedema of the face, eye lid oedema, macroglosy, 
deep voice. Anaemia is usually normochromic, pernicious in about 10% of cases and 
associated with autoimmunity, gynaecological symptoms include menstrual cycle disorders, 
menorrhagia, infertility and galactorrhoea (Brunová, 2008). 
2.2.2.1 Pathophysiology of hypothyreosis 
Hypothyreosis is one of the most important endocrine primarily non-gyneacological 
endocrinopaties that affect female fertility. Untreated hypothyreosis reduces fertility, 
increases the incidence of spontaneous abortions and increases the incidence of premature 
deliveries (Ďuriš, 2001). Manifest hypothyreosis is frequently linked to anovulation, 
oligomenorrhoea or amenorrhoea and infertility. Thyroid hormones directly impact on the 
correct function of oocytes, lutein cells and granulosa cells. In addition, hypothyreosis is 
associated with a reduction of gonadotropins (particularly the luteinizing hormone) and 
with an increase in prolactin levels; this results in a decreased production of ovarian 
steroids. Reduced levels of thyroid hormones result in their reduced production and, 
consequently, the sex hormone binding globulin (SHBG) levels also decline, the level of free 
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testosterone increases as does peripheral aromatization of androstendione to estrone 
(Krassas, 2000). Thyroid hormones are very important for intrauterine foetal development, 
particularly for the development of the brain and for the development of the hypothalamic-
pituitary-thyroid axis. Gravidity represents a period when an increased production of 
thyroid hormones is required. The foetus depends completely on the mother during the first 
trimester, and the contribution of the mother to foetal hormonal levels remains significant 
throughout (maternal productions after birth represent about 30% of thyroxin in the 
umbilical cord blood) and its importance increases during foetal thyreopathies and 
insufficient production of thyroid hormones by the foetus. Total production of thyroid 
hormones in gravidity increases by about 25 – 30% (Karásek, 2007). A tendency to 
subclinical hypothyreosis during pregnancy was observed in a significant proportion of 
women with normal free thyroxin and TSH levels. The impact of subclinical or even 
manifest hypothyreosis during pregnancy on recurrent miscarriages is evidenced by the 
time when miscarriages occur - usually during the first trimester when the foetus is 
completely dependent on its mother’s production of thyroid hormones (Poppe, 2003). 
2.2.2.2 Diagnosis of hypothyreosis 
Primary hypothyreosis by increased TSH levels and reduced free T3 and free T4 levels, 
central hypothyreosis is then characterized by decreased or normal (i.e. not adequately 
increased) TSH levels (Brunová, 2008). 
2.2.2.3 Treatment of hypothyreosis 
Treatment of hypothyreosis is initiated with small doses of 25 μg/day and sometimes just 12.5 
μg/day of thyroxin. The dose is increased every 7 – 14 days to the expected maintenance dose. 
The dose is reduced again if the patient poorly tolerates the treatment, i.e. suffers from 
palpitations, angina pectoris or has signs of heart failure. The demand for thyroid hormone 
secretion increases during pregnancy and thus thyroxin dose in mothers previously treated for 
hypothyreosis should be increased during pregnancy by 30% or even 50% (Brunová, 2008). 
2.2.3 Diabetes mellitus 
Diabetes mellitus is a group of metabolic diseases characterized by chronic hyperglycaemia 
developing as a result of insulin secretion disorder or as an effect of insulin or a combination 
of these factors. The main symptom is hyperglycaemia. From biochemical perspective, 
diabetes influences metabolism of carbohydrates, lipids and proteins. Clinically, it is 
responsible for the development of microvascular and macrovascular complications 
associated with organ specific degenerative processes and leading to neuropathic 
complications (diabetic ketoacidosis, cardiovascular complications, diabetic retinopathy, 
neuropathy, nephropathy), (Ďuriš, 2001). 
Classification of diabetes mellitus: 
a. Diabetes mellitus 
1. Type 1 diabetes mellitus - insulin-dependent 
2. Type 2 diabetes mellitus - non-insulin-dependent 
3. Malnutrition-related diabetes mellitus 
4. Other specific types (secondary) of diabetes mellitus – hyperglycaemia associated 
with another cause (e.g. pancreatic disease, endocrinopathy). 
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testosterone increases as does peripheral aromatization of androstendione to estrone 
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pituitary-thyroid axis. Gravidity represents a period when an increased production of 
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throughout (maternal productions after birth represent about 30% of thyroxin in the 
umbilical cord blood) and its importance increases during foetal thyreopathies and 
insufficient production of thyroid hormones by the foetus. Total production of thyroid 
hormones in gravidity increases by about 25 – 30% (Karásek, 2007). A tendency to 
subclinical hypothyreosis during pregnancy was observed in a significant proportion of 
women with normal free thyroxin and TSH levels. The impact of subclinical or even 
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palpitations, angina pectoris or has signs of heart failure. The demand for thyroid hormone 
secretion increases during pregnancy and thus thyroxin dose in mothers previously treated for 
hypothyreosis should be increased during pregnancy by 30% or even 50% (Brunová, 2008). 
2.2.3 Diabetes mellitus 
Diabetes mellitus is a group of metabolic diseases characterized by chronic hyperglycaemia 
developing as a result of insulin secretion disorder or as an effect of insulin or a combination 
of these factors. The main symptom is hyperglycaemia. From biochemical perspective, 
diabetes influences metabolism of carbohydrates, lipids and proteins. Clinically, it is 
responsible for the development of microvascular and macrovascular complications 
associated with organ specific degenerative processes and leading to neuropathic 
complications (diabetic ketoacidosis, cardiovascular complications, diabetic retinopathy, 
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b. Impaired glucose tolerance 
c. Gestational diabetes mellitus 
2.2.3.1 Pathophysiology of diabetes mellitus 
Diabetic female patients are more frequently diagnosed with an ovulatory disorder 
leading to infertility. A comparison of hormonal profile of diabetic patients suffering from 
amenorrhoea and women with regular menses suggests different pathophysiological 
mechanisms, specifically the presence of hyperandrogenism. The effects of 
hyperinsulinaemia are particularly important. Hyperinsulinaemia stimulates 
androgenesis in the ovaries. This stimulation is via IGF receptors found in the ovaries 
present in sufficient amount. This is either a traditional example of the linkage between 
insulin and steroidogenesis or a hyperreactivity of ovarian receptors for a different reason 
(Svačina, 1997). According to this theory, changes to pituitary hormones might be 
secondary, determined by higher level of androgens. Defect of serine phosphorylation 
with a common manifestation on peripheral insulin receptors, ovaries and adrenal glands 
represents another significant theory. A slight increase in total testosterone and 
androstendione levels occur despite concurrent increase in catabolism of androgens. 
Under normal circumstances, around 66% of the circulating testosterone is bound to the 
sex-hormone-binding globulin (SHBG). When fasting (e.g. anorexia), SHBG concentration 
increases. On the contrary, SHBG level decreases with increasing BMI, mainly in android 
obesity and polycystic ovary syndrome (particularly if associated with obesity) and in 
association with diabetes mellitus; this further increases android hormone concentrations. 
Hyperinsulinism that is associated with this disease, is one of the possible explanations. 
Experimental in vitro studies show that insulin has an inhibitory effect on SHBG synthesis 
in the liver (Cogswel, 2001). 
Hyperinsulinaemia is diagnosed in as many as 27% of women with a history of habitual 
abortion (Carrington, 2005) Hyperinsulinaemia influences endometrial functions by 
reducing the levels of the two main endometrial hormones, glycodelin and IGFBP (insulin-
like growth factor binding protein). Hyperinsulinaemia is diagnosed in 40–50% of women 
with the polycystic ovary syndrome (Kauffman, 2003). 
Spontaneous abortion is seen more often in women with decompensated diabetes mellitus 
(DM) during early pregnancy. It is more frequent in poorly compensated type 1 DM 
patients, although it is sometimes diagnosed in patients with type 2 DM that had not been 
diagnosed prior to their pregnancy. Pregnancy is considered a diabetogenic state and the 
onset of gestational diabetes mellitus is associated with an increased insulin resistance 
(Hájek, 2004).  
Decompensated type 1 diabetic females suffer more frequently from spontaneous abortions 
(even repeatedly), particularly as a consequence of higher incidence of diabetic 
embryopathy DE (2-3x more frequent in diabetics in comparison to healthy population). 
Diabetic embryopathy is a congenital developmental defect or a malformation of the foetus 
not compatible with life. Etiopathogenesis of DE has not been elucidated yet. Clinical and 
experimental knowledge confirm that hyperglycaemia is the main metabolic teratogen. 
Direct link between HbA1c level at the beginning of pregnancy and the incidence of diabetic 
embryopathy has been confirmed (Ďuriš, 2001). 
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2.2.3.2 Diagnosis of diabetes mellitus 
Diagnosis of diabetes mellitus is made from patient’s urine glucose levels and blood testing 
with oral Glucose Tolerance Testing (oGTT). Prior to conception, current metabolic 
compensation – glycaemic profile, glycosylated haemoglobin (HbA1C) and diabetic 
complications assessment – is reviewed. Pregnancy is not recommended in women with 
severe diabetic organ complications (Hájek, 2004) 
2.2.3.3 Treatment of diabetes mellitus 
Treatment should focus on supplementing or inhibiting the effects of the relevant hormones 
and careful diabetes mellitus control (dietary regimen, insulinotherapy). 
Classification of DM therapies: 
1. Non-pharmacological therapy 
 Patient education 
 Diet 
 Physical activity 
2. Pharmacological treatment 
 Insulin (in insulin-dependent type 1 DM and always during pregnancy with any 
type of diabetes) 
 Oral antidiabetics (non-insulin dependent type 2 DM) 
Treatment should be comprehensive, managed by an experienced diabetologist (Ďuriš, 
2001). Prescribing metformin, an insulin sensitizer, in women with PCOS represents 
therapeutic application of an agent with promising effects in the area of anovulation sterility 
and dysfertility (Višňová, 2003). 
2.2.4 Hyperprolactinaemia 
Prolactin is a polypeptide hormone synthesised by lactotropic cells of the anterior pituitary. 
The main effect of this hormone is ensuring adequate postpartum lactation. In collaboration 
with other hormones, prolactin influences the growth of mammary glands during pregnancy. 
Prolactin levels in women who do not breast feed decline quickly within two weeks after birth 
and ovulation is likely to restart within 10 weeks. Hyperprolactinaemia is a disease with a 
pathological increase in prolactin levels out of postpartum period (Ďuriš, 2001). 
2.2.4.1 Pathophysiology of hyperprolactinaemia 
Excessive prolactin levels reduce the effects of hypothalamic GnRH and thus normal pulsate 
secretion of luteinizing hormone and follicle-stimulating hormone. Elevated prolactin levels 
also have a negative effect on luteinizing hormone increase in the middle of a menstrual 
cycle (peak LH). Basal levels of gonadotropins are within the norm. Lack of pulsate 
gonadotropin secretion leads to the functional hypogonadism with anovulation. 
Anovulation cycles are clinically manifested as oligomenorrhoea or amenorrhoea with 
subsequent reduction in fertility. The clinical picture typically also includes galactorrhoea, 
symptoms of estrogen insufficiency (reduced vaginal secretion, osteoporosis), mood swings 
and hirsutism. Hyperprolactinaemia is found in women with chronic renal insufficiency, 
with liver cirrhosis and those using certain drugs (psychotropics, antiemetics, 
antihypertensives, H1 and H2 receptor antagonists). It is found in patients with 
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hypothalamic disease (cranial and nasopharyngeal irradiation), pituitary disease (tumours – 
prolactinoma, metastases, meningioma), with primary hypothyreosis or it may be idiopathic 
(Ďuriš, 2001). 
2.2.4.2 Diagnosis of hyperprolactinaemia 
The diagnosis of hyperprolactinaemia is made from rigorous medical history, detailed 
clinical assessment and blood prolactin levels. Prolactin levels above 16 ng/mL are 
considered as hyperprolactinaemia. Levels exceeding 200 ng/mL suggest prolactinoma, 200 
- 500 ng/mL is pathognomonic for prolactinoma and the levels exceeding 1000 ng/mL 
evidence an invasive tumour expanding to sinus cavernosum. Levels below 100 ng/mL are 
usually not a symptom of a pituitary tumour (Ďuriš, 2001). 
2.2.4.3 Treatment of hyperprolactinaemia 
Treatment of hyperprolactinaemia is determined by the primary cause. Surgery, specifically 
the transsphenoidal hypophysectomy (transcranial approach is required when large 
macroprolactinomas are treated), is the method of choice for diagnosed microprolactinomas 
and macroprolactinomas. Radiation therapy is a complementary method in patients with 
incurable microprolactinomas. Pharmacological treatment is used in patients with 
hyperprolactinaemia caused by hypothalamo-pituitary dysfunction or in those with 
idiopathic hyperprolactinaemia. Pharmacological agents used include dopamine agonists 
that normalize prolactin secretion in about 85 – 90% of patients and reduce the tumour in 
about 50%. The most frequently used agents include ergoline derivatives bromocryptine, 
lisuride and terguride (Ďuriš, 2001). 
3. Conclusion 
A comprehensive and interdisciplinary approach is required to diagnose the causes of 
habitual miscarriage in a woman. The use of simple and widely available assessment 
methods in the basic differential diagnosis algorithm is preferred. If these do not provide a 
clear identification of aetiology of infertility, it is suitable to use more specific and 
technically demanding techniques. Adequate differential diagnosis enables determination of 
likely aetiology and a use of an appropriately targeted therapy.  
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1. Introduction 
Polycystic ovary syndrome (PCOS) is an endocrine and metabolic heterogeneous disorder, 
with a likely genetic origin, influenced by environmental factors such as nutrition and 
physical activity. The main clinical features of PCOS are related to hyperandrogenism, such 
as hirsutism, acne and menstrual disorders (Moran et al., 1994; Azziz, et al., 2004; Carmina 
et al., 2006). PCOS is also associated with overweight or obesity (Azziz, et al., 2004), mainly 
abdominal adiposity (Moran et al., 1999). The etiology of PCOS is unknown. The genetic 
origin is based on the observation that PCOS is more frequent among the sisters and 
mothers of these patients (Lunde et al., 1989; Govind et al., 1999). Moreover, in a study done 
with twins, a higher correlation in the presence of PCOS is observed more in monozygotic 
than in dizygotic (Vink et al., 2006). Multiple genes related to the production of androgen, 
the function of the gonadotropin, the action of insulin and the regulation of energy have 
been evaluated. Although associations of some genes with clinical disorders of PCOS have 
been found, in specific regions and determined polymorphisms, the findings of studies and 
in different populations have not been consistent (Wood et al., 2003).  
The hypothesis of the origin of PCOS by environmental factors is based on the beneficial 
results observed by weight loss, and the worsening with increasing weight in these patients. 
The interaction of environmental factors of PCOS in women affected starts from their 
prenatal and postnatal life (Abbott et al., 2002). Food habits and lifestyle are also factors in 
the presentation and the development of PCOS. The influence of the environmental 
component of PCOS and its interaction with the genetic component has been less studied. 
Obesity plays an important role in the pathogenesis of PCOS, and the majority of patients 
with PCOS are overweight or obese; however, these disorders are not considered as 
diagnostic criteria for PCOS, since not all obese women present hyperandrogenism.  
2. Diagnosis 
The major criteria of PCOS, proposed in the consensus of the National Institutes of Health in 
Bethesda, M.D., were (in order of importance): a) hyperandrogenism and/or 
hyperandrogenemia, b) oligoovulation, c) exclusion of other known disorders, and d) possibly 
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1. Introduction 
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physical activity. The main clinical features of PCOS are related to hyperandrogenism, such 
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origin is based on the observation that PCOS is more frequent among the sisters and 
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with twins, a higher correlation in the presence of PCOS is observed more in monozygotic 
than in dizygotic (Vink et al., 2006). Multiple genes related to the production of androgen, 
the function of the gonadotropin, the action of insulin and the regulation of energy have 
been evaluated. Although associations of some genes with clinical disorders of PCOS have 
been found, in specific regions and determined polymorphisms, the findings of studies and 
in different populations have not been consistent (Wood et al., 2003).  
The hypothesis of the origin of PCOS by environmental factors is based on the beneficial 
results observed by weight loss, and the worsening with increasing weight in these patients. 
The interaction of environmental factors of PCOS in women affected starts from their 
prenatal and postnatal life (Abbott et al., 2002). Food habits and lifestyle are also factors in 
the presentation and the development of PCOS. The influence of the environmental 
component of PCOS and its interaction with the genetic component has been less studied. 
Obesity plays an important role in the pathogenesis of PCOS, and the majority of patients 
with PCOS are overweight or obese; however, these disorders are not considered as 
diagnostic criteria for PCOS, since not all obese women present hyperandrogenism.  
2. Diagnosis 
The major criteria of PCOS, proposed in the consensus of the National Institutes of Health in 
Bethesda, M.D., were (in order of importance): a) hyperandrogenism and/or 
hyperandrogenemia, b) oligoovulation, c) exclusion of other known disorders, and d) possibly 
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the characteristic morphology of polycystic ovaries on ultrasound (Zawadzki & Dunaif, 1992). 
At the Rotterdam consensus, the presence of two out of the three following criteria was 
considered as diagnostic for PCOS: a) oligoovulation or anovulation, b) clinical and/or 
biochemical signs of hyperandrogenism, and c) polycystic ovaries by ultrasound, after 
exclusion of other related disturbances (ESHRE/ASRM-Sponsored PCOS Consensus, 2004). 
The Androgen Excess and PCOS Society considers as PCOS: hyperandrogenism (hirsutism 
and/or hyperandrogenemia), ovarian dysfunction (oligo-anovulation and/or polycystic 
ovaries), and the exclusion of other androgen excess or related disorders (Azziz, et al., 2006). 
3. Phenotypes 
Overweight and obesity are not considered for PCOS phenotypes (Azziz, et al., 2006). 
Phenotypes of PCOS patients can be classified as follows: A) hyperandrogenism, oligo-
anovulation and polycystic ovaries by ultrasound; B) hyperandrogenism and oligo-
anovulation (and normal appearance of the ovaries by ultrasound); C) hyperandrogenism and 
polycystic ovaries by ultrasound (with regular ovulatory menstrual cycles); and D) oligo-
anovulation and polycystic ovaries by ultrasound (without hyperandrogenism). The National 
Institutes of Health criteria recognizes A and B phenotypes. The Rotterdam ESHRE/ASRM-
Sponsored PCOS Consensus Workshop Group accepts all these phenotypes. The AE-PCOS 
Society admits A, B and C phenotypes (Table 1). However, each one of the phenotypes can be 
subdivided considering the presence of obesity, when body mass index is (BMI) ≥ 27.  
 
Table 1. Phenotype classification in 172 patients with polycystic ovary syndrome taking into 
account obesity (body mass index ≥ 27) to subdivide each group. The frequencies of 
different phenotypes are unpublished data yet, Moran C, 2011.  
4. Prevalence of PCOS and/or obesity 
Polycystic ovary syndrome (PCOS) affects 4-7% of women in reproductive age 
(Knochenhauer et al., 1998; Diamanti-Kandarakis et al., 1999; Asuncion et al., 2000; Moran et 
al., 2010). It is considered one of the most frequent endocrine disorders in women of 
reproductive age (Moran et al., 2010). It is noteworthy that PCOS affects 60-80% of the 
patients with hyperandrogenism (Table 2) (Moran et al., 1994; Azziz et al., 2004, Carmina et 
al., 2006). Overweight or obesity affects approximately 60-80% of PCOS patients (Azziz et 
al., 2004).  
 




Table 2. Classification of hyperandrogenism in women. PCOS: polycystic ovary syndrome, 
CAH: Congenital adrenal hyperplasia, HAIRAN: Hyperandrogenisim, insulin resistance 
and acanthosis nigricans. *Hyperandrogenic overweight or obese patients with regular 
menstrual cycles. Taken from 1Moran et al., Archives of Medical Research, 1994; 2Azziz et al., 
The Journal of Clinical Endocrinology & Metabolism, 2004; 3Carmina et al., The Journal of Clinical 
Endocrinology & Metabolism, 2006.  
5. Clinical presentation in obese and nonobese PCOS patients 
It has been reported that obese PCOS patients have a greater prevalence of some clinical 
manifestations, such as hirsutism and menstrual disorders (Kiddy et al., 1990); however, other 
studies have not found differences (Singh et al., 1994). The discrepancies between these studies 
may be the result of different diagnostic criteria used to classify obesity and PCOS. 
6. Role of obesity in the pathophysiology of PCOS  
6.1 Gonadotropic dysfunction 
The main pathophysiological components of PCOS are gonadotropic dysfunction and 
insulin resistance (Dale et al., 1992; Fulghesu et al., 1999; Moran et al., 2003). It has been 
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the characteristic morphology of polycystic ovaries on ultrasound (Zawadzki & Dunaif, 1992). 
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of carbohydrate intolerance and type 2 diabetes mellitus (Legro et al., 1999; Ehrmann et al., 
1999). Insulin resistance appears in women with PCOS with suitable weight (Chang et al., 
1983), and overweight or obesity (Moran et al., 2003), but is more frequent and of greater 
magnitude when there is obesity (Dunaif et al., 1989; Moran et al., 2003). The insulin 
resistance is approximately two-fold that of non obese PCOS patients (Table 3) (Moran et al., 
2003). The magnitude of overweight and obesity is directly related to insulin resistance in 
PCOS patients (Figure 1) (Moran et al., 2003). 
 
Table 3. Frequency of pathophysiologic components of polycystic ovary syndrome (PCOS). 
All the determinations were performed in one sample in fasting conditions. *Statistically 
significant difference (P< 0.01). From Moran et al, Fertility and Sterility, 2003. 
 
Fig. 1. Relationship between body mass and insulin resistance in patients with polycystic 
ovary syndrome. Modified from Moran et al, Fertility and Sterility, 2003. 
6.3 Body fat distribution  
Obesity is associated mainly to abdominal adiposity in PCOS patients (Moran et al., 2003). It 
is important to recognize the presence of obesity and its upper body distribution or 
abdominal adiposity, which changes in accordance to race and geographical distribution 
(ESHRE/ASRM-Sponsored PCOS Consensus, 2004). The upper body adiposity is related to 
insulin resistance in PCOS patients (Figure 2) (Moran et al., 2003). To this matter, upper 
body adiposity has been found to be associated with a higher percentage of anovulation in 
comparison to lower body adiposity (83% vs. 65%, respectively) (Moran et al., 1999). 
 




Fig. 2. Relationship between body fat distribution and insulin resistance in patients with 
polycystic ovary syndrome. Modified from Moran et al, Fertility and Sterility, 2003. 
6.4 Ovarian morphology of polycystic ovaries 
There is some evidence indicating the relationship of anthropometric and hormonal 
measures with the characteristic polycystic ovarian morphology. On analyzing the 
anthropometric variables of PCOS patients, BMI is significantly greater in PCOS patients 
with a characteristic polycystic ovary image than in those without it; also, it has been found 
that the hip perimeter is significantly greater in PCOS patients with characteristic image of 
polycystic ovary than in those without this ultrasonographic morphology (Tena et al., 2011). 
In addition, PCOS patients with the polycystic ovarian morphology by ultrasound present 
greater levels of testosterone than patients without it.  
6.5 Adipocytokines  
Patients with PCOS-in comparison to control women–present lower serum levels of 
adiponectin but not of leptin. A decrease was observed in the expression of the ribonucleic 
acid (RNA) messenger of adiponectin in the subcutaneous and visceral adipose tissue, while 
that of leptin has been found significantly less only in the subcutaneous adipose tissue. Also, 
it has been observed an inverse relationship among adiponectin and leptin expression and 
the measurement of subcutaneous and visceral adipose tissue by ultrasound (Carmina et al., 
2008). Other authors have reported that obese PCOS but not normal weight PCOS patients 
have significantly lower adiponectin levels than control women (Olszanecka-Glinianowicz 
et al., 2011).  
6.6 Metabolic syndrome 
The prevalence of metabolic syndrome is higher in PCOS patients than in control women (47% 
vs. 4%, respectively) (Dokras et al., 2005). Free fatty acids, total cholesterol and low density 
lipoprotein cholesterol are higher in obese PCOS patients than in non obese PCOS patients 
(Holte et al., 1994). Both PCOS and obesity are associated with dyslipidemia and endothelial 
dysfunction that increase the cardiovascular risk. Although metabolic disorders prevail in the 
climacteric period, the risk of metabolic syndrome is high even at reproductive age.  
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Both PCOS and obesity induce an increase in serum inflammatory cardiovascular risk 
markers (Samy et al., 2009). Increased C-reactive protein, interleukin-6 and tumor necrosis 
factor alpha have been reported in obese PCOS patients with respect to control women; in 
addition, these markers have correlated with BMI and insulin resistance (Samy et al., 2009). 
Fatty liver has been reported present until 40% of PCOS patients associated to higher BMI, 
abdominal obesity and worse lipid profile (Ma et al., 2011). The pathogenetic relation among 
PCOS, obesity, metabolic and cardiovascular disease is controversial. A low-grade chronic 
inflammation has been proposed as the potential cause of the long-term complications of 
PCOS (Repaci et al., 2011).  
7. Androgen production in obese and non obese PCOS patients 
In normal women, androstenedione and testosterone are produced mainly in the ovaries, 
while dehydroepiandrosterone and dehydroepiandrosterone sulfate are secreted 
predominantly in the adrenals (Parker, 2006). The ovaries produce approximately 50% of 
testosterone and androstenedione while the adrenals 70% of dehydroepiandrosterone and 
almost all dehydroepiandrosterone sulfate (Longcope, 1986). Dehydroepiandrosterone is the 
main precursor of androgens and estrogens, and it is sulfated by the enzyme SULT2A1 in 
adrenals (Miller et al., 2006).  
Controversy exists about the effect of obesity on serum androgen concentrations in PCOS. 
Some investigators have reported that testosterone and androstenedione levels are similar in 
obese and non obese PCOS patients (Dale et al., 1992; Dos Reis et al., 1995). However, it is 
well known that obesity generates a decrease in the sexual hormone-binding globulin 
(SHBG), and therefore an increase in the free androgens (Kiddy et al., 1990; Holte et al., 
1994). Other studies have found that obesity generates an increase of testosterone levels in 
PCOS patients (Figure 3) (Holte et al., 1994; Acien et al., 1999, Moran et al., 2008). In contrast, 
dynamic studies have shown a decrease in androstenedione levels in obese PCOS patients 
(Dunaif et al., 1988; Moran et al., 2008). 
Hyperandrogenism may be of ovarian or adrenal origin (Rosenfield et al., 1972). 
Participation in PCOS by the increment of dehydroepiandrosterone sulfate is found in 22-
25% of PCOS patients (Moran et al., 1999). However, some studies have found frequencies 
of hyperandrogenism due to dehydroepiandrosterone sulfate of 48-52% in different 
populations (Carmina et al., 1992). Hyperandrogenic patients with higher adrenal androgen 
excess have been informed to be leaner, younger and present more hirsutism than patients 
with lower levels of these steroids (Moran et al., 1999).  
8. Obesity in pregnant PCOS patients 
Due to obesity and PCOS determine independently a deleterious effect on pregnancy and 
reproductive outcome, their impact of both conditions together are expectedly adverse in 
pregnant women and their fetuses. Obese patients with PCOS are characterized by a more 
severe hyperandrogenic and metabolic state, more irregular menses, less ovulatory cycles 
and lower pregnancy rates, compared with normal weight PCOS patients; the importance of 
obesity in the pathogenesis of PCOS is evidenced by the efficacy of weight loss to improve 
metabolic alterations, to decrease hyperandrogenism, to increase ovulatory menstrual cycles 
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and to improve fertility (Pasquali et al., 2006). The information with respect to the impact of 
obesity in hormonal and metabolic factors during intrauterine life is scarce yet.  
 
Fig. 3. Values of total testosterone and androstenedione in obese and nonobese patients with 
PCOS and in control women. Box-and-whiskers plots of basal levels of androgens. The line 
within each box represents the median. Upper and lower boundaries of each box indicate 
75th and 25th percentiles, respectively. The whiskers (above and below) show the upper and 
lower adjacent values, respectively. The levels of testosterone were significantly greater in 
the obese patients with PCOS compared with non obese PCOS patients and controls. Also, 
the testosterone levels were significantly greater in non obese PCOS patients than in control 
women. There were no significant differences in the levels of androstenedione. Modified 
from Moran et al, Fertility and Sterility, 2008. 
9. Treatment of obesity and metabolic abnormalities in PCOS patients 
The current management of PCOS has to attend to the clinical, hormonal and metabolic 
abnormalities. The change in PCOS concept of the treatment is that it is not considered only 
a reproductive problem but also an endocrine and metabolic disorder that requires a long 
term follow-up. Furthermore, the treatment must address specific problems that affect 
PCOS patients, such as hirsutism, acne, overweight or obesity, menstrual disorders and 
infertility (Moran et al., 1994; Azziz et al., 2004, Carmina et al., 2006).  
9.1 Modifications in life style 
Weight loss is the principal recommendation as the first line of treatment in obese women 
with PCOS. The treatment of obesity in PCOS must include nutritional counselling in food 
habits and lifestyle (Kiddy et al., 1992; L.J. Moran et al., 2003). The weight loss partially 
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ameliorates hirsutism (Pasquali et al., 1989; Kiddy et al., 1992), regularizes menstrual cycles 
and ovulation, as well as improves the endocrine and metabolic abnormalities (Pasquali et 
al., 1989; Kiddy et al., 1992; Guzick et al., 1994; Holte et al., 1995).  
9.1.1 Food habit 
There is a known beneficial effect of the decrease of body weight and a worsening with the 
increase of excess weight in PCOS patients. It has been observed that some patients with 
PCOS can present menstrual cycles and ovulation after having reduced at least 5 % of her 
body weight (Kiddy et al., 1992). The studies on food habits in patients with PCOS have 
shown that the most important thing is caloric restriction, achieving a reduction of about 7% 
body weight, and that there is no difference in the metabolic results changing the 
composition of the diet (L.J. Moran et al., 2003). However, it has been reported that low 
glycemic index diet improved insulin sensitivity and menstrual periodicity more than the 
conventional healthy diet in PCOS patients (Marsh, 2010).  
9.1.2 Exercise 
Physical activity has been shown lower in PCOS patients than in control women (Write et 
al., 2004). The changes in lifestyle that incorporate an increase of physical activity and 
limited caloric intake have been beneficial in some studies. Regular physical activity is an 
important component to support the reduction of long-term weight; the results are minimal 
with exercise alone (Hoeger, 2008). An increase in physical activity is recommended for 
women with obesity and PCOS, as long as cardiovascular and orthopaedic limitations are 
considered (Moran et al., 2006).  
9.2 Insulin sensitizer agents 
9.2.1 Metformin 
The temporary use of metformin is considered, as a coadjutant of diet and exercise to control 
insulin resistance, especially in patients with obesity and glucose intolerance (Velazquez et 
al., 1994; ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, 2008). 
Nevertheless, the duration of this therapy is unknown yet. The metformin diminishes the 
hepatic glucose synthesis, inhibiting the gluconeogenesis; it also increases the glucose use by 
the striated muscle (Kirpichnikow et al., 2002).  
Administration of metformin to obese PCOS patients reduces the levels of circulating 
insulin, the activity of the complex P450c17 and the ovarian secretion of androgens 
(Nestler & Jakubowicz, 1996). Metformin can reduce the circulating androgen levels, may 
normalize the menstrual cycles and improve ovulation (Velazquez et al., 1994). The 
combined use of metformin and clomiphene has been recommended for PCOS patients with 
overweight or obesity who present more insulin resistance, especially in those refractory to 
the clomiphene (ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, 2008). 
Metformin has contraindications and some side effects (Lord et al., 2003). It must not be 
used in patients with renal insufficiency, hepatic malfunction, congestive heart failure and 
those with a history of alcoholism. It is important to take into account that metformin in rare 
cases can produce lactic acidosis; it is necessary to evaluate renal function before and 
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periodically during its administration, even though this complication is extremely rare. The 
gastrointestinal adverse effects, mainly nausea and diarrhoea, affect 10 to 25% of the 
patients taking metformin. The undesirable effects are transitory; however, in a minority of 
patients these can cause discontinuation of the treatment. To minimize adverse effects, 
metformin must be administered gradually. Metformin can induce bad absorption of 
vitamin B12 in patients who use it for long periods of time, even though this effect is very 
rare. In patients who wish to use contraception, it is necessary to add an oral contraceptive 
while still taking metformin. In those cases of hirsutism it is possible to add antiandrogens, 
oral contraceptives or both. 
9.2.2 Thiazolidindiones 
Among thiazolidindiones are troglitazone, rosiglitazone and pioglitazone, which improve the 
sensitivity of the insulin in the liver, striated muscle and adipose tissue; they also reduce the 
concentrations of insulin and circulating androgens (Lord et al., 2003). The use of troglitazone 
was ceased in research protocols conducted in PCOS patients because of hepatotoxicity 
reports. Although rosiglitazone and pioglitazone are as effective as metformin to treat insulin 
resistance in PCOS patients, it appears they are less effective to lower BMI than metformin. 
These drugs have been used less due to the concern of their use during pregnancy.  
9.3 Drugs for obesity and dyslipidemia 
Drugs to control obesity have been used in obese patients with PCOS, although few studies 
exist to support this therapeutic approach. It is known that orlistat blocks the absorption of 
intestinal fat (Jayagopa et al., 2005), and sibutramine suppresses the appetite (Sabunku et al., 
2003); both favor weight loss independently from the androgen excess and insulin 
resistance. It is important to take into account that these treatments must not be considered 
first line treatments for obesity in patients with PCOS.  
There are little evidences that statins, apart from specific action on lipid profile decreasing 
total cholesterol and low density lipoprotein cholesterol, can reduce serum androgens, 
inflammatory markers and insulin resistance (Banaszewska et al., 2009; Sathyapalan et al., 
2009, Raja-Khan et al., 2011). However, statins and bezafibrate (Hara et al., 2010) should only 
be used in women with PCOS who meet current indications for those treatments.  
9.4 Bariatric surgery 
Few studies exist on the impact of bariatric weight loss surgery on manifestations of PCOS 
in patients with morbid obesity. The initial results of bariatric surgery in patients with 
morbid obesity and PCOS seem encouraging, since aside from the weight reduction there is 
a decrease of hyperandrogenemia, hirsutism, insulin resistance and restoration of menstrual 
cycles and ovulation (Escobar-Morreale et al., 2005). 
10. Research of obesity and PCOS for the future 
The differences in the hormonal and metabolic profile, as well as the different response to 
treatment of obese and non obese PCOS patients suggest that obesity has to be considered as 
a secondary characteristic for the PCOS phenotype classification in prospective trials.  
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those with a history of alcoholism. It is important to take into account that metformin in rare 
cases can produce lactic acidosis; it is necessary to evaluate renal function before and 
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periodically during its administration, even though this complication is extremely rare. The 
gastrointestinal adverse effects, mainly nausea and diarrhoea, affect 10 to 25% of the 
patients taking metformin. The undesirable effects are transitory; however, in a minority of 
patients these can cause discontinuation of the treatment. To minimize adverse effects, 
metformin must be administered gradually. Metformin can induce bad absorption of 
vitamin B12 in patients who use it for long periods of time, even though this effect is very 
rare. In patients who wish to use contraception, it is necessary to add an oral contraceptive 
while still taking metformin. In those cases of hirsutism it is possible to add antiandrogens, 
oral contraceptives or both. 
9.2.2 Thiazolidindiones 
Among thiazolidindiones are troglitazone, rosiglitazone and pioglitazone, which improve the 
sensitivity of the insulin in the liver, striated muscle and adipose tissue; they also reduce the 
concentrations of insulin and circulating androgens (Lord et al., 2003). The use of troglitazone 
was ceased in research protocols conducted in PCOS patients because of hepatotoxicity 
reports. Although rosiglitazone and pioglitazone are as effective as metformin to treat insulin 
resistance in PCOS patients, it appears they are less effective to lower BMI than metformin. 
These drugs have been used less due to the concern of their use during pregnancy.  
9.3 Drugs for obesity and dyslipidemia 
Drugs to control obesity have been used in obese patients with PCOS, although few studies 
exist to support this therapeutic approach. It is known that orlistat blocks the absorption of 
intestinal fat (Jayagopa et al., 2005), and sibutramine suppresses the appetite (Sabunku et al., 
2003); both favor weight loss independently from the androgen excess and insulin 
resistance. It is important to take into account that these treatments must not be considered 
first line treatments for obesity in patients with PCOS.  
There are little evidences that statins, apart from specific action on lipid profile decreasing 
total cholesterol and low density lipoprotein cholesterol, can reduce serum androgens, 
inflammatory markers and insulin resistance (Banaszewska et al., 2009; Sathyapalan et al., 
2009, Raja-Khan et al., 2011). However, statins and bezafibrate (Hara et al., 2010) should only 
be used in women with PCOS who meet current indications for those treatments.  
9.4 Bariatric surgery 
Few studies exist on the impact of bariatric weight loss surgery on manifestations of PCOS 
in patients with morbid obesity. The initial results of bariatric surgery in patients with 
morbid obesity and PCOS seem encouraging, since aside from the weight reduction there is 
a decrease of hyperandrogenemia, hirsutism, insulin resistance and restoration of menstrual 
cycles and ovulation (Escobar-Morreale et al., 2005). 
10. Research of obesity and PCOS for the future 
The differences in the hormonal and metabolic profile, as well as the different response to 
treatment of obese and non obese PCOS patients suggest that obesity has to be considered as 
a secondary characteristic for the PCOS phenotype classification in prospective trials.  
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The intrauterine milieu in pregnancy and the reproduction outcome of PCOS patients with 
overweight or obesity are important topics for research in prospective studies.  
PCOS and obesity induce an increase in serum inflammatory cardiovascular risk markers. 
The precise mechanisms underlying these associations require additional studies, to 
determine the relative contribution of different factors on cardiovascular disease.  
11. Summary 
PCOS is associated with overweight or obesity, mainly abdominal adiposity; approximately 
80% of patients with PCOS are either overweight or obese. The insulin resistance, present in 
most of patients with obesity and/or PCOS, is a risk factor to develop carbohydrate 
intolerance and type 2 diabetes mellitus. Insulin resistance is higher and of greater 
magnitude in obese than non obese PCOS patients. A decrease in the synthesis of SHBG has 
been found, and therefore an increase in the free androgens in obese PCOS patients. It has 
been observed in some studies that obese PCOS patients present an increase of testosterone 
levels and a decrease in androstenedione. Weight loss is the main recommendation in obese 
PCOS patients. The treatment of obesity in PCOS must include nutritional counselling in 
food habits and life style. An increase in physical activity is recommended for PCOS 
patients. The temporary use of metformin may be useful, in conjunction with diet and 
exercise, to control insulin resistance, especially in PCOS patients with obesity and glucose 
intolerance. The combined use of metformin and clomiphene for ovulation induction has 
been suggested mainly in patients with overweight or obesity, who present more insulin 
resistance, refractory to the clomiphene alone. Drugs used to control obesity, as orlistat or 
sibutramine, must not be considered as the first choice for obesity in patients with PCOS. 
The initial results of bariatric surgery in patients with morbid obesity and PCOS seem 
encouraging, since aside from the weight reduction, a decrease of hyperandrogenemia, 
insulin resistance, hirsutism, and the restoration of menstrual cycles and ovulation have 
been observed. Obesity decreases or delays the results of several treatments for infertility 
such as the administration of clomiphene, gonadotropins and ovarian drilling. The 
differences in the hormonal and metabolic profile, as well as the different response to 
treatment between obese and non obese PCOS patients suggest that obesity has to be 
considered as a secondary characteristic for the determination of PCOS phenotypes.  
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To evaluate the prevalence of gestational diabetes mellitus (GDM) in women with polycystic 
ovary syndrome (PCOS) and to investigate the efficacy of Metformin in reduction of 
gestational diabetes in women with polycystic ovary syndrome. 
1.2 Design 
Review of literature on prevalence of gestational diabetes and evaluation of efficacy of 
Metformin in reducing the prevalence of gestational diabetes in women with polycystic 
ovary syndrome. 
1.3 Setting 
Reproductive Endocrinology section of Department of Obstetrics and Gynecology of Aga 
Khan University Hospital Karachi Pakistan. 
1.4 Patient(s) 
Women with PCOS and gestational diabetes  
1.5 Intervention(s) 
Literature search in the electronic databases MEDLINE, study of the references of all 
relevant trials or reviews, and manual search of the abstracts from the major meetings in the 
field of human reproduction. 
1.6 Main outcome measure 
Odds Ratio( OR) for the occurrence of gestational Diabetes. 
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relevant trials or reviews, and manual search of the abstracts from the major meetings in the 
field of human reproduction. 
1.6 Main outcome measure 
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1.7 Result(s) 
Women with PCOS demonstrated a significantly higher risk for the development of GDM as 
compared with women without PCOS 
1.8 Description 
The Polycystic Ovarian Syndrome (PCOS) is a common endocrinopathy, affecting 
approximately 5–10% of women of reproductive age. In its classical form, the syndrome is 
characterized by oligo- or anovulation, biochemical or clinical hyperandrogenismand 
polycystic ovarian morphology on ultrasonography. Although much remains unknown 
regarding the underlying path physiology of PCOS, a form of insulin resistance intrinsic to 
the syndromeappears to play a central role in its development. Among many women with 
PCOS, the observed insulin resistance is partially explained by excess adiposity; however, it 
is increasingly recognized that even lean women with PCOS have increased insulin 
resistance compared with normal controls. Affected women have an increased risk of 
glucose intolerance, gestational diabetes mellitus (GDM) and type 2 diabetes. Some, studies 
suggest the risk of GDM is higher among PCOS versus non-PCOS women, and several 
studies note an increased prevalence of polycystic ovarian morphology and symptoms in 
women with prior GDM.  
Insulin resistance is defined as the decreased ability of insulin to stimulate glucose disposal 
into target tissues, or a reduced glucose response to a given amount of insulin. Chronic 
hyperinsulinemia is a compensatory response to this target tissue resistance. Several 
mechanisms have been suggested to explain insulin resistance, including peripheral target 
tissue resistance, decreased hepatic clearance, or increased pancreatic sensitivity. The 
peripheral insulin resistance in PCOS is uniquely due to a defect beyond the activation of 
the receptor kinase, namely, reduced tyrosine autophosphorylation of the insulin receptor 
and enhances the expression of hyperandrogenism by its inhibitory effect on hepatic sex 
hormone binding globulin (SHBG) production thereby increasing the bioavailability of 
androgens which leads to metabolic and obstetrical complications. Significant metabolic 
burden of insulin resistance is seen in women with PCOS, affected women may have an 
increased risk of impaired glucose tolerance (IGT), GDM and type 2 diabetes mellitus (DM).  
In pregnant women with PCOS, the increasing tissue resistance to insulin, mainly caused by 
placental hormones, adds on the preexisting state of insulin resistance, which may 
accompany the syndrome. This pathogenic mechanism could lead to hyperglycemia, 
reflected in a higher incidence of GDM. However, studies on GDM prevalence in women 
with PCOS gave conflicting results; considering the heterogeneity of PCOS and the diversity 
in methodology of screening and diagnosing GDM, these results should have been 
expected. 
A method of combining the results of the studies addressing the risk of Incidence of GDM in 
women with PCOS was one of the endpoints in addressing pregnancy complications in 
women with PCOS. Women with PCOS demonstrated a significantly higher chance of the 
development of GDM, though with significant statistical heterogeneity among the studies. 
This heterogeneity was not further analyzed or accounted for. To examine whether women 
with PCOS have a greater risk for the development of GDM than women without PCOS, we 
performed a review of literature and analysis of available trial 
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2. PCOS, Gestational Diabetes Mellitus (GDM) and diabetes  
It has been recognized that women with PCOS have a higher risk for developing type 2 
diabetes mellitus and gestational diabetes .In a retrospective cohort follow-up of patients 
with PCOS, the prevalence of diabetes mellitus was 7-fold higher than in controls. 
Gestational diabetes is defined as impaired glucose tolerance diagnosed for the first time 
during pregnancy, occurs in 2–5% of pregnancies and usually resolves at the end of 
gestation. However, between one half and one third of women with gestational diabetes 
may develop diabetes 2–11 years post-partum. Different studies have shown that women 
with PCOS have a higher risk for the development of gestational diabetes in relation to 
insulin resistance . Moreover, other authors have demonstrated a high incidence of 
polycystic ovaries in women with history of gestational diabetes Gestational diabetes is 
associated with a high neonatal morbidity and given that patients with PCOS have a high 
prevalence of gestational diabetes, these women should be considered to be at risk. 
Therefore, preventive measures before pregnancy to minimize neonatal morbidity should be 
recommended, including dietary advice and physical exercise as well as to indicate insulin-
sensitizing treatments before; and during pregnancy. 
In reproductive age, the prevalence of type 2 diabetes mellitus is estimated between 1.7 and 
6.1%. This prevalence would be expected to be from 5–10-fold higher in women with PCOS. 
On the other hand, PCOS may be considered a pre-diabetic state with a prevalence of 
impaired glucose tolerance of 31–35% and a prevalence of type 2 diabetes of 7.5–10%. 
Impaired glucose tolerance is characterized by moderate increases of fasting glucose levels 
that may precede diabetes. Women with impaired glucose tolerance are asymptomatic; 
therefore, an oral glucose tolerance test is required for diagnosis. Conversion of impaired 
glucose tolerance to frank diabetes in women with PCOS is 5–10 times more frequent 
compared with normal women The mean age at diagnosis of type 2 diabetes mellitus in 
patients with PCOS (30–40 years of age) is lower than in normal women (60–70 years of age) 
Additionally, a family history of diabetes and the presence of obesity are important 
predictors for the development of type 2 diabetes mellitus. 
The diagnostic criteria of diabetes based on the 1999 World Health Organization definition 
and the 1997 recommendations of the Expert Committee of the ADA is a fasting glucose 
level ≥126mg/dl (7mmol/l) or oral glucose tolerance test (2h plasma glucose after 75g oral 
glucose challenge) ≥200mg/dl (11.1mmol/l). Diagnostic criteria of impaired glucose 
tolerance include normal fasting glucose levels (<126mg/dl) in association with oral glucose 
tolerance test ≥140 and <200mg/dl (7.8–11.1mmol/l). Normal baseline plasma glucose levels 
are 110mg/dl (6.1mmol/l). The principal difference between the 1997 ADA criteria and the 
1999 WHO criteria is that the ADA criteria discourage the use of the oral glucose tolerance 
test as a routine diagnostic tool whereas the WHO criteria do not. However, it seems that 
the WHO criteria are more adequate for the diagnosis of diabetes in women with PCOS 
tolerance test . 
These data indicate that women with PCOS are at high risk for long-term development of 
type 2 diabetes mellitus, and support the importance of an early diagnosis and treatment of 
insulin resistance to help reduce the incidence and severity of diabetes, dyslipidemia, 
hypertension and cardiovascular disease 
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3. Review of role of insulin sensitizing agents (metformin) in prevention of 
gestational diabetes in women with pcos 
A major change in the treatment of PCOS was initiated by the understanding that many 
women with this disorder compensate insulin resistance with a period of hyper secretion 
of insulin by the pancreatic beta cell. This understanding has been incorporated into the 
framework of PCOS treatments through the beneficial effects of insulin-sensitizing 
treatments on the PCOS phenotype Agents that improve insulin sensitivity (and lower 
circulating insulin levels) include metformin as well as thiazolidinediones, pioglitazone 
and rosiglitazone as alternative pharmacotherapies for those who cannot tolerate 
metformin as a result of gastrointestinal side effects .These treatments have resulted in 
beneficial changes in PCOS phenotype with increased menstrual and ovulatory frequency, 
pregnancy and decreased hirsutism. On the other hand, an increase in obstetrical 
pathology in women with PCOS has been documented, including increased rates of 
miscarriage, gestational diabetes, macrosomia, caesarean deliveries and pre-eclampsia. 
Given that hyperinsulinaemia may play a role in the pathophysiology of these conditions, 
maintenance of oral antidiabetic agents during pregnancy may decrease the incidence of 
these complications. Metformin, with a high safety profile for use during pregnancy, has 
been given to pregnant women with PCOS resulting in a reduction of the aforementioned 
conditions in these patients.  
 
Fig. 1. Postulated role for insulin sensitizing agents on target tissues affected in woman with 
PCOS Harborne L etal  
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These concepts have quickly become the cornerstone of diagnosis and treatment of PCOS 
and other diseases also associated with insulin resistance. Type 2 diabetes mellitus and 
gestational diabetes. Recent observations regarding the effect of insulin-sensitizing drugs on 
ovarian stimulation in patients with PCOS undergoing IVF are also discussed, as well as the 
current status of the use of insulin-sensitizing drugs during pregnancy. Finally, substantial 
progress has been made to elucidate the cellular and molecular mechanisms of insulin 
resistance in PCOS. The insulin receptor and genetics of PCOS are complex areas that are 
extensively being investigated. 
These agents increase the tissue sensitivity to insulin action in vivo .The agent commonly 
used in clinical practice is metformin, an oral hypoglycemic biguanide. Newer agents 
include the thiazolidinediones group of drugs like troglitazone. Hepatotoxocity of this drug 
has lead to its withdrawal, but pioglitazone and D-chiroinositol has been used with some 
success in an insulin sensitization in women with PCOS  
3.1 Metformin 
It acts primarily by increasing peripheral glucose uptake in response to insulin at post 
receptor level, with some basal reduction in gluconeogenesis. It improves the insulin 
sensitivity in adipose tissues and skeletal muscles. All of the action are mediated by CAMP 
activated by protein kinase .It has been suggested that various insulin sensitizing drugs 
specifically inhibits the 17 , 20 lyase activity of P450c 17 . While it true that these drugs lower 
the C19 steroids but still the exact mechanism of action of metformin is not clear.  
Until now the use of insulin sensitizing agents are targeted toward symptoms and signs of 
PCOS, like in ovulation induction, as an anti androgen therapy and for hirsutism. In this 
chapter we will be discussing the role of insulin sensitizers particularly metformin in 
prevention of Gestational diabetes associated with PCOS in light of recent evidence support.  
3.2 Use of metformin and prevention and treatment of gestational diabetes mellitus 
Metformin has been used to treat diabetes in second and third trimesters of pregnancy after 
the main teratogenic period, no significant perinatal morbidity and mortality was noticed 
except relatively high frequency of neonatal jaundice. Coetzee et al.14, has published the 
experience of 118 pregnant women with PCOS, who received an oral hypoglycemic 
medication and found the higher frequency of preeclampsia and perinatal mortality. 
However when these study results were critically analyzed it was found these women were 
older, more obese than their reference group which accounted for the baseline 
characteristics rather than Metformin alone.  
The incidence of gestational diabetes in women with PCOS appears to be increased but data 
are not consistent .Insulin resistance in PCOS and the inability of pancreatic beta cells to 
compensate for increased needs of insulin during pregnancy are risk factors for gestational 
diabetes. 
Different studies have documented a decrease in the incidence of gestational diabetes in 
PCOS women treated with metformin during pregnancy. Although in most of them 
retrospective controls were used. Prospective randomized studies with a sufficient number 
of patients are necessary in order to provide good evidence to recommend the use of 
metformin during pregnancy. 
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4. Conclusion 
PCOS is one of the most common hormonal disorder affecting women and has 
reproductive, metabolic, cardiovascular health implications across the life span. Insulin 
resistance in PCOS has been considered as main etiological factor for major health related 
consequences. Significant heterogeneity among studies and dependence of the outcome on 
study type make the higher risk of GDM in women with PCOS a questionable finding. The 
conduction of properly designed studies should precede any recommendation to pregnant 
women with PCOS in regard to the risk of GDM. 
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1. Introduction 
Young women have an inferior risk of cardiac events, but this benefit fades after 
menopause, leaving them at risk to develop a cardiovascular disease (CVD) (Stramba-
Badiale, Fox et al. 2006). Endocrine and gynecologic diseases may have impact on this 
pattern. Ever since the classical notice of Stein and Leventhal in 1935 (Stein and Leventhal. 
1935), interest in polycystic ovaries (PCO) and its accompanying syndrome (PCOS) has 
grown from a ‘‘gynecological curiosity to a multisystem endocrinopathy’’ (Homburg 1996). 
Actually, polycystic ovary syndrome (PCOS), is the most common female endocrinopathy in 
up to 10% in reproductive age and appears to be related with an increased cardiovascular 
risk (Talbott, Guzick et al. 1995; Cibula, Cifkova et al. 2000). The syndrome is characterized 
by chronic anovulation and hyperandrogenism (Franks 1995; Scarpitta and Sinagra 2000). 
Cardiovascular disease and type 2 diabetes are two potential major long-term sequelae of 
this condition that is worth of examination. 
Even though the first description occurred almost 70 years ago, there has not been 
agreement about its definition. At a recent collective European Society of Human 
Reproduction and Embryology/American Society for Reproductive Medicine 
(ESHRE/ASRM) consensus meeting, a refined definition of PCOS was agreed: particularly, 
the presence of two out of the following three criteria: 
i. oligo- and/or anovulation 
ii. hyperandrogenism (clinical and/or biochemical) 
iii. polycystic ovaries, with the exclusion of other etiologies (2004). 
It is widely accepted that polycystic ovary syndrome (PCOS) is correlated with an increased 
risk of cardiovascular disease. Dyslipidaemia (Legro, Kunselman et al. 2001; Pirwany, 
Fleming et al. 2001), hypertension (Dahlgren, Janson et al. 1992; Luque-Ramirez, Alvarez-
Blasco et al. 2007) and diabetes (Ehrmann, Barnes et al. 1999; Legro, Kunselman et al. 1999) 
are appeared to be more common in women with PCOS. Obesity, especially central obesity, 
is a pivotal factor for predicting the long-term risk of cardiovascular disease (Franks, Kiddy 
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et al. 1991; Luque-Ramirez, Alvarez-Blasco et al. 2007). There is substantial convergence 
among these features found in PCOS and the metabolic syndrome, and it is potential that 
these are interrelated conditions. Alterations in clotting (Manneras-Holm, Baghaei et al. 
2011) and blood vessel function (Paradisi, Steinberg et al. 2001) might describe why 
cardiovascular disease is a long-term risk in women with PCOS. 
However metabolic abnormalities aforementioned and obesity were not recognized until 
reduced sensitivity to insulin and compensatory hyperinsulinemia were demonstrated in 
PCOS patients. The metabolic profile well known in women with PCOS, is equivalent to the 
insulin resistance syndrome, a clustering within an individual with hyperinsulinemia, mild 
glucose intolerance, dyslipidemia, and hypertension. The insulin resistance syndrome (or 
syndrome X) has been recognized as a risk factor for developing type 2 diabetes and CVD 
(Legro, Kunselman et al. 1999; Korhonen, Hippelainen et al. 2001). 
There is also a strong association between hyperandrogenemia and insulin resistance in 
PCOS (Bremer and Miller 2008). This may mainly consider the stimulatory effect of 
hyperinsulinemia on ovarian androgen production, although hyperandrogenemia may 
finally contribute to insulin resistance (Baptiste, Battista et al. 2010). This may also underlie 
the association between hyperandrogenemia and impaired vascular function and reported 
in some studies involving PCOS subjects (Wu and von Eckardstein 2003). Nevertheless, 
even though insulin resistance per se has been associated with endothelial dysfunction and 
increased cardiovascular risk, there is no stable proof that hyperandrogenemia is a risk 
factor for cardiovascular disease in women (Gorgels, v d Graaf et al. 1997). 
Notwithstanding the fact that PCOS is increasingly recognized as being associated with a 
cluster of cardiovascular risk factors, there is no final evidence for increased cardiovascular 
events in PCOS. Nor is there, evidently, data show that PCOS alone imparts increased risk 
independent of associated risk factors. This article intends to review the spectrum of 
cardiovascular risk factors, the cardiovascular epidemiology and especially the most recent 
studies of subclinical cardiovascular disease in PCOS, investigating cardiovascular structure 
and function. Although, these latter sets of studies have, in particular, further elucidated the 
causal links between PCOS and cardiovascular disease. 
2. Cardiovascular risk factors in PCOS 
2.1 Biochemical 
2.1.1 Hyperinsulinemia and insulin resistance 
Insulin resistance, described as a reduced glucose response to a given amount of insulin, is a 
typical metabolic disturbance related with PCOS. Resistance to the activity of insulin in 
target tissues is a main pathogenic factor in metabolic syndrome and type 2 diabetes. 
Association of PCOS with insulin resistance was known nearly three decades ago (Burghen, 
Givens et al. 1980). Hyperinsulinemic euglycemic clamp measurements have shown that 
insulin-mediated glucose uptake have decreased by 35-40% in both lean and obese women 
with PCOS, similar to the degree of insulin resistance seen in patients with type 2 diabetes 
(Dunaif, Segal et al. 1989). Insulin resistance causes compensatory hyperinsulinemia, which 
is related to many of the phenotypic features of PCOS (menstrual disturbances, evolvement 
of ovarian cysts, hirsutism and other associated disorders) through multiple mechanisms, 
involving ovarian steroidogenesis, gonadotrophin secretion, and sex hormone binding 
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globulin production (Ehrmann 2005). Insulin can enhance ovarian steroidogenesis and 
enhance directly, independently and/or augment LH-mediated androgen production 
(Barbieri, Makris et al. 1984; Poretsky, Cataldo et al. 1999; Bremer and Miller 2008). Hence, 
hyperinsulinemia and hyperandrogenemia are two essential characteristics of PCOS. Their 
cause and effect relationship is still debated (Dunaif 1997; Poretsky, Cataldo et al. 1999; Legro, 
Gnatuk et al. 2005; Bremer and Miller 2008). However, several evidences suggest that 
hyperinsulinemia may be the principal cause leading to the ovarian hyperandrogenemia. 
Insulin level reduction pharmacologically, has been ameliorating hyperinsulinemia as well as 
hyperandrogenemia and restore ovulation in the women with PCOS. Even though, a decrease 
in androgen levels by bilateral oophorectomy, administration of GnRH agonist (Bremer and 
Miller 2008), or antiandrogenic combinations (Dunaif 1997) had no impact on IR or 
hyperinsulinemia in the PCOS women, which would have been expected if 
hyperandrogenemia was the factor of hyperinsulinemia. Besides, the peripheral insulin 
resistance in PCOS was related to defective pancreatic ß-cell function (Ehrmann, Sturis et al. 
1995). Additionally, insulin resistance increases the risk for evolvement of glucose intolerance, 
type 2 diabetes mellitus (T2DM), hypertension, dyslipidemia and cardiovascular abnormalities 
in these patients (Maitra, Pingle et al. 2001; Legro, Gnatuk et al. 2005). 
PCOS patients have a higher incidence of insulin resistance and hyperinsulinemia than age-
matched controls in both obese and nonobese patients. Nonetheless, obese women with 
PCOS have significantly decreased insulin sensitivity compared with nonobese women who 
have PCOS. Insulin resistance has been known to lead to the progression of type 2 diabetes 
mellitus. PCOS patients have progress to impaired glucose tolerance in 30% to 40% of the 
cases, and as many as 10% of them develop type 2 diabetes mellitus by the age of 40 
(Clayton, Ogden et al. 1992; Guzick 2004; Tsilchorozidou, Overton et al. 2004). Strong 
association between insulin resistance and hyperandrogemia has been shown by several 
studies. This association was first reported by Achard and Thiers in 1921 in a bearded 
woman who was also a diabetic (Guzick 2004). Androgen production is magnified 
synergistically with LH and insulin action in the ovarian theca cells. In addition insulin 
decreases hepatic synthesis and release of sex hormone-binding globulin, the hormone that 
binds testosterone in the blood flow, hence increasing the amount of free testosterone that is 
biologically attainable (Tsilchorozidou, Overton et al. 2004). Free testosterone levels 
typically have been increased in hyperinsulinemic PCOS patients. Although the total 
testosterone concentration may be at the upper range of normal or only moderately elevated 
(Tsilchorozidou, Overton et al. 2004).The exact cellular and molecular mechanisms of insulin 
resistance in PCOS remain elusive in spite of the crucial role of insulin resistance in the 
pathogenesis of this syndrome. Together intrinsic and acquired defects in insulin signaling, 
have been known as mediators of insulin resistance in women with PCOS.  
In PCOS the “central paradox” is characterized by responsive ovaries to insulin effect to 
produce androgens in spite of systemic insulin resistant state; nonetheless, classical target 
organs of insulin as well as ovary remains resistant to its metabolic activity. Distinct insulin 
target tissues and ovary have comprised optimal number and affinity of insulin receptors, 
and as well as no structural and mutational abnormalities could be detected in the PCOS 
women (Dunaif 1997; Ciaraldi, Morales et al. 1998; Book and Dunaif 1999; Poretsky, Cataldo 
et al. 1999). Therefore, a post-receptor binding defect in the insulin signaling pathway 
appears to play a consequential function in the etiology of selective IR. Notwithstanding the 
fact that several in vitro and in vivo researches have been carried out in various tissues to 
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illuminate the possible mechanism of IR and hyperandrogenemia (ovarian cells) (Ovarian 
cells, adipocytes, fibroblasts, myocytes) (Dunaif 1997; Poretsky, Cataldo et al. 1999; Pessin 
and Saltiel 2000; Nelson-Degrave, Wickenheisser et al. 2005; Diamanti-Kandarakis and 
Papavassiliou 2006) in PCOS patients, however the data has not been yet conclusive. 
Pancreatic β-cell dysfunction has been described in women with PCOS, whereby there is 
augmented basal secretion of insulin in spite of an insufficient postprandial response 
(Ehrmann, Sturis et al. 1995). This imperfection remains even after weight loss, despite an 
amelioration in glucose tolerance (Holte, Bergh et al. 1995). Insulin performs its effects via 
insulin receptor to begin a cascade of post-receptor events within the target cell. 
Phosphorylation stimulates insulin receptor substrates (IRS1-4) to promote glucose uptake 
through the transmembrane glucose transporter (GLUT4) and additionally intracellular 
protein synthesis. Tyrosine phosphorylation increments the tyrosine kinase activity of the 
insulin receptor, while serine phosphorylation inhibits it, and it appears that at least 50% of 
PCOS patients have excessive serine phosphorylation and inhibition of normal signaling 
(Tsilchorozidou, Overton et al. 2004). This influences merely glucose homeostasis and not 
the other pleiotropic activity of insulin, so that cell growth and protein synthesis continue. 
In addition, serine phosphorylation boosts activity of P450c17 in both the ovary and adrenal 
gland, hence promoting androgen synthesis, and this may be a reason for both insulin 
resistance and hyperandrogenism in some PCOS patients (Zhang, Rodriguez et al. 1995). 
The source of hyperinsulinemia in patients with PCOS also remains unknown. The post 
receptor insulin signaling pathway and/or defective insulin secretion may be associated 
with an intrinsic abnormality (Holte, Bergh et al. 1995; Dunaif 1997). Probably, the metabolic 
abnormalities in PCOS begin very early in life, during the prenatal or prepubertal period, 
and an early exposure to androgens during growth may affect the body fat distribution and 
insulin action (Abbott, Dumesic et al. 2002; Eisner, Barnett et al. 2002). These observations 
have shown convincing proof that PCOS patients have insulin resistance and/or 
hyperinsulinemia, especially when they are anovulatory and obese with central fat 
distribution. Given that insulin resistance is an independent risk factor for metabolic 
abnormalities, the presence of insulin resistance in PCOS women implies the future 
possibility of cardiovascular disease and type 2 diabetes. Moreover, applying a 
cardiovascular risk score, insulin resistance in PCOS was established to be an important 
independent determining factor of cardiovascular risk in women with PCOS (Mather, Kwan 
et al. 2000). 
The 2003 Rotterdam Consensus Conference (at least two of three features: 
oligo/anovulation, clinical and/or biochemical hyperandrogenism, polycystic ovaries) 
(2004) revised the 1990 US National Institutes of Health (NIH) definition of PCOS 
(hyperandrogenism and/or hyperandrogenemia plus oligo-ovulation, with the exclusion of 
other causes) (Zawadzki and Dunaif 1992), started a great debate. The majority of the 
studies investigating the metabolic associations of PCOS have used the 1990 NIH definition. 
Existing proofs support an increased risk of metabolic dysfunction in patients with clinical 
and/or biochemical hyperandrogenism and oligoovulation, and also in women with 
hyperandrogenism and normoovulation with polycystic ovaries (Azziz, Carmina et al. 
2006). Women with or without oligoovulation with polycystic ovaries have nil or very subtle 
metabolic characteristics that makes it difficult for their involvement as a syndrome (Azziz, 
Carmina et al. 2006; Barber, Wass et al. 2007). 
 




Dyslipidemia is one of the most verified independent risk factors for the development of 
atherosclerotic cardiovascular disease, especially elevated low-density lipoprotein (LDL) 
and triglyceride (TG) levels. The most common metabolic abnormality in PCOS may be 
dyslipidemia, with a prevalence of up to 70% according to National Cholesterol Education 
Program criteria (Dunaif, Segal et al. 1989; Talbott, Clerici et al. 1998; Legro, Kunselman et 
al. 1999).  
Insulin resistance, and its common, but not constant companion, compensatory 
hyperinsulinemia, have been linked with other different patterns of dyslipidemia. These 
include low levels of high-density lipoprotein(HDL)-cholesterol (HDL-C), increased values 
of triglycerides and total and low-density lipoprotein (LDL)-cholesterol (LDL-C), as well as 
varied LDL quality (Talbott, Clerici et al. 1998; Legro, Kunselman et al. 2001; Pirwany, 
Fleming et al. 2001; Essah, Nestler et al. 2008; Valkenburg, Steegers-Theunissen et al. 2008). 
However, lower HDL levels, higher low-density lipoprotein (LDL)/HDL ratios and higher 
triglyceride levels are seen most often in both lean and obese women with PCOS (Wild, 
Painter et al. 1985). This lipid pattern is similar to that found in T2DM. And it is mostly the 
result of IR that impairs the capability of insulin to suppress lipolysis, thereby expanding 
mobilization of free fatty acids from adipose stores. As a result, raised hepatic delivery of 
free fatty acids impairs insulin inhibition of hepatic very low-density lipoprotein 1 synthesis, 
causing altered catabolism of very low-density lipoprotein (Brunzell and Ayyobi 2003). 
Excessive adipose tissue increase insulin resistance, and this pattern is more common in 
obese patients with PCOS. These different patterns may be linked to the accompanying 
effects of IR and hyperandrogenism that merge with environmental (diet, physical exercise) 
and genetic factors (Dunaif 1997). 
LDL subclasses are consequential predictors of CVD (Gardner, Fortmann et al. 1996). LDL 
particles are diverse in magnitude, density, and structure. CAD has been associated with 
small dense LDL particles and increased relative risk of CAD, that ranges from 3- to 7-fold 
(Austin, Breslow et al. 1988). Numerous studies have revealed a high prevalence of small 
LDL size in PCOS patients (Wild, Pierpoint et al. 2000; Dejager, Pichard et al. 2001). The 
differences in lipid profile are sharper at earlier ages and minor divergence is notable 
beyond the age of 40 years among to PCOS and control women, suggesting an incresaed risk 
for atherosclerosis at an earlier age (Talbott, Guzick et al. 1995; Talbott, Clerici et al. 1998). 
Existance of hormonal discordance may cause an earlier occurrence of atherosclerosis. 
Obesity and intraabdominal fat distribution in PCOS patients or may reflect the LDL-C 
increment with age among controls.  
Recently, several studies have shown that similar changes of plasma lipids, distinct 
alterations of Lp and apoB substantially increase the cardiovascular risk (2002; Wierzbicki 
2008). ApoB is the principal constitutional component of LDL and a true indicator of the 
number of particles promoting arteriosclerosis (2002). Some studies found no differences in 
apoB levels between women with PCOS and the controls (Valkenburg, Steegers-Theunissen 
et al. 2008). However, the others have shown significant increments in PCOS patients than 
the controls (Demirel, Bideci et al. 2007). Almost certainly, genetic and environmental 
influences may cause different lipid patterns. Based on these present data the determination 
of apoB levels is not advisable in women with PCOS. 
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Lipoprotein(a) is a miscellaneous class of lipoproteins constructed of an apo(a) molecule 
connected to an apoB-100 and a lipid. Lp(a) levels are determined genetically, and its 
metabolic characteristics are different from LDL. The concentration an Lp(a) is remaining 
stable during the life of a subject (Scanu 1992). Elevated Lp(a) concentrations represent an 
independent risk factor for cardiovascular events, associated to a raised risk of myocardium 
infarction, stroke and coronary heart disease (Sandkamp, Funke et al. 1990; Nagayama, 
Shinohara et al. 1994). Many studies and metaanalysis suggest that Lp(a) levels are 
increased in women with PCOS (Rizzo, Berneis et al. 2009; Toulis, Goulis et al. 2011). 
Lipid disorders in PCOS appear to be connected to hyperinsulinemia (Mather, Kwan et al. 
2000) and central obesity (Pirwany, Fleming et al. 2001). Some of the researchers suggested 
that androgen levels were associated with triglyceride levels, and lipids did not have any 
association (Legro, Kunselman et al. 2001). Nevertheless, others found no association 
between androgen levels and dyslipidemia (Pirwany, Fleming et al. 2001). 
The current data suggest that distinct lipid profiles may be present in women with PCOS. 
Furthermore, distinctions among diverse racial and geographical characteristics cannot be 
entirely explained with body weight variations solely (Essah, Nestler et al. 2008; 
Valkenburg, Steegers-Theunissen et al. 2008). These distinctions may depend on the 
combination of genetic, environmental, and hormonal influences. In support of this issue, 
nonobese women with PCOS also can have raised levels of lipoprotein (a), a steady, 
genetically and racially determined, lipid-rich, LDL-like lipoprotein that is metabolically 
different from LDL-C (Scanu 1992; Rizzo, Berneis et al. 2009). 
2.1.3 Hyperandrogenism 
Hyperandrogenism is a dominant characteristic of PCOS with rises of ovarian androgens, 
testosterone, and androstenedione. Sex hormone binding globulin (SHBG) is usually low in 
PCOS, principally due to obesity, leading to higher free testosterone levels (Carmina 2002). 
Hyperandrogenism in PCOS patients, is an indefinite diagnosis of “androgen excess” that 
does not virilize. However, goes beyond the normal limits. Some depend on the clinical 
presentation of peripheral androgen excess in women, involving midline hirsutism, acne, 
and androgenic alopecia to make the diagnosis of hyperandrogenism as part of the PCOS 
phenotype (Hatch, Rosenfield et al. 1981; Lookingbill, Demers et al. 1991). Hirsutism is quite 
more common than the PCOS in the populations. Biochemical criteria, in contrast to clinical 
criteria, are more often used to report hyperandrogenism (Azziz, Ehrmann et al. 2001). 
Generally, it is concluded with serum tests to document increase in circulating androgen 
levels. In many multicenter clinical trials of women with PCOS, testosterone and/or some 
measurements of bioavailable testosterone has been frequently used to determine 
hyperandrogenism (Hines, Moran et al. 2001). 
The gender distinction in vulnerability to cardiovascular disorder has been referred to the 
difference in sex steroids with oestrogen being seen as cardioprotective and androgens as a 
potential for exacerbating cardiovascular risk factors (Wu and von Eckardstein 2003). 
Clinical signs of hyperandrogenism, hirsutism and acne have been recognized as common 
characteristics of women suffering catheterization for coronary artery disease and were 
related with more serious disease (Wild, Grubb et al. 1990). There is little proof of an 
association among androgenic alopecia and raised cardiovascular risk in men, and there is 
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even less in women (Rebora 2001). Iatrogenic hyperandrogenism in female-to-male 
transsexuals does not cause increased cardiovascular mortality (van Kesteren, Asscheman et 
al. 1997). Nevertheless, in an experimental model, testosterone management in female 
primates was related with raised premature atherogenesis, independent of lipid property 
(Adams, Williams et al. 1995). Equivalent trials in animal models of PCOS have not been 
reported to date. 
The CVD is very low in premenopausal women and there was no evidence about correlation 
with increased androgens in circulation or urinary excretion with subsequently developed 
CVD (Gorgels, v d Graaf et al. 1997). Furthermore, prospective researches of 
postmenopausal populations, circulating androgen levels did not correlate with 
cardiovascular events (Price, Lee et al. 1997). The few studies that examined the correlation 
between endogenous androgens and the evolvement of cardiovascular disorder have not 
shown that androgen level performs a significant role in women with PCOS (Barrett-Connor 
and Goodman-Gruen 1995). The carotid intima-medial thickness (CIMT) has been shown to 
be inversely correlated with endogenous dehydroepiandrosterone sulphate (DHEAS) and 
testosterone in premenopausal and postmenopausal women (Bernini, Sgro et al. 1999). 
It looks likely that in spite of the accepted consistent gender disproportion in the prevalence 
of cardiovascular disease, nonhormonal, genetic and environmental circumstances may play 
a greater role than that of androgens. In summary, the evidence for a association between 
hyperandrogenism per se and CVD in women is faint. 
2.1.4 Novel risk factors 
Recent cardiovascular studies have identified new biochemical markers for early 
atherosclerosis, and many of these have been found to be elevated in women with PCOS. 
Preliminary investigations suggest that serum biomarkers of cardiovascular disease, such as C-
reactive protein (Kelly, Lyall et al. 2001; Mohlig, Spranger et al. 2004), adiponectin (Panidis, 
Kourtis et al. 2003; Spranger, Mohlig et al. 2004), plasminogen activator-1 (Sampson, Kong et 
al. 1996), endothelin-1 (Diamanti-Kandarakis, Spina et al. 2001), Von Willebrand factor 
(Dahlgren, Janson et al. 1994), homocysteine (Loverro, Lorusso et al. 2002) and markers of 
oxidative stress (Sabuncu, Vural et al. 2001) were abnormal in women with PCOS. 
Whilst hyperhomocysteinemia is a risk factor for cardiovascular diseases, it has been 
assumed that homocysteine levels are higher in women with PCOS than controls. 
Homocysteine is an amino acid created by the transformation of methionine to cysteine. 
Homocysteine is metabolized by one of two mechanisms: trans-sulfuration and 
remethylation. This procedure needs vitamin B as a cofactor (Dahlgren, Janson et al. 1992; 
Talbott, Guzick et al. 1995; Wild, Pierpoint et al. 2000). 
Potential pathophysiologic mechanisms of the impact of homocysteine comprise intensified 
peroxidation injury, proliferation of the smooth vessel, initiative of monocytic chemotaxis, 
enhanced cytotoxicity and inflammation, promotion of clotting, inhibition of anticoagulation, 
through effects on endothelial cells, and activation of platelet aggregation (Fermo, Vigano' 
D'Angelo et al. 1995; Mayer, Jacobsen et al. 1996; D'Angelo and Selhub 1997). 
Numerous epidemiological reports have established hyperhomocysteinemia as an 
independent risk factor for cardiovascular disease, cerebrovascular disease, recurrent 
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venous thromboembolism. It may arise from genetic defects in the enzymes within 
homocysteine pathways such as a methylene tetrahydrofolate reductase (MTHFR), 
imperfections in vitamin cofactors, or other causes, which contain drugs, such as fibrates 
and nicotinic acid and several chronic medical conditions (D'Angelo, Coppola et al. 2000; 
Orio, Palomba et al. 2003; Dierkes, Westphal et al. 2004; Baccarelli, Zanobetti et al. 2007). 
Many studies have evaluated homocysteine levels in women with PCOS. Most have 
revealed that women with PCOS have increased homocysteine levels when compared with 
controls (de la Calle, Gallardo et al. 2007; Atamer, Demir et al. 2008; Yilmaz, Pektas et al. 
2008; Oktem, Ozcimen et al. 2009). 
The role of inflammation in the evolvement of atherosclerosis has been well clarified. 
Epidemiological researches to have displayed that markers of inflammation, such as C-
reactive protein (CRP) and white cell count, are independent predictors of cardiovascular 
disease odds. Several studies have been displayed elevated levels of high sensitivity CRP 
(Kelly, Lyall et al. 2001; Boulman, Levy et al. 2004), but not all (Mohlig, Spranger et al. 2004), 
in women with PCOS, independent of BMI. Recently, a higher white cell count was found to 
be correlated with a degree of insulin resistance in women with PCOS independent of BMI 
(Orio, Palomba et al. 2005). Predictors of vascular endothelial activation and damage, and 
oxidative stress has also been associated to a raised incidence of cardiovascular hazard, and 
peculiarities of these have been reported in women with PCOS. This issue is controversial if 
these correlations are independent of co-existent causes such as age, obesity, insulin 
resistance, blood pressure, serum glucose and lipid levels. 
The circulating levels of tumour necrosis factor? α (TNF α), interleukin (IL)-6, as well as 
white blood count (WBC) and neutrophil count have been found to be elevated in PCOS 
patients compared with age- and /body mass index- (BMI-) matched controls (Alexander 
1994; Kelly, Lyall et al. 2001; Amato, Conte et al. 2003). However, it has been revealed that 
obesity, and not PCOS status per se, was a major determinant of the circulating 
inflammatory markers TNF α, soluble type 2 TNF receptor, IL-6, and hs-CRP (Escobar-
Morreale, Villuendas et al. 2003; Mohlig, Spranger et al. 2004). Increment in both low-grade 
chronic inflammation and insulin resistance in women with PCOS is related with raised 
central fat excess rather than PCOS status (Puder, Varga et al. 2005). Furthermore, TNF α is 
over expressed in adipose tissue and induces insulin resistance throughout acute and 
chronic effects on insulin-sensitive tissues (Hotamisligil, Shargill et al. 1993). The origin of 
redundant TNF α in PCOS is likely to be adipose tissue in the obese but remain obscure in 
lean women with PCOS. Nevertheless, increased visceral obesity could be a origin of 
redundant TNF α in lean women with PCOS. Other proinflammatory cytokine is IL-18, 
which was showed to be raised in PCOS patients (Stephens, Butts et al. 1992). IL-18 causes 
the production of TNF α which promotes the synthesis of IL-6, which is also thought about a 
strong risk marker for cardiovascular disease (Blankenberg, Tiret et al. 2002). Collectively, 
the above findings reveal that low-grade chronic inflammation could be a novel mechanism 
contributing to increased risk of coronary heart disease in PCOS. 
Adiponectin, leptin and resistin, are bioactive peptides that are known as adipocyokines 
secreted by adipocytes, can affect insulin sensitivity and energy balance. Whether or not they 
have a function in the pathogenesis of PCOS is mysterious. Still the peculiarities in the plasma 
concentrations of adipocytokines independent of obesity and insulin resistance in PCOS have 
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not been consistently demonstrated (Panidis, Kourtis et al. 2003; Spranger, Mohlig et al. 2004). 
The low plasma adiponectin levels have been related with an increased risk of the 
development of type 2 diabetes (Lindsay, Funahashi et al. 2002). Low adiponectin levels have 
also been connected with endothelial dysfunction (Tan, Xu et al. 2004), inflammation (Ouchi, 
Kihara et al. 2003) and coronary artery disease (Kumada, Kihara et al. 2003) 
2.2 Clinical factors 
2.2.1 Obesity 
Obesity is a well defined independent risk factor for the development of type 2 diabetes and 
cardiovascular disorder. The western lifestyle is a major cause that increased the obesity 
prevalence (Kuczmarski, Flegal et al. 1994). The hyperinsulinemia appears to be the 
principal metabolic characteristic in normoglycemic normotensive obese subjects, while 
insulin resistance is not as extensive as formerly thought (Ferrannini, Natali et al. 1997). 
Most momentously, cardiovascular morbidity and mortality are raised in obese women 
independently of other hazardous influences (Manson, Colditz et al. 1990). 
The PCOS patients are usually more obese than age matched controls, and have a rise of both 
BMI and waist/hip ratio (Talbott, Guzick et al. 1995). The appearance of obesity in women 
with PCOS diverges according to geographic location and the obese phenotype being 
remarkably common in the United States of America (Knochenhauer, Key et al. 1998). The UK 
researches showed the prevalence of obesity in PCO women was 35–38% (Kiddy, Sharp et al. 
1990; Balen, Conway et al. 1995). The prevalance of PCOS was 10–38% in Mediterranean 
countries (Diamanti-Kandarakis, Kouli et al. 1999; Asuncion, Calvo et al. 2000) and Norman et 
al. found a prevalance as high as 63% in Australia (Norman, Masters et al. 1995). 
Obesity is related with the insulin resistance, hypertension, dyslipidemia, subclinical 
inflammation and increased platelet activation, which are risk factors for atherosclerosis 
(Despres, Moorjani et al. 1990; Davi, Guagnano et al. 2002; Dalton, Cameron et al. 2003). A 
central obesity, which is demonstrated with an elevated waist/hip ratio, is an important and 
independent cardiovascular risk factor (Norman, Masters et al. 2001). The correlation 
between central obesity and cardiovascular disease in PCOS may be relatively linked to low 
plasma adiponectin levels, even though this postulate has not yet been seriously evaluated 
(Nishizawa, Shimomura et al. 2002).  
2.2.2 Hypertension 
Whether the prevalence of hypertension is increased in women with PCOS is obscure. 
Relevant researches to have utilized varying definitions of PCOS, and a wide diversity of 
techniques to evaluate blood pressure. Furthermore, studies, including those utilizing 24-h 
ambulatory blood pressure monitoring procedures, have stated inconsistent consequences 
(Dahlgren, Janson et al. 1992; Mather, Kwan et al. 2000; Wild, Pierpoint et al. 2000). Obese 
PCOS patients were found to have raised systolic but not diastolic BP compared to weight 
matched control women, although there was no divergence in blood pressure degrees between 
the non-obese group (Legro, Kunselman et al. 2001). Women with oligomenorrhea and 
hirsutism had increased levels of systolic and diastolic blood pressures compared to control 
women (Taponen, Martikainen et al. 2004). Additionally, some research indicated that an 
increased risk of having prehypertension (SBP 120 to 139 mm Hg or DBP 80 to 89 mmg Hg) in 
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women with PCOS (Lo, Feigenbaum et al. 2006), a condition related with a two-times an 
increased risk of death from a cardiovascular disease (Masi, Feigenbaum et al. 1995). 
However, existing data need to be assessed with caution, since small differences in blood 
pressure could have a great effect on the population cardiovascular risk (Rose 1981). The 
absence of momentous association with hypertension is surprising while considering the 
close link between PCOS and the metabolic syndrome. Pertinent studies have, however, 
utilized variable definitions of PCOS and employed a wide variety of techniques to assess 
blood pressure. 
2.2.3 Metabolic syndrome 
Metabolic syndrome, or the insulin resistance syndrome which has been known as a 
constellation of endocrine and biochemical markers that places affected individuals at 
important cardiovascular risk. The metabolic syndrome is described by the presence of three 
out of the five following criteria: fasting serum glucose of 100 mg/dL or greater, blood 
pressure higher than 130/85 mmHg, fasting triglyceride level greater than 150 mg/dL; 
serum high density lipoprotein cholesterol less than 50 mg/dL in females and a woman’s 
waist circumference equal to or greater than 35 inches (88 cm) (2002). 
Individuals with the metabolic syndrome have a raised likelihood of having CVD and 
increased all-cause mortality, nevertheless, in the absence of diabetes or cardiovascular 
disease at baseline (Korytkowski, Mokan et al. 1995). PCOS patients have been found to 
have an increased incidence of the metabolic syndrome (Dahlgren, Landin et al. 1998; 
Baillargeon, Jakubowicz et al. 2004). The prevalence has been stated to be as high as 43% in 
these patients, which is twofold more than the age-adjusted prevalence rate of 24% 
nationally, displayed in the NHANES III survey data analysis (Morin-Papunen, Vauhkonen 
et al. 2000). Dokras et al. revealed the age- and BMI-adjusted prevalence of the metabolic 
syndrome to be 47% in women with PCOS compare to 4.3% in controls, which renders to an 
eleven-fold increased risk (Elter, Imir et al. 2002). 
A waist circumference >88 cm (35 in) or >85 cm defined a central obesity, as proposed by 
the International Diabetes Foundation, appears to be the most common element of the 
metabolic syndrome in PCOS. Unexpectedly, Dokras et al. also displayed a 23% 
prevalence of the metabolic syndrome in those women with PCOS under 30 years of age, 
compared to 0% for their counterparts without PCOS and 6.7% prevalence among the 
same demografic values in women in the NHANES study (Elter, Imir et al. 2002; Shroff, 
Kerchner et al. 2007). Consequently, these researchers suggested that all women with 
PCOS be screened for the metabolic syndrome. Other experts related to this area also 
agreed with this suggestion. 
Furthermore, the important issue is that the usefulness of the metabolic syndrome as a 
predictor of cardiovascular disease and type 2 diabetes was recently elucidated when 
compared with established alternative, more specific risk prediction models. The Diabetes 
Predicting Model and the Framingham cardiovascular risk score estimate the future risk of 
developing type 2 diabetes and cardiovascular disease respectively. They take into 
consideration several risk factors such as ethnicity, age, gender, fasting blood glucose, blood 
pressure, lipids, smoking status and family history. When compared with the metabolic 
syndrome in a population-based cohort study these specific prediction models were found 
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to have raised the sensitivity and specificity in predicting diabetes and cardiovascular 
disease respectively (Stern, Williams et al. 2004). 
2.2.4 Mood disturbances and reduced quality of life 
Accumulating data indicated that mood disturbances, principally severe depression were 
independent risk factors for CVD (Ounpuu, Negassa et al. 2001) and prevalent in PCOS 
(Jones, Hall et al. 2008; Bishop, Basch et al. 2009). Various studies displayed increased 
prevalence of depression and anxiety in women with PCOS. These mood alterations and 
impaired quality of life cause tiredness, sleep disturbances, phobia, appetite changes, and 
binge eating (Hollinrake, Abreu et al. 2007; Bishop, Basch et al. 2009; Jedel, Waern et al. 
2010). Consequenctly, depressed women with PCOS have higher BMI and greater IR as 
CVD risk factors than nondepressed women with PCOS without discrepancies in androgen 
status(Hollinrake, Abreu et al. 2007), whereas weight loss by an energy-restricted diet 
ameliorates their depression and quality of life (Thomson, Buckley et al. 2010). It remains to 
be resolved how mood disturbances as CVD risk factors are associated with shifted stress 
responsiveness in PCOS patients, as demonstrated by excessive ACTH and cortisol stress 
responses, disabled IL-6 reply following stres (Benson, Arck et al. 2009), and raised 
sympathetic nerve activity (Sverrisdottir, Mogren et al. 2008). 
2.2.5 Obstructive sleep apnea 
Reports in recent years have revealed on another comorbidity connected with PCOS, 
obstructive sleep apnea (OSA). OSA has significant clinical consequences, involving raised 
daytime sleepiness, decreased quality of life, and lessened cognitive performance. Serious 
cardiovascular effects have also been shown to consequences from OSA, comprising 
hypertension (Brooks, Horner et al. 1997; Lavie, Herer et al. 2000),stroke (Dyken, Somers et 
al. 1996), and myocardial infarction (Hung, Whitford et al. 1990). Fogel et al. was shown that 
obese women with PCOS had substantially raised Apnea- Hypopnea Index (AHI) when 
compared to age- and weight-matched controls. Moreover, this research demonstrated that 
PCOS patients were also nine times as more likely to suffer from OSA when compared to 
the control group (Fogel, Malhotra et al. 2001). Another study performed by Vgontzas et al. 
displayed sleep-disturbed breathing prevalence 30 times more in PCOS patients than the 
control group (Vgontzas, Legro et al. 2001). 
The high prevalence of OSA has been regard to be a role of both increased levels of 
testosterone as well as the obesity that prevalently accompanies PCOS. Nevertheless, it 
looks that the high commonness of OSA in PCOS cannot be completely explained for based 
on these two causes solely (Nitsche and Ehrmann 2010). Insulin resistance was found to be a 
sharper predictor of sleep disordered breathing than was age, circulating testosterone 
concentrations and BMI (Vgontzas, Legro et al. 2001). It also revealed that women with 
PCOS taking oral contraceptives were reduced probability to have sleep disordered 
breathing, uniform with new consequences from the Sleep Heart Health Study Research 
Group in which hormone-replacement treatment was related with an inferior possibility of 
sleep disordered breathing among post-menopausal women (Shahar, Redline et al. 2003). 
Obese PCOS patients are more likely to suffer from OSA compared to lean patients. The 
important morbidity and mortality, associated with this condition. PCOS patients should be 
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screened meticulously with regard to characteristics of daytime sleepiness, morning 
headaches, snoring, and other symptoms of OSA and directed for proper studies to verify 
this diagnosis. 
3. Subclinical atherosclerosis 
Even though the epidemiologic data on cardiovascular events are sparse in women with 
PCOS, the evaluation of cardiovascular structure and function is providing proof that PCOS 
and its related clinical phenotype clearly affects the arterial wall and/or myocardium. 
3.1 Carotid intima media thickness 
The CIMT has been displayed in numerous studies to predict cardiovascular events, with 
increasing CIMT correlated with an elevated age-adjusted cardiovascular risk (Bots, Dijk et 
al. 2002). Increased carotid intima media thickness (IMT), reminiscent of a raised risk for 
atherosclerosis, was displayed in a small group of PCOS patients over 40 years of age. 
However, there were no important discrepancies in the prevalence of carotid plaque 
amongst cases and controls (Guzick, Talbott et al. 1996). This result was independent of 
dyslipidemia but not plasma insulin levels and obesity. Nevertheless, Talbott et al. stated 
that CIMT measurements were only distinctive in older PCOS patients compared with 
controls, and after adjusting for coexistent cardiovascular risk factors PCOS was not a 
significant predictor of CIMT. This study additionally reported a substantially greater 
carotid plaque index in the PCOS subjects compared with controls. These results imply that 
in women with PCOS, subclinical atherosclerosis may not be obvious up to the time of the 
perimenopause (Talbott, Guzick et al. 2000). 
Recently, two researches to have displayed a significant difference in CIMT among young, 
normal weight PCOS patients compared with controls (Orio, Palomba et al. 2004; Vural, 
Caliskan et al. 2005). Vural et al. demonstrated that PCOS, BMI and a reduced sex hormone 
binding globulin were all independent predictors of CIMT (Vural, Caliskan et al. 2005). 
However, the report by Orio et al ., showed a strong association between CIMT and the free 
androgen index that suggests a contribution of hyperandrogenemia to evolvement of 
atherosclerosis in PCOS (Orio, Palomba et al. 2004). Contrarily, in a larger study raised 
CIMT was conversely correlated with plasma DHEAS and androstenedione concentrations, 
proposing a fascinating vasculoprotective influence of hyperandrogenemia in PCOS 
(Vryonidou, Papatheodorou et al. 2005). Meyer et al. also found a similar vasculoprotective 
effect of DHEAS in a study involving 80 obese women with PCOS, where higher DHEAS 
corresponded to notably lower CIMT (Meyer, McGrath et al. 2005). Whether the DHEAS has 
actually beneficial effects on atherogenesis in PCOS obscure and needs further studies to 
elucidate this issue. 
3.2 Coronary artery calcification 
Coronary artery calcification (CAC) demonstrates the grade of atherosclerosis and is early 
marker for clinical events. The electron beam computer tomography, has been employed to 
show raised arterial calcification in the coronary circulation in PCOS women compared with 
controls (Christian, Dumesic et al. 2003). Since adjusting for BMI, dyslipidemia remained a 
useful prognosticator of coronary calcification. The research of Mayo Clinic found a 3-fold 
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rise in CAC in non-diabetic PCOS cases than population controls (Christian, Dumesic et al. 
2003). Moreover, when these same participants were compared to obese control women, the 
participants with PCOS had 2-fold higher degrees of CAC. The intriguing prospective, case-
control research with over a nine year follow-up period in PCOS reported by Talbott et al. 
display an increased incidence of coronary and aortic arterial calcification (Talbott, Zborowski 
et al. 2004). Young obese PCOS patients have been shown to have a five times raised 
prevalence of subclinical CAD with the presence of momentous CAC as contrasted to age- and 
weight matched women (Shroff, Kerchner et al. 2007). The features of metabolic syndrome 
affect the grade of calcification, comprising central obesity, elevated blood pressure and 
dyslipidemia, and as a consequence insulin resistance. In that study, the degree of aortic 
calcification was also positively associated with plasma testosterone concentrations, 
questioning a presumed atheroprotective nature of hyperandrogenemia in PCOS. These 
reports, accompanied with angiographic statistics in women displayed a correlation among 
coronary artery disease and polycystic ovaries (Birdsall, Farquhar et al. 1997). 
3.3 Endothelial dysfunction 
Endothelial dysfunction is recognized to be an early characteristic in the progression of 
atherosclerosis, and the greater part of researches of macro- and micro-vascular endothelial 
function in women with PCOS has displayed significant peculiarities. The findings of the 
studies revealed that arterial dilatory function was a sign for the presence of endothelial 
dysfunction in distinct arterial beds in women with PCOS and was related to endothelial 
dysfunction among insulin resistance and less consistently to hyperandrogenemia. Related 
mechanisms almost certainly account for the effect of insulin resistance on the biology of 
NO in both conduit and resistance arteries in PCOS patients (Paradisi, Steinberg et al. 2001; 
Kelly, Speirs et al. 2002; Orio, Palomba et al. 2004). These studies collectively confirmed that 
increased arterial stiffness, myocardial and endothelial dysfunction showed solid 
pathophysiological proof for arterial atherosclerosis in women with PCOS. Many of these 
studies have shown a correlation between insulin resistance and cardiovascular 
abnormalities, and supported the hypothesis that insulin resistance remains at the vascular 
level in women with PCOS. However, still needs further proof for the associate with the 
clinical cardiovascular events. 
3.4 Ventricular function 
One of the early manifestations of diabetic cardiomyopathy is left ventricular (LV) diastolic 
dysfunction which has been recognized as a predictor for cardiovascular events in 
hypertensive patients (Schannwell, Schneppenheim et al. 2002; Schillaci, Pasqualini et al. 2002). 
Its etiology is multifactorial and refers to hypertension, coronary artery disease, insulin 
resistance, autonomic neuropathy, microangiopathy, dyslipidemia, endothelial dysfunction 
and oxidative stres (Brutsaert, Sys et al. 1993). The case control prospective studies that utilize 
echocardiographic methods demonsrated that women with PCOS were found to have a raised 
isovolumetric relaxation time (IVRT), an indicator of the early LV diastolic dysfunction, and 
lower ejection fraction in contrast to weight matched controls. In addition, an important clear 
connection among plasma insulin levels and IVRT was displayed in PCOS patients (Tiras, 
Yalcin et al. 1999). These results were consistent with another study which demonstrated an 
independent association between hyperinsulinemia and LV mass (Orio, Palomba et al. 2004). 
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The postulate that insulin resistance may contribute to myocardial dysfunction in PCOS has 
been supported with these studies’ findings. 
3.5 Aortic stiffness 
The peripheral circulation arterial stiffness is related to raised systolic blood pressure, pulse 
pressure and ventricular load, as well as to decreased diastolic perfusion of the coronary 
blood flow. Arterial stiffness may be assessed by two approaches. One is the 
ultrasonographic evaluation of carotid artery distensibility by measuring pulse wave 
velocity (PWV) and the other one analysis of the diastolic part of the radial waveform (Bots, 
Dijk et al. 2002). Arterial stiffness is increased in other diseases such as in renal failure it has 
been indicated to have prognostic value for cardiovascular events (London, Marchais et al. 
2004). Kelly et al. found increased pulse wave velocity of the brachial artery, but not of the 
aorta, in PCOS patients in a small case control study (Kelly, Speirs et al. 2002). Likewise, 
Lakhani et al. showed raised stiffness of both internal and external carotid arteries in 
women with both PCOS and PCO (ultrasonographic polycystic ovaries alone) compared 
with controls. Multivariate analysis implied independent influences of PCOS and PCO on 
arterial stiffness (Lakhani, Constantinovici et al. 2000). 
4. Cardiovascular events 
In spite of the fact that cardiovascular risk factors are more frequently found in PCOS 
patients, reliable proof for a raised prevalence of cardiovascular disease is lacking. The 
predicted relative risk of myocardial infarction was found 7,4 by the calculated risk factor 
profile in a small group of women (n = 33) with histopathological verification of polycystic 
ovaries (PCO) compared with aged-matched controls (Dahlgren, Janson et al. 1992).  
A subsequent study that included 142 women undergoing coronary angiography revealed 
that polycystic ovaries were independently correlated with the presence of an extent of 
coronary atherosclerosis determined during catheterization. The examination of pelvic 
ultrasonography imaging showed that forty two percent of these women had polycystic 
ovaries. Moreover, these patients had more extensive coronary artery disease than the group 
without polycystic ovaries, established on a number of segments by more than 50% stenosis 
(Fogel, Malhotra et al. 2001). 
Nevertheless, a larger retrospective cohort found that PCOS patients (n = 345) diagnosed 
primarily with ovarian morphology, had further cardiovascular risk factors, comprising 
obesity, diabetes, hypertension and hyperlipidemia. Their mortality and morbidity from 
coronary heart disease didn't show a disparity from age-matched controls (n = 1060) (Wild, 
Pierpoint et al. 2000). This remarkable result could be explained with the ascertainment bias, 
to application of a non-standard description of PCOS, or perhaps to a cardiovascular 
defensive impact of hyperandrogenemia. Even though, after adjusting for BMI, the odd's 
ratios for developing diabetes and cerebrovascular disease in this analysis were raised 
considerably at 2.3 and 2.8, respectively. 
The Women’s Ischemia Syndrome Evaluation (WISE) is the most important study that 
evaluated both cardiovascular risk and consequences in women with PCOS. WISE is a 
multicenter research that intends to ameliorate diagnostic testing for ischemic heart disease 
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in women and to study pathophysiology and prognosis in women with symptoms and 
proof of myocardial ischemia in the absence or presence of obstructive coronary artery 
disease (CAD). The researchers included 390 postmenopausal women and diagnosed PCOS 
with the rise in blood serum androgen concentrations integrated with a premenopausal 
history of irregular menses (n =104). Notably, the prevalence (27%) of PCOS was 
considerably higher than the population anticipation (5%–8%). However, women with 
ischemia may represent a refined pool for women with PCOS. Clinically most significant 
consequence is the cumulative 5-year cardiovascular event-free survival was 78.9% for 104 
women with PCOS and 88.7% for 286 women without PCOS (Shaw, Bairey Merz et al. 2008).  
Two more studies provided further support to the link between PCOS and CVD. One of them 
is a cross-sectional study, which included 713 postmenopausal women (mean age, 73.8 yr) and 
found in nondiabetic women with intact ovaries, a step-by-step categorized association 
between CVD and quantities of features of assumed PCOS, as described by premenopausal 
menstrual irregularity, hirsutism, or present biochemical hyperandrogenism (Krentz, von 
Muhlen et al. 2007). The other case-control study recruited 414 postmenopausal women (mean 
age, 60.4 yr), used premenopausal menstrual irregularity as a putative sign of PCOS, and 
found an increased odd's ratio for coronary vascular disorder (Azevedo, Duarte et al. 2006). 
Since the majority of studies centered on surrogate results and there are weak at detecting true 
discrepancies in these consequences, we need extended-course of data to evaluate real risk. 
5. Management of CVD risk factors 
The PCOS treatment aims at amelioration of ovarian function, involving regulating and 
averting anovulatory uterine hemorrhagia, diminishing obesity, controlling cardiovascular 
risk factors such as insulin resistance, diabetes, hypertension, hyperlipidemia. Nevertheless, 
there is no better treatment alternative distinct from lifestyle modification. Numerous 
researches indicated that improving insulin sensitivity with lifestyle modifications or 
pharmacological treatment can diminish circulating androgen levels, and increase 
spontaneous ovulation and pregnancy. 
5.1 Lifestyle modification 
The most valuable approaches for improving insulin sensitivity in overweight, obese PCOS 
patients are diet, weight reduction, and physical activity. Obesity has changed into an 
epidemic in most parts of the world and has a marked on reproductive and metabolic 
peculiarities in women with PCOS. Regrettably there are no optimized medical therapies at 
this point that causes a permanent weight loss. Moreover, it was reported that 90–95% of 
subjects who achieved a weight loss will generally relapse (Rosenbaum, Leibel et al. 1997). 
The efficacious surgical alternative for the morbidly obese PCOS patients may be a bariatric 
surgery. However, there has been a few reports of this intervention in this special group. 
The lifestyle modification for overweight/ obese patients, comprising diet, exercise, 
termination of smoking, and behavioral modification (Norman, Davies et al. 2002), may 
have beneficial effects to decrease CVD risk (De Backer, Ambrosioni et al. 2003). The 
researches revealed that short-period weight-loss intervention in PCOS patients lowers 
abdominal fat (Andersen, Seljeflot et al. 1995; Holte, Bergh et al. 1995), lessens androgen 
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The postulate that insulin resistance may contribute to myocardial dysfunction in PCOS has 
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levels (Holte, Bergh et al. 1995), IR and in addition ameliorates dyslipidemia, depression, 
and quality of life, even though long-term weight loss is improbable (Andersen, Seljeflot et 
al. 1995; Thomson, Buckley et al. 2010). 
Numerous studies in PCOS patients have demonstrated, that weight reduction can 
ameliorate the main characteristics of the endocrine syndrome of PCOS. Weight reduction 
decrease circulating androgen levels and restart the menstrual cycle (Guzick, Wing et al. 
1994; Okajima, Koyanagi et al. 1994; Clark, Ledger et al. 1995).These alterations can be 
obtained with a weight loss as small as 5% of the initial weight (Franks, Kiddy et al. 1991; 
Kiddy, Hamilton-Fairley et al. 1992). Additional advantages that have been reported to have 
lowered circulating insulin levels (Kiddy, Hamilton-Fairley et al. 1989; Kiddy, Hamilton-
Fairley et al. 1992). The reduction of free testosterone concentrations, subsequent weight loss 
mostly mediated through increases by SHBG (Franks, Kiddy et al. 1991; Kiddy, Hamilton-
Fairley et al. 1992). 
The hypocaloric, low saturated fat, increased mono- and polyunsaturated fat nutrition is 
advocated, simultaneously with at least 30 min of intermediate-strength physical activity 
every day to maintain weight. Together both decrease BMI and ameliorate IR and 
cardiopulmonary function in overweight/obese PCOS patients (Vigorito, Giallauria et al. 
2007) and performed greater decreases in fat mass in PCOS women (Bruner, Chad et al. 
2006). Altering a dietary macronutrient constitution does not offer a benefit for weight loss 
over prevalent dietetic approaches solely (Moran, Pasquali et al. 2009). 
However, the majority of PCOS patients difficult to achieve desirable weight loss, despite a 
caloric reduction and modification to healthier diets and physical activity. It may be even 
harder for these subjects to maintain weight loss, especially whether they are insulin 
resistant. As well as 10-30% of women with PCOS are lean, weight loss is not a choice for 
their management. 
5.2 Insulin sensitizers 
Medications developed to treat type 2 diabetes that have insulin sensitizing properties (ie, 
metformin and thiazolidinediones) have been utilized to treat PCOS, because both diseases 
are thought to be developed based on impaired insulin action. This class of medication 
enhance insulin sensitivity and transform impaired to normal glucose tolerance in non-
diabetic women with PCOS. These drugs, additionally improve metabolic predictors of 
cardiovascular risk in PCOS patients, comprising serum triglycerides, PAI-I, and lower 
blood pressure (Diamanti-Kandarakis, Kouli et al. 1998; Moghetti, Castello et al. 2000). The 
data provided from the UKPDS, a research of diabetic men and women, showed that there 
may be lesser cardiovascular events in insulin-resistant individuals treated with insulin-
sensitizing drugs (1998). 
5.2.1 Metformin 
Metformin is one of the most frequently prescribed drugs to treat PCOS. Metformin has 
constantly shown an insulin lowering effect, and that may be its prime mechanism of action. 
Metformin was certified for the usage of type 2 diabetes by the FDA in 1994, although has 
been used clinically for approximately to 20 years formerly in other parts of the world 
(Coetzee and Jackson 1979). 
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Study results regarding the effects of metformin on primary prevention of CVD are not 
coherent (Moghetti, Castello et al. 2000; Diamanti-Kandarakis, Alexandraki et al. 2005; Rautio, 
Tapanainen et al. 2005). Metformin has a little influence on body weight (less than 2–3% of 
BMI) (Moghetti, Castello et al. 2000; Rautio, Tapanainen et al. 2005; Nieuwenhuis-Ruifrok, 
Kuchenbecker et al. 2009) and may ameliorate atherogenic dyslipidemia, raising HDL-C and 
lowering triglycerides (Rautio, Tapanainen et al. 2005; Trolle, Flyvbjerg et al. 2007). 
Nevertheless, no alterations in HDL-C or triglycerides were seen in some studies 
(Banaszewska, Pawelczyk et al. 2009). Metformin cannot improve LDL-C or non-HDL-C 
(Rautio, Tapanainen et al. 2005; Trolle, Flyvbjerg et al. 2007; Banaszewska, Pawelczyk et al. 
2009). Furthermore, several studies with metformin have shown that, it lessens of circulating 
C-reactive protein, PAI-1 (Velazquez, Acosta et al. 1997; Morin-Papunen, Rautio et al. 2003) 
and may ameliorate premature atherosclerosis, decrease carotid IMT and enhance endothelial 
function (Diamanti-Kandarakis, Alexandraki et al. 2005; Agarwal, Rice et al. 2010).  
The research of Sharma et al. investigated the efficacy of metformin in averting progression 
to type 2 diabetes, particularly in PCOS patients. During 43.3 months of treatment with 
metformin, 5% (N.=2) of the 39 patients with normal glucose tolerance at baseline 
transformed to impaired glucose tolerance, bearing an annual conversion rate of 1.4%. The 
published article's stated a 16-19% annual conversion rate for PCOS women, therefore, 
rendering a 11-fold decrease in the annual conversion to impaired glucose tolerance in this 
metformin given PCOS women. Moreover, none of the fifty PCOS women developed 
diabetes throughout the study period (Sharma, Wickham et al. 2007). 
5.2.2 Thiazolidinediones 
Thiazolidinediones (TZDs) have been proposed as a treatment option for many of the 
metabolic aspects of PCOS. These drugs act by increasing insulin stimulated glucose uptake, 
principally in adipose and skeletal muscle tissues. The activation of γ-peroxisome proliferation 
activator receptors (PPAR-γ) activates the genes that encode insulin. Troglitazone was the first 
to be used in this class. Troglitazone treatment improved endothelial function in obese PCOS 
patients when compared to age and weight matched controls (Paradisi, Steinberg et al. 2003) . 
The same result was obtained with rosiglitazone (Tarkun, Cetinarslan et al. 2005) and 
pioglitazone (Romualdi, Guido et al. 2003). Troglitazone additionally lowered circulating 
insulin levels, improved hirsutism, and increased the ovulation rates of PCOS patients 
(Paradisi, Steinberg et al. 2003)(Dunaif, Scott et al. 1996). A study examined the effects of 
metformin, rosiglitazone, and a combination of these drugs in non-obese PCOS patients with 
no clinical or biochemical proof of insulin resistance. Together with other findings, measures 
of insulin sensitivity was ameliorated meaningfully with metformin and combination therapy, 
but not with rosiglitazone solely (Baillargeon, Jakubowicz et al. 2004). 
Troglitazone and rosiglitazone, at present, are not available due to liver toxicity and 
cardiovascular side effects respectively. Pioglitazone is the only available molecule in this 
class and to date did not have the hepatic side effects of their predecessors. A new study 
closely assessed cardiovascular risk factors in women with PCOS randomized to 
pioglitazone or placebo for 16 weeks (Glintborg, Hojlund et al. 2008). Enhancement of 
insulin sensitivity determined with clamp technique, however a serum marker of 
atherosclerosis sCD36 and hs-CRP significantly diminished. Insignificant alterations were 
measured in body weight or body composition in the treatment patients, which was 
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unexpected, given the tendency to weight gain with thiazolidinedione remedies. Another 
recent analysis randomized 60 women with PCOS for 24 weeks to exenatide (a glucagon-like 
peptide-1 [GLP-1] analogue in the incretin class of drugs), metformin, or a combination of 
both (Elkind-Hirsch, Marrioneaux et al. 2008). The research revealed greater weight loss 
with exenatide than with metformin and found an additive effect of both. Even though no 
serious side effects (ie, pancreatitis with exenatide) were noted althought the knowledge 
with incretins in women with PCOS is very limited. 
5.3 Cholesterol lowering drugs 
The HMG-CoA reductase inhibitors are a class of cholesterol- lowering agents, also 
recognized as statins, are blocking the rate limiting step of cholesterol synthesis. Restriction 
of mevalonate production may furthermore cause diminished maturation of insulin 
receptors, inhibition of steroidogenesis (via restricting the substrate cholesterol), and change 
of signal transduction pathways that mediate cellular proliferation (Kodaman and Duleba 
2008). They are thought to have a favorable influence on cardiovascular risk independent of 
their lipid-lowering effect as well, expectedly by pleiotropic activity on systemic 
inflammation and oxidative stress, the mechanism of which is still to be determined. Stress 
and inflammation are also thought to play a role in the progression of ovarian theca cell 
hyperplasia, lead to anovulation and hyperandrogenism in PCOS. 
Even though several lipid-lowering medications have been tried (Rizzo, Berneis et al. 2008; 
Rosenzweig, Ferrannini et al. 2008), only statins have been adequately studied in women 
with PCOS and have efficiently lowered LDL-C levels (Banaszewska, Pawelczyk et al. 2009; 
Sathyapalan, Kilpatrick et al. 2009) . Several studies found that, statins decrease IR and 
inflammation, reduce serum total and free testosterone concentrations, and ameliorate 
endothelial dysfunction in PCOS patients (Duleba, Banaszewska et al. 2006; Banaszewska, 
Pawelczyk et al. 2009; Sathyapalan, Kilpatrick et al. 2009). Nevertheless, their usage in 
gestation is contraindicated, and contraception is needed. 
Patients with serious dyslipidemia that is not adequately corrected by lifestyle modification 
and statins may need double pharmacotherapy. It has been found that the addition of 
metformin does not ameliorate lipid levels furthermore (Banaszewska, Pawelczyk et al. 
2009). Statins combined with a fibrate may be required when hypertriglyceridemia and low 
HDL levels coexist. Fenofibrate is favored because of less drug interactions and the 
diminished possibility of myopathy (Zambon and Cusi 2007; Rosenzweig, Ferrannini et al. 
2008). Nicotinic acid causes a beneficial effect on lipoproteins however needs cautious 
monitoring for deterioration of glycemic control (Rosenzweig, Ferrannini et al. 2008). 
5.4 Hypertension theraphy 
Antihypertensive drug medication is recommended for blood pressure of more than 140 
mmHg systolic or 90 mmHg diastolic. Since milder elevation of BP (or prehypertension), 
increase CVD risk, diminishing BP to 120/80 mm Hg is desirable for longtime CVD 
protection (Rosenzweig, Ferrannini et al. 2008). Most of the researchers recommend merging 
pharmacotherapy accompanied by lifestyle modification for incessant hypertension in PCOS 
patients. Even though some investigators favor angiotensin-converting enzyme inhibitors 
and angiotensin receptor blockers over diuretics and beta-blockers, utilitization of 
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angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, diuretics and beta-
blockers is contraindicated in pregnancy and requires contraception. 
5.5 Antiobesity medications 
Phenteramine, sibutramine, and orlistat are FDA-approved weight loss medicines. A 
number of researches have found that sibutramine combined with a hypocaloric diet 
enhances weight loss, improves IR, and hypertriglyceridemia, decrease serum free 
testosterone concentrations, to a greater extent than hypocaloric diet alone. However, this 
drug may raise diastolic BP and heart rate and is not approved in the course of gestation. 
Orlistat causes a smaller degree of weight loss. Since the clinical experience with these 
agents is limited in PCOS and unexpected side effects may happen, authorities do not 
advocate the utilitization of weight loss medicines in women with PCOS. 
6. Conclusion and future aspects 
Although the epidemiologic data is uncertain, current study results strongly support a 
correlation between PCOS and cardiovascular risk factors, which are represented in Figure 1. 
Discrepancies among some of the reports reviewed in this chapter, may be due to small 
sample sizes, bias in case-control designs and the non-standard delineations of PCOS criteria.  
Data accumulated to date, indicate that insulin resistance, and obesity may be responsible for 
early ventricular functional abnormalities, arterial stiffness, endothelial dysfunction and both 
carotid and coronary atherosclerosis. These abnormalities may be detrimental consequences of 
insulin resistance per se, such as dyslipoproteinemia, hypertension, low grade inflammation, 
raised oxidative stress, changed hemostasis and coagulation system alterations. The 
diminished synthesis of nitric oxide (NO) and excess production of peroxinitrite are 
apparently principal factors to initiate endothelial dysfunction and atherothrombosis. 
The function of hyperandrogenemia in subscribing to the cardiovascular abnormalities 
surveyed remains obscure and debatable. Most researches detected androgens as a 
cardiovascular risk in women with PCOS. Even though the minority of reports examined 
indicated an independent correlation of androgens with impaired cardiovascular structure or 
function. This additionally strengthens the thought that cardiovascular risk in PCOS resides to 
insulin resistance rather than hyperandrogenemia. Furthermore, some studies showed that in 
PCOS patients, androgens, particularly DHEAS, have been a negative association with CIMT. 
Weight loss is realizable with lifestyle alterations, bariatric surgery, and pharmaceutical 
treatment, involving antiobesity and antidiabetic medications. Insulin sensitizers and 
statins, particularly in combination with hormonal remedies such as OCPs, oral 
contraceptives seem to have beneficial properties. Nonetheless, greater and longer trials are 
required previously to elucidate, which is the best treatment to impede cardiovascular 
events in women with PCOS can be advocated. 
The postulation for the development of cardiovascular disease in PCOS founded on the 
studies surveyed and permitting the illustration in Figure 1.It summarizes possible pathways 
throughout the cardiovascular risk factors to CVD. However, the presence of these 
cardiovascular risk factors in women with PCOS, at this time sufficient prospective results that 
supporting the actual prevalence of cardiovascular events in PCOS patiens are lacking. 
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both (Elkind-Hirsch, Marrioneaux et al. 2008). The research revealed greater weight loss 
with exenatide than with metformin and found an additive effect of both. Even though no 
serious side effects (ie, pancreatitis with exenatide) were noted althought the knowledge 
with incretins in women with PCOS is very limited. 
5.3 Cholesterol lowering drugs 
The HMG-CoA reductase inhibitors are a class of cholesterol- lowering agents, also 
recognized as statins, are blocking the rate limiting step of cholesterol synthesis. Restriction 
of mevalonate production may furthermore cause diminished maturation of insulin 
receptors, inhibition of steroidogenesis (via restricting the substrate cholesterol), and change 
of signal transduction pathways that mediate cellular proliferation (Kodaman and Duleba 
2008). They are thought to have a favorable influence on cardiovascular risk independent of 
their lipid-lowering effect as well, expectedly by pleiotropic activity on systemic 
inflammation and oxidative stress, the mechanism of which is still to be determined. Stress 
and inflammation are also thought to play a role in the progression of ovarian theca cell 
hyperplasia, lead to anovulation and hyperandrogenism in PCOS. 
Even though several lipid-lowering medications have been tried (Rizzo, Berneis et al. 2008; 
Rosenzweig, Ferrannini et al. 2008), only statins have been adequately studied in women 
with PCOS and have efficiently lowered LDL-C levels (Banaszewska, Pawelczyk et al. 2009; 
Sathyapalan, Kilpatrick et al. 2009) . Several studies found that, statins decrease IR and 
inflammation, reduce serum total and free testosterone concentrations, and ameliorate 
endothelial dysfunction in PCOS patients (Duleba, Banaszewska et al. 2006; Banaszewska, 
Pawelczyk et al. 2009; Sathyapalan, Kilpatrick et al. 2009). Nevertheless, their usage in 
gestation is contraindicated, and contraception is needed. 
Patients with serious dyslipidemia that is not adequately corrected by lifestyle modification 
and statins may need double pharmacotherapy. It has been found that the addition of 
metformin does not ameliorate lipid levels furthermore (Banaszewska, Pawelczyk et al. 
2009). Statins combined with a fibrate may be required when hypertriglyceridemia and low 
HDL levels coexist. Fenofibrate is favored because of less drug interactions and the 
diminished possibility of myopathy (Zambon and Cusi 2007; Rosenzweig, Ferrannini et al. 
2008). Nicotinic acid causes a beneficial effect on lipoproteins however needs cautious 
monitoring for deterioration of glycemic control (Rosenzweig, Ferrannini et al. 2008). 
5.4 Hypertension theraphy 
Antihypertensive drug medication is recommended for blood pressure of more than 140 
mmHg systolic or 90 mmHg diastolic. Since milder elevation of BP (or prehypertension), 
increase CVD risk, diminishing BP to 120/80 mm Hg is desirable for longtime CVD 
protection (Rosenzweig, Ferrannini et al. 2008). Most of the researchers recommend merging 
pharmacotherapy accompanied by lifestyle modification for incessant hypertension in PCOS 
patients. Even though some investigators favor angiotensin-converting enzyme inhibitors 
and angiotensin receptor blockers over diuretics and beta-blockers, utilitization of 
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angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, diuretics and beta-
blockers is contraindicated in pregnancy and requires contraception. 
5.5 Antiobesity medications 
Phenteramine, sibutramine, and orlistat are FDA-approved weight loss medicines. A 
number of researches have found that sibutramine combined with a hypocaloric diet 
enhances weight loss, improves IR, and hypertriglyceridemia, decrease serum free 
testosterone concentrations, to a greater extent than hypocaloric diet alone. However, this 
drug may raise diastolic BP and heart rate and is not approved in the course of gestation. 
Orlistat causes a smaller degree of weight loss. Since the clinical experience with these 
agents is limited in PCOS and unexpected side effects may happen, authorities do not 
advocate the utilitization of weight loss medicines in women with PCOS. 
6. Conclusion and future aspects 
Although the epidemiologic data is uncertain, current study results strongly support a 
correlation between PCOS and cardiovascular risk factors, which are represented in Figure 1. 
Discrepancies among some of the reports reviewed in this chapter, may be due to small 
sample sizes, bias in case-control designs and the non-standard delineations of PCOS criteria.  
Data accumulated to date, indicate that insulin resistance, and obesity may be responsible for 
early ventricular functional abnormalities, arterial stiffness, endothelial dysfunction and both 
carotid and coronary atherosclerosis. These abnormalities may be detrimental consequences of 
insulin resistance per se, such as dyslipoproteinemia, hypertension, low grade inflammation, 
raised oxidative stress, changed hemostasis and coagulation system alterations. The 
diminished synthesis of nitric oxide (NO) and excess production of peroxinitrite are 
apparently principal factors to initiate endothelial dysfunction and atherothrombosis. 
The function of hyperandrogenemia in subscribing to the cardiovascular abnormalities 
surveyed remains obscure and debatable. Most researches detected androgens as a 
cardiovascular risk in women with PCOS. Even though the minority of reports examined 
indicated an independent correlation of androgens with impaired cardiovascular structure or 
function. This additionally strengthens the thought that cardiovascular risk in PCOS resides to 
insulin resistance rather than hyperandrogenemia. Furthermore, some studies showed that in 
PCOS patients, androgens, particularly DHEAS, have been a negative association with CIMT. 
Weight loss is realizable with lifestyle alterations, bariatric surgery, and pharmaceutical 
treatment, involving antiobesity and antidiabetic medications. Insulin sensitizers and 
statins, particularly in combination with hormonal remedies such as OCPs, oral 
contraceptives seem to have beneficial properties. Nonetheless, greater and longer trials are 
required previously to elucidate, which is the best treatment to impede cardiovascular 
events in women with PCOS can be advocated. 
The postulation for the development of cardiovascular disease in PCOS founded on the 
studies surveyed and permitting the illustration in Figure 1.It summarizes possible pathways 
throughout the cardiovascular risk factors to CVD. However, the presence of these 
cardiovascular risk factors in women with PCOS, at this time sufficient prospective results that 
supporting the actual prevalence of cardiovascular events in PCOS patiens are lacking. 
 




Fig. 1. Postulation for the pathogenesis of cardiovascular disease in PCOS. This figure 
outlines possible pathways which cardiovascular risk factors associated with PCOS may 
render into manifest cardiovascular disease.  
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Definitive prospective data to support a rise in adverse cardiovascular events in women 
with PCOS is non-existent. However, the most recent studies have firmed up the connection 
among women with PCOS and CVD events, even though they tend to present in menopause 
and not in reproductive-age women. Former prediction models have appraised a 
proportional risk of myocardial infarction of 7.4 PCOS patients. Nevertheless, a large 
retrospective report of PCOS women showed elevated ratios of diabetes and 
cerebrovascular disease but not cardiovascular disease, proposing that the earlier estimate 
of cardiovascular risk may have been extreme. Consequently, that researches perform 
hereafter have to analyses cardiovascular health results and endeavour to clarify those 
subgroups that are sharper risk for cardiovascular disease in women with PCOS. 
From a clinical aspect, the current statistics imply that management should focus on the 
designation and treatment of peculiar cardiovascular risk factors recognized to occur more 
frequently PCOS patients. In particular, lifestyle modification, the avoidance of weight gain 
and obesity, and the long-term surveillance for evolvement of type 2 diabetes should be 
accented. After menopause conventional cardiovascular risk accelerates in women, have to 
be evaluated with precisely mentioning to PCOS. The consequences of interferences such as 
exogenous oestrogens and anti-androgen treatment on cardiovascular risk in PCOS also 
required to be investigated further. The high prevalence of this disease in reproductive age 
women, and the possible correlation with cardiovascular disease, cause future examinations 
in this issue a priority importance from both a public health and clinical aspect. 
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1. Introduction 
During a recent high-level endocrinology congress, the session on the polycystic ovary 
syndrome (PCOS) included a lecture on fertility problems. This was started with a remark 
that the gynaecologist and other medical professionals should bring their treatment efforts 
closer. I was glad to hear this but thereafter the lecturer talked exclusively about ovulation 
induction and in vitro fertilisation; and did not say anything about how these efforts 
affected other medical problems related to PCOS, or the future course of the disease, or what 
else could be done if the discussed fertility approaches fail (in a high proportion of cases). 
Why then did he call attention to bringing treatment protocols closer? 
Somebody remarked that in their experience even a few months’ pre-treatment with 
metformin improved the results but this was rebuffed by the lecturer that such efforts had 
not reached sound evidence. After the session, I asked him in private if his patients should 
have been treated for other existing problems beyond infertility like acne, hirsutism or 
obesity. The answer was short “They didn’t complain about anything else” and he turned 
his back to me. Well, in all likelihood the patients must have had some hyperandrogenic 
symptoms as a prerequisite of the diagnosis. In addition, most published fertility studies in 
the PCOS literature include grossly obese patients. Since obesity alone is a well known 
contributor to infertility; would be wiser to wait until these women slim down... we have 
not come closer. 
I was a bit angry for not having been taken seriously but it was not the first time I experienced 
a similar attitude. The patients with irregular periods usually visit the gynaecologist. The 
general advice that follows is the use of the contraceptive pill if the lady is not interested in 
becoming pregnant at the moment; or the pharmaceutical stimulation of the ovaries or the 
laparoscopic drilling to remove the cysts from them if the lady desires a baby. 
I bring forth a story of a young girl. Eleni has no plans to get pregnant for years so upon the 
gynaecologist’s advice she starts taking the pill. Her acne spots (all teenagers have pimples, 
haven’t they) and some ugly hairs under her nose were not mentioned and were not 
commented on either during the visit. Since she doesn’t remember or it had not been 
explained for how long the pills should be taken, she stops the pill after a year or so. She has 
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no boyfriend; the pill might have caused side effects. Despite her spots decreasing and 
having to remove hair from her face less frequently while on the pill, she gained more 
weight, interestingly, mainly around the waistline. Was it this why she has not attracted the 
boys? Off the pill, the annoying spots and hair growth return and the weight gain continues. 
Slowly she becomes more and more depressed and experiences sudden attacks urging her to 
take some chocolate or other sweets every now and again. She visits cosmeticians, 
dermatologists, and dieticians – everything in vain: the problems do not get solved; 
symptoms come back worsened. 
Nobody mentions the suspicion of a chronic disorder that would require a different 
treatment approach. The irregularity of the periods persists but it is not a disturbing 
phenomenon; if she visits the gynaecologist, the answer is the same as before. Eventually 
Eleni gets married and despite making love unprotected for years she is still not pregnant. 
In desperation she visits fertility clinics where courses of medication are started in 
increasing doses. Sometimes she gets pregnant but the pregnancy is lost early; on other 
occasions the medication must be stopped due to dangerous side effects. After six months of 
ineffective stimulation more complicated and costly in vitro fertilization procedures follow. 
She is fortunate, with the aid of some further hormonal treatment, the pregnancy goes 
ahead. She gains more weight than she ought to, there is some fuzz about her elevating 
blood sugar, she hardly escapes insulin treatment. She can’t deliver per vias naturales - 
Caesarean section is required for the oversized but otherwise healthy baby girl. Eleni is now 
more obese than ever, the menstrual cycles are just as irregular as before pregnancy, and she 
wonders what problems are inherited by this lovely creature from her. 
Dozens of similar stories can be heard from overall the world. Nobody raises the suspicion 
that thousands of young women might have a very common endocrine-metabolic disorder 
that can be supposed from the very beginning by a proper look at them and by listening to 
their medical history?  
Without meaning to exaggerate issues, this is a very grim picture. Every article on PCOS 
starts with the statement that this is the most common endocrine disorder. Despite the 
prevalence varying according to the diagnostic criteria, it is around 10% of the fertile female 
population (Azziz et al., 2004; March et al., 2010). PCOS is grossly under-recorded and 
insufficiently diagnosed in primary care – data from a well-developed country with widely 
respected health care (Mani et al., 2010). 
When one thinks of PCOS, the diagnostic procedure looks complicated and the therapy 
advice is ambiguous. Usually the treatment options are listed according to the symptoms or 
explicitly state to start with the main complain of the patient. This is controversial as 
patients’ considerations about their health problems may differ significantly from those 
regarded important in medical experience. 
The most recent review of the American College of Physicians says “Drug therapy is aimed 
at treating the symptoms of PCOS ... If infertility is not the primary concern, then treatment 
is aimed at reducing the undesired effects of excess androgen and restoring regular menses 
to prevent endometrial hyperplasia” (Wilson, 2011). Does this mean that if infertility is the 
primary concern, nothing else matters? We don’t treat tuberculosis only for cough or fever 
that could be the “primary concern” of the infected. Wherever possible, we use 
aetiopathogenetic treatment. 
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Something is missing from the general conception. The advice is definitely misunderstood 
by those who take it word by word and provide treatment to PCOS patients according to the 
patient’s complain only. Shouldn’t we give her the complete information about the nature of 
the problem with all possible late complications in order that salus aegroti will meet voluntas 
aegroti to avoid medico-legal confrontation? 
Fortunately, the above cited review on PCOS (Wilson, 2011) says in the third paragraph at 
the beginning: “The information contained herein should never be used as a substitute for 
clinical judgment.” I agree totally with this statement as it supports my concerns. However, 
my views will be detailed later in this chapter. 
Around 1993 Roy Homburg addressed a lecture on PCOS to the endocrinologists in Cyprus 
in which he interestingly stated that PCOS had an insulin resistance component in the 
background; and he advised to start co-cyprindiol (a contraceptive pill containing 
ethinyloestradiol and ciproterone acetate, a contraceptive combination with anti-androgenic 
effect which had already been in use on this side of the Atlantic for long) as soon as PCOS is 
diagnosed to regulate menstruation and to counteract hyperandrogenism; this way 
preventing progression of the disease. Despite the last part of this opinion being debatable, 
this lecture raised my curiosity. I started seeing patients with PCOS from this point of view. 
In the meanwhile the addition of the insulin sensitizer metformin to the treatment repertoire 
boosted my interest. 
Now, nearly two decades on, several substantial aspects of PCOS have still remained 
unclear (Pasquali et al., 2011). In this chapter only the practical clinical approach to PCOS 
will be discussed comparing my experience with that of others known from the literature; 
arguing for a positive answer to the question raised in the chapter title. 
2. Diagnostic problems: What is PCOS? 
Until the exact pathomechanism is not fully explored PCOS will remain a syndrome: a 
rather diverse configuration of several endocrine-metabolic features of variable severity. 
2.1 Contrasting diagnostic criteria 
There have been three recently proposed sets of diagnostic criteria: those of the National 
Institutes of Health, the NIH criteria (NIH, 1991, as cited in The Rotterdam ESHRE/ASRM-
sponsored PCOS consensus workshop group, 2004); the Rotterdam criteria (The Rotterdam 
ESHRE/ASRM-sponsored PCOS consensus workshop group, 2004); and The Androgen 
Excess and PCOS Society, the AES criteria (Azziz et al., 2009). They differ in what positive 
findings are required for the diagnosis but agreed in one: other related (mainly endocrine) 
disorders must be excluded. I start with a short comment on this statement. 
2.1.1 Exclusion of other related disorders 
Even this common part of the diagnostic criteria may confuse the unwary. Most endocrine 
diseases present with symptoms found in PCOS (hyperandrogenic signs, infertility, 
polycystic ovaries, insulin resistance etc.) but PCOS has no discriminative diagnostic 
symptoms (none has been found yet) hence the differentiation from other endocrine 
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diseases must be an essential part of the diagnostic procedure. The problem is that PCOS is 
so frequent (whatever criteria are used) that merely on statistical grounds the same person 
may suffer from another endocrine disease synchronously. 
How can this controversy between the diagnostic criteria and the probability of co-existence 
of PCOS with another endocrine disorder be solved? It must be obvious that the exclusion 
statement is meant to say this: any positively diagnosed endocrine disease should be 
controlled satisfactorily and if the criteria for PCOS still apply one can conclude that the 
same person suffers also from PCOS. 
This coincides with the necessary medical steps emerging from the findings of the 
diagnostic procedure. Usually the “other” endocrine disorder is of more progressive or 
dangerous nature than PCOS and its treatment must have priority over PCOS. In 
consequence, the exclusion criterion would be more equivocal sounding like this: “PCOS 
exists (if the required diagnostic features apply) with the exclusion of other uncontrolled 
related disorders.” Definitions must be robust but equivocal; ambiguity causes hesitation. 
Most often hypothyroidism, hyperprolactinaemia or late-onset adrenocortical hyperplasia 
may coincide with PCOS. Less frequent but more dangerous conditions in the initial phase 
may also cause problems in the diagnostic procedure. 
2.1.2 Positive findings required for the diagnosis 
The real debate has been on what positive findings should be included in the diagnostic 
criteria. There are three main features in question: hyperandrogenism (HA), chronic oligo-
anovulation (ANO), and the polycystic appearance of the ovaries on ultrasound (PCO). 
The PCO sign was not included in the NIH criteria. The Rotterdam criteria include all three 
features of which at least two must be present. Later several participants of the Rotterdam 
consensus meeting realised that hyperandrogenism (androgen excess) is an essential part of 
PCOS; and their new proposal became known as the AES criteria. This joins ANO and/or 
PCO in one term, ovarian dysfunction (OD); and PCOS is a combination of HA and OD. In 
other terms, the combination of PCOS and ANO without HA (one possibility allowed by the 
Rotterdam criteria) should not be regarded as PCOS. Hyperandrogenism and ovarian 
dysfunction may not be independent contributors to the development of PCOS but the 
discussion of this is beyond the scope of this chapter. 
2.2 Understanding the differences in the three sets of criteria 
The differences of the different diagnostic criteria can be perceived easier using Venn 
diagrams. Circles represent the population suffering from features specified in the 
Rotterdam criteria (HA, ANO, and PCO). The overlapping areas (the intersections) of the 
circles mean the set of people with the common features. 
For didactic reasons let us start with the Rotterdam criteria (Fig. 1). The trilobate gray area 
represents patients who meet at least two of the three possible features; the central 
pseudo-circle (the intersection of all three circles) includes those who have all three 
features. 
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Fig. 1. Visual representation of the patient population diagnosed using the Rotterdam criteria 
The gray coloured area in Fig. 2 shows the patients diagnosed by the AES criteria. Ovarian 
dysfunction is the union of ANO and PCO (and/or). Those who have no hyperandrogenism 
(the intersection of ANO and PCO less HA) are excluded from the diagnosis. 
 
Fig. 2. Visual representation of the patient population diagnosed using the AES criteria 
Patients diagnosed by the NIH criteria are those who have both HA and ANO (the 
intersection of HA and ANO); see in Fig. 3. The PCO sign plays no role in the diagnosis; its 
inclusion in the diagram is solely for comparative purposes. The number of patients found 
with PCOS using these NIH criteria is the smallest among the three sets. 
 
Fig. 3. Visual representation of the patient population diagnosed using the NIH criteria 
The size of the circles in Fig. 1, 2, and 3 is arbitrary. The prevalence of HA and ANO in the 
fertile female population is not known. Around 30% have polycystic ovaries but only a 
fraction suffers from PCOS (depending on the criteria used for the diagnosis). 
The prevalence of PCOS in a community sample of 728 women was found as follows: NIH 
criteria, 8.7%; AES criteria, 12%, Rotterdam criteria, 17.8% (March et al., 2010). The study 
used interviews of women who were born in a certain area. The article also emphasizes that 
at least two third of the cases were previously undiagnosed. 
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3. PCOS patients in a medical outpatient practice 
I work as a private medical practitioner in the Republic of Cyprus on an island in the Eastern 
Mediterranean; a member state of the EU; with almost exclusively Europid (white, 
“Caucasian”) population. Beyond doing general medicine I am a specialist for endocrinology, 
diabetes, and metabolic diseases. Private practitioners in Cyprus work independently from the 
governmental health services, free of territorial or insurance company obligations. 
Such practice experience may not be representative for the whole Cypriot population but there 
have been no published PCOS related data in Cyprus. What we do know is that the prevalence 
of both Type 2 diabetes and the metabolic syndrome is of the highest in Europe therefore one 
can suspect a relatively high number of patients living in Cyprus suffering from of all kinds of 
disorders related to insulin resistance including PCOS (Loizou & al., 2006). 
3.1 Patient selection and diagnosis 
I raise the possibility of PCOS each time when a female patient turns up presenting any 
symptom which is compatible with the syndrome; independently of her primary complaint. 
On detection of other symptoms compatible with PCOS during history taking and physical 
examination, the suspicion is discussed thoroughly with the patient. Upon informed 
consent, we continue with the formal diagnostic procedure. 
Related disorder Number % 
Subclinical hypothyroidism 45 61.6
Thyrotoxicosis 3 4.1
Multinodular euthyroidic goitre 10 7.3
De Quervain thyroiditis 1 1.4
Late-onset adrenocortical hyperplasia 3 4.1
Microprolactinoma 3 4.1
Impaired fasting glucose 3 4.1
Impaired glucose tolerance 1 1.4
Type 2 diabetes mellitus 1 1.4
Type 1 diabetes mellitus 1 1.4
Metabolic syndrome 1 1.4
HAIRAN syndrome 1 1.4
Total 73 100
Table 1. The distribution of related disorders co-existing with PCOS in 73 patients 
Since 2003, 323 women who had not been using hormonal contraceptives for at least six 
months have undergone the full diagnostic procedure. The necessary hormonal tests and 
pelvic ultrasound were performed as recommended by the Rotterdam criteria; occasionally 
further tests became necessary for differentiation from related disorders. A formal 75 g oral 
glucose tolerance test was performed in all women diagnosed positively for PCOS except 
those with known diabetes. 
Late-onset adrenocortical hyperplasia was found in one patient and the HAIR-AN 
syndrome (Hyperandrogenism – Insulin Resistance – Acanthosis Nigricans) in another one 
without PCOS. 
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321 women were diagnosed positively for PCOS using the Rotterdam criteria; aging 14 – 46 
years (mean 25 years). Only 2 women had no hyperandrogenic signs therefore 319 women 
(>99%) met also the AES criteria; and only 180 (56%) could have been diagnosed by the NIH 
criteria. 
In 73 patients (22.7%) PCOS was a secondary diagnosis where after the satisfactory control 
of any related disorder the Rotterdam criteria still applied. The distribution of co-existing 
disorders of these 73 patients is shown in Table 1. 
3.2 Initial symptoms 
The following definitions, grading of symptom severity, and abbreviations will be used in 
this and consecutive sections: 
 Acne score: The Global Acne Grading System (Doshi et al., 1997) for its simplicity; 
requiring only visual assessment of signs in six body areas. 
 Hirsutism: Score higher than 8 in the classical Ferriman-Gallwey scale (Ferriman, 1962, 
as cited in Rosenfield, 1990); by visual assessment of hairiness in nine body areas. 
 Weight surplus: body mass index (BMI) ≥25 kg/m2 
 Overweight:  BMI between 25 and 29.9 kg/m2 
 Obese:   BMI between 30 and 34.9 kg/m2 
 Grossly obese:  BMI over 35 kg/m2 
 Abdominal obesity: Waist-to-hip circumference ratio (W/H) ≥0.80 
 Irregular menses: menstrual periods <9/year; or periods shorter than 21 or longer than 
35 days 
 Infertility: no spontaneous pregnancy despite active, non-protected sexual life for at 
least two years 
 Early pregnancy loss (EPL): spontaneous abortion during the first trimester. 
 
Fig. 4. The distribution of symptoms in 321 women with PCOS at time of diagnosis 
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The distribution of the initial symptoms of the 321 women found with PCOS according to 
the Rotterdam criteria (including those with co-existing disorders after full control) is shown 
in Fig. 4. 
The overall majority had easily detectable acne and/or hirsutism with or without laboratory 
hyperandrogenism; only three patients (0.93%) had laboratory hyperandrogenism without 
acne or hirsutism. 57% had irregular menstrual periods. 44.3% had weight surplus in the 
following proportions: overweight, 21.5%; obese, 10.6%; and grossly obese, 12.1%. 
Acanthosis nigricans occurred only in obese or grossly obese patients. 
The fertility rate cannot be verified for the whole group because the majority had not 
planned pregnancy. Infertility was revealed by history taking in 23 of 108 married women 
(21.3%); 5 had early pregnancy losses (4.6%). 11 early pregnancy losses occurred in 11 of 85 
women (12.9%) having had live births from earlier pregnancies. 
4. Testing the efficacy of treatment forms 
The following symbols will be used for statistical analysis in this section: 
 ***: P<0.001 
 ** : P<0.01 
 * : P<0.05 
 n.s.: not significant 
The other symbols and abbreviations are as described in Section 3.2. 
4.1 Choice between taking the contraceptive pill or metformin 
Before 2002 the standard treatment advice for my patients was the anti-androgenic 
combined contraceptive pill as mentioned in the introduction. The pill was stopped when 
the woman wanted to become pregnant; usually the previous symptoms recurred while 
waiting for (in many cases, only hoping for) conception.  
Between 2002 and 2006 I offered the insulin sensitizer metformin treatment to all freshly 
diagnosed PCOS patients who had contraindications or negative experience with the pill, or 
simply did not want to take hormonally active medication, or wanted to become pregnant. 
The efficacy of the two treatment forms (the pill or metformin) was compared in those who 
completed twelve moths’ treatment. The two groups were comparable in size and age 
distribution. Table 2 shows the results.  
 
 Pill Metformin 
Number of patients 17 19 
Age (year) 24 (20-31) 23 (15-36) 
Acne score 16.9 ± 7.1 – 2.7±2.9 *** 19.7 ± 11.2 – 6.6 ± 6.9 *** 
F-G score 15.2 ± 2.7 – 6.6 ± 3.5 *** 16.4 ± 7.2 – 10.9 ± 6.0 *** 
BMI 24.0 ± 6.4 - 23.7 ± 5.8 n.s. 26.7 ± 7.8 - 25.4 ± 7.8 n.s. 
W/H ratio 0.73 ± 0.1 - 0.71±0.1 n.s. 0.75 ± 0.1 – 0.74 ± 0.1 n.s. 
Table 2. Changes during a twelve-month treatment period on the pill or metformin 
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Both the acne and hirsutism scores decreased significantly during the twelve-month treatment 
period; BMI and W/H did not change significantly in either group. Further statistical analysis 
was not made since the two groups differed in the indication of treatment; and the metformin 
group had more severe symptoms in average. However, this study convinced me that 
metformin was a simple, safe; and effective first choice of medical treatment in PCOS. In many 
patients metformin restored the regularity of the menstrual cycles. Spontaneous pregnancies 
with live births also occurred (Petrányi, 2005; Petrányi & Zaoura, 2007). 
4.2 Metformin treatment with or without lifestyle changes 
Since 2006 lifestyle changes (Tang & al., 2006) have been advised parallel to the 
pharmacological treatment for all new patients: the increase of daily physical activity and 
low glycaemic index diet; including calorie restriction to the overweight. The two treatment 
forms (metformin with or without lifestyle changes) were compared in the following way 
(Petrányi & Zaoura, 2011). 
Patients from the metformin monotherapy era served as historical control group consisting 
of 29 women (age 18 to 39 y, mean, 26) to whom the recent metformin + lifestyle changes 
group was compared consisting of 34 patients with comparable age distribution. The 
following parameters were recorded every three months during the 6-month observation 
period: acne and hirsutism scores, body mass index (BMI), waist-to-hip ratio (WH), and the 
regularity of the menstrual periods. Patients with carbohydrate metabolic disorders 
(impaired fasting glucose, impaired glucose tolerance, diabetes mellitus) or those who 
became pregnant during the six-month period were not included in the evaluation. 
Table 3 shows the changes of the four easily measurable symptoms during the six-month 
observation period by the mean ± SD, and the difference (Δ) both in the metformin and the 
metformin + lifestyle treatment groups; and the difference between the two treatment forms. 
Not all patients suffered from acne or hirsutism; their number within the groups is also 
included in the table. 
 Metformin (n=29) Metformin +lifestyle (n=34) Difference 
Acne (n=27) (n=32)  
 20.3±9.9 – 12.4±8.9 25.2±8.2 – 15.9±7.7  
 Δ=7.9 *** Δ=9.3 *** 1.4 n.s. 
Hirsutism (n=22) (n=21)  
 15.1±6.0 – 12.8±6.2 11.7±2.1 - 9.2±2.7  
 Δ=2.3 *** Δ=2.5 *** 0.2 n.s. 
BMI 26.6±6.9 - 26.4±6.7 27.5±7 - 26.7±6.3  
 Δ=0.26 n.s. Δ=0.88 *** 0.62 * 
W/H 0.74±0.07 - 0.74±0.07 0.76±0.08 - 0.74±0.07  
 Δ=0.001 n.s. Δ=0.019 ** 0.017 * 
Table 3. Comparison of the efficacy of metformin versus metformin + lifestyle treatment 
Acne and hirsutism score improved significantly and similarly in both treatment forms. 
BMI did not show significant change during the metformin monotherapy but it improved 
significantly in the combined therapy group. The combined therapy diminished BMI in the 
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overweight women by 1.1 kg/m2 *** and 0.64 kg/m2 * in those of normal weight; without 
causing problem to them. 
W/H did not change during metformin monotherapy but decreased significantly with 
metformin + lifestyle changes. 
Table 4 shows the changes in the regularity of menstrual cycles during the six-month 
treatment period. The proportion of patients who changed from irregular to regular was not 
significantly different between treatment forms (Fisher’s exact test, P=0.29).  
 Metformin 
(n = 29)
Metformin + lifestyle 
(n = 34)
Irregular menses at start 12 22 
     Remained irregular 4 8 
     Became regular 8 14 
Regular menses at start 17 12 
     Remained regular 17 12 
     Became irregular 0 0 
Table 4. Number of patients changed regularity of the menstrual cycle during six months 
The individual changes in the acne and the hirsutism scores during the combined therapy 
are shown in the following two figures. The acne score improved in all patients by three 
months with further improvement by six months (Fig. 5). The hirsutism score did not 
improve in few patients by three months but everybody improved by six months (Fig. 6). 
 
Fig. 5. Individual changes of the acne score under metformin + lifestyle treatment 
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Fig. 6. Individual changes of the hirsutism score under metformin + lifestyle treatment 
The favourable change in the body size indexes (BMI and W/H) has been the significant 
difference between the two treatment forms. In conclusion, the combined treatment can be 
regarded as superior to metformin monotherapy and therefore I have been offering this 
combined treatment (under the name of triple basal treatment) for all newly diagnosed 
patients and for long term use. 
4.3 Additional treatment experience with metformin in PCOS 
4.3.1 Recurrence of symptoms when treatment is stopped 
Whatever treatment option is used its efficacy is limited; stopping treatment results in the 
renewal of the symptoms. It is most obvious for treatment approaches which have nothing 
to do with the pathophysiology of PCOS like hair removal, dermatological treatment for 
acne (local agents, antibiotics, and isotretinoin). After stopping the contraceptive pill, 
symptoms usually come back within a few months. This applies also to lifestyle changes 
and/or metformin. 
 
Fig. 7. Relapse of acne on stopping metformin; improvement on treatment restart 
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The individual changes in the acne and the hirsutism scores during the combined therapy 
are shown in the following two figures. The acne score improved in all patients by three 
months with further improvement by six months (Fig. 5). The hirsutism score did not 
improve in few patients by three months but everybody improved by six months (Fig. 6). 
 
Fig. 5. Individual changes of the acne score under metformin + lifestyle treatment 
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Fig. 6. Individual changes of the hirsutism score under metformin + lifestyle treatment 
The favourable change in the body size indexes (BMI and W/H) has been the significant 
difference between the two treatment forms. In conclusion, the combined treatment can be 
regarded as superior to metformin monotherapy and therefore I have been offering this 
combined treatment (under the name of triple basal treatment) for all newly diagnosed 
patients and for long term use. 
4.3 Additional treatment experience with metformin in PCOS 
4.3.1 Recurrence of symptoms when treatment is stopped 
Whatever treatment option is used its efficacy is limited; stopping treatment results in the 
renewal of the symptoms. It is most obvious for treatment approaches which have nothing 
to do with the pathophysiology of PCOS like hair removal, dermatological treatment for 
acne (local agents, antibiotics, and isotretinoin). After stopping the contraceptive pill, 
symptoms usually come back within a few months. This applies also to lifestyle changes 
and/or metformin. 
 
Fig. 7. Relapse of acne on stopping metformin; improvement on treatment restart 
 




Fig. 8. Stagnation of hirsutism on stopping metformin; improvement on treatment restart 
Fig. 7 and Fig. 8 show this happen in a patient who initially was responding favourably to 
long-term metformin treatment. After a while the improvement became unsatisfactory and 
by 21 months acne relapsed; by 24 months hirsutism stagnated. Then she acknowledged that 
she had stopped metformin taking months before. On restart of metformin both symptoms 
improved and one year later she was free from acne and hirsutism. 
This case demonstrates that acne responds to metformin treatment within three months and 
worsens within three months after stopping treatment. The effect on hirsutism takes more 
months to show; and the beneficial effect still lasts for more months after stopping 
treatment. 
This was not the only case of non-compliance with long-term treatment recommendations. 
More difficult to maintain is the adherence to lifestyle changes; especially the achievement 
of slimming in the overweight; like in other metabolic disturbances. 
4.3.2 Improvement of fertility 
Ten previously infertile women expressed the desire for having a baby before the initiation 
of metformin treatment. Metformin taking during pregnancy and breast feeding were 
discussed and encouraged; all consented. 
Eleven conceptions happened among nine women while taking metformin; notably varying 
between the first and 29th month of treatment; the majority (seven conceptions) occurred 
after the 6th month of treatment. No gestational diabetes or other complications occurred 
during pregnancy. Two pregnancies ended with early loss. Nine healthy and normal weight 
babies were born in term and were breast fed for at least three months. All children showed 
normal development. 
4.3.3 No recurrence of preeclampsia during the next pregnancy when taking 
metformin 
One woman had five previous pregnancies with preeclampsia; one pregnancy was 
terminated because of the serious condition and one pregnancy was lost early. She 
presented with thyrotoxicosis caused by toxic multinodular goitre but PCOS could be 
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diagnosed after thyroidectomy and stabilisation with levothyroxine. She conceived during 
the first month of taking metformin and she continued metformin throughout this 
pregnancy upon my advice. Preeclampsia did not recur during this pregnancy and a healthy 
baby was born in term (Petrányi, 2005). 
5. Discussion 
I have seen many, mostly young women suffering from PCOS. Despite growing interest by 
the medical public and remarkable progress in research during the past two decades, the 
medical literature has not provided equivocal help how to treat PCOS. It is true that there is 
no evidence based universal treatment option but the advice found in textbooks, consensus 
statements and “experts’ opinions” does not give clear guidance what to do in general with 
these patients. The treatment advice is usually grouped around the symptoms of PCOS but 
not against PCOS as a pathophysiological entity, which is a chronic, progressive disorder 
leading to irreversible damage through late complications. 
Most publications deal with the fertility aspects of PCOS regardless of the other endocrine 
and metabolic aspects of the disease. Infertility is an just once important issue but does not 
affect all women with PCOS and even so only for a limited period while the other 
problems exist and cause harm throughout their life. Usually fertility studies are limited 
to six months – the time length beyond clomiphene stimulation (the advocated treatment 
of choice for PCOS related infertility) cannot be recommended (BNF 2010). Such studies 
are unsuitable to demonstrate whether other but longer treatment forms could not result 
in similar or better outcome and safety records (avoiding overstimulation, ensuring 
singleton pregnancies, prevention of macrosomia, gestational diabetes, preeclampsia etc). 
Longer treatment would of course require more patience from the patient but could give 
more chance to improve other pathological processes in favour of the general health of the 
woman. Fertility results are especially disappointing in obese women; they have only a 
1:4 chance to give live birth using clomiphene stimulation (Legro et al., 2007). Assisted 
reproduction methods are complicated, very costly; and increase the risk of 
malformations (El-Chaar et al., 2009). 
The majority of my patients have been suffering from disturbing symptoms of 
hyperandrogenism (almost all from acne and/or hirsutism, rarely from alopecia); and the 
metabolic consequences of insulin resistance (obesity, abdominal obesity). Irregular menses 
is also frequent among them but it is rarely the main complaint. Few in my clientele wanted 
to be pregnant urgently. According to my medical judgement these women need a long-
term, uniform treatment (knowing that short-term attempts are unsuitable) which is simple, 
cheap, safe, effective for almost all features of PCOS, and can be combined with other 
treatment forms if the improvement is not satisfactory in certain symptoms. 
Whatever is the main complaint of the patient, we will certainly find a long list of symptoms 
during the diagnostic procedure. Some of these are pre-requisites of the diagnosis like 
hyperandrogenism (that rarely exists without somatic signs); anovulation related symptoms 
(oligo-amenorrhoea, sub- or infertility); and the well-known metabolic consequences of 
PCOS cannot be left out: weight surplus that can be extreme, carbohydrate metabolic 
problems, lipid disorders – all these deserve treatment and/or preventive measures not to 
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develop into late cardiovascular problems. We should also think of the increased dangers 
during pregnancy of PCOS patients: pregnancy loss, gestational diabetes, macrosomia. 
These all should be discussed with the patient before offering any treatment. 
My observations with metformin in PCOS proved to meet these requirements, and the 
combination with lifestyle changes helped also the weight problems, too. I cannot use 
placebo control; the patients come for effective treatment not for experimenting. 
It is not only my opinion that PCOS should be dealt with like any other chronic metabolic 
disorders (diabetes, obesity or the metabolic syndrome), which all have insulin resistance in 
the background and end up with similar late complications. We have to think about the 
future of the patient, not only the actual complaints. 
Insulin resistance is hypothesised in the background of PCOS even if there is no simple and 
precise method to prove it individually. Fortunately, the measurement of insulin during the 
oral glucose tolerance test is not included in the recommendations of the diagnostic 
procedure; this imprecise method may be used only for statistical comparisons of different 
populations or treatment forms. Treatments which increase insulin sensitivity have been 
proved useful in PCOS for all aspects of the disease. Reduction of obesity, increased 
physical activity (lifestyle changes), and insulin sensitizers – primarily, metformin has been 
found effective in treating PCOS. Other insulin sensitizers have also been tested but because 
of their controversy in diabetes and unknown safety in pregnancy they cannot be 
recommended in PCOS for the time being. 
Metformin is not a miracle drug but it is cheap and safe, it can be administered without time 
limitation; and has very few contraindications in the relatively young and (in this respect) 
healthy female population suffering from PCOS. Its long-term and lasting metabolic benefits 
are well known from more than fifty years’ clinical experience in diabetes and beyond; and 
can be used from the age of ten onwards (Bailey et al., 2007). 
Metformin has not been licensed for PCOS in any country in the world. This prevents or 
restricts its prescription for PCOS in some countries. The patients’ acceptance of metformin 
is overwhelming (Hillary et al., 2009); researchers complain that patients do not want to 
cease treatment, even for few months because they considered the treatment as effective 
(Muth at al., 2004). 
Some patients experience gastrointestinal disturbance (bloating, abdominal pain, watery 
diarrhoea) or sometimes nausea, metallic taste while taking metformin. This can be 
avoided in the majority of cases by gradual dose increase. Only few patients cannot 
tolerate even one 500 mg tablet daily. I have no personal experience with the extended 
release formulation or the powdered form, which have been developed to overcome these 
unpleasant symptoms. 
One side effect deserves real consideration: metformin may cause or exaggerate vitamin B12 
deficiency; therefore annual test for B12 level is advisable for long-term metformin users to 
select who needs vitamin B12 supplementation. 
Treatment experience with metformin in PCOS comes from relatively short studies but 
longer ones has also been published (Cheang et al., 2009, Oppelt et al., 2010). Detailed 
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discussion in favour of the use, including long-term use of metformin in PCOS for all 
possible aspects, indications, contraindications, and safety issues has also been published in 
growing numbers (Diamanti-Kandarakis et al., 2010; Nestler, 2008; Palomba et al., 2009) 
including metformin taking during pregnancy and lactation. 
Vitamin D is probably the next candidate substance to be used widely in PCOS especially in 
the obese patients (Kosta et al., 2009). The high prevalence of depression in patients with 
PCOS (Dokras et al., 2011) also requires true consideration but these topics are not discussed 
in this chapter. 
6. Conclusions 
The patients want (and deserve) effective treatment. There is no evidence based general 
treatment option for all patients suffering from PCOS but the advice to treat the patients 
according to their main complaint (or symptomatically) is also not evidence based. 
We’d better do our best using common sense; based on available evidence combined with 
our experience to provide benefit (Stuebe, 2011). 
For the time being the combination of lifestyle changes and metformin treatment appears to 
be beneficial for the majority of patients suffering from PCOS by controlling their symptoms 
with potentials for preventing progression and most complications. 
Until a sound and better solution is found, my medical advice to all newly diagnosed 
patients with PCOS from the time of diagnosis (even from puberty) is this: 
 The patient diagnosed with PCOS should be fully informed about her medical 
condition; which of her symptoms are connected to this disorder, and what other ill 
conditions may develop by time. 
 The patient should know that at present there is no final cure for the problem but a 
long-term, cheap and safe treatment combination may revert or attenuate most of the 
symptoms. 
 The initial treatment (triple basal treatment) consists of long-term lifestyle changes: the 
increase of the daily physical activity and a low glycaemic index diet (with calorie 
restriction for the overweight to normalize body weight) and taking metformin tablets. 
 Metformin should be started stepwise. The starting dose is one 500 mg tablet after 
dinner; increased to twice daily (after breakfast – after dinner) after one week and to 
three times daily (after breakfast, after lunch and after dinner) from the third week 
onwards. Eventual side-effects must be consulted with the doctor; any dose increase 
should be postponed until the dissolution of the disturbing phenomena. 
 If certain symptoms do not improve satisfactorily in suitable time (depending on the 
nature of the symptom; for example, acne in six months, and hirsutism in one year; 
stagnation of weight surplus; oligo-amenorrhoea continues, infertility) the following 
options should be considered: 
 Revision of diagnosis 
 Compliance with treatment recommendations 
 Further calorie restriction in the overweight with or without increased dose of 
metformin (up to daily 2000-2500 mg) 
 Addition of other medication depending on the nature of the problem: 
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 Anti-androgenic contraceptives, spironolactone, flutamide 
 Dermatological treatment for acne (antibiotics, isotretinoin) 
 Ovarian stimulation and/or other fertility interventions upon consultation with the 
fertility specialist. 
 The triple basal treatment may help the patient conceive. Effective contraceptive 
methods should be discussed with all those who do not want become pregnant or take 
teratogenic medication (anti-androgens, isotretinoin) before commencing treatment. 
 The patient should be reviewed for symptoms and adherence to the therapeutic advice 
every three months for at least one year and thereafter at least twice yearly if the 
condition improves satisfactorily. 
 Annual monitoring of kidney and liver function, lipid profile, glycosylated 
haemoglobin, vitamin B12 levels is mandatory. 
This proposal remains a working hypothesis until properly planned, long-term clinical 
studies find a better alternative. 
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1. Introduction 
One of the most common reproductive endocrine diseases that impact many young women 
worldwide is polycystic ovary syndrome (PCOS). This hormonal problem affects 4 – 18% of 
women of reproductive age exhibiting various symptoms, such as irregular menstruation, 
hirsutism, infertility and metabolic disorders (LJ. Moran, et al. 2011). These symptoms in 
PCOS women are strongly correlated with overweight and obesity. Also, women with PCOS 
are likely to have metabolic disorders, such as abnormality of glucose and lipid metabolisms 
that are inevitably involved in diabetes mellitus and coronary artery diseases, respectively 
(ML. Traub, 2011). Concerning metabolic syndrome in young women, abnormalities in 
glucose metabolism are seen earlier than dyslipidemia as the initial manifestation; thus, 
glucose metabolism is suggested to be evaluated first (A. Fulghesu, et al. 2011). Insulin 
resistance / hyperinsulinemia is frequently associated with 40-50 % of women having 
PCOS, especially obese women (JE. Nestler, et al. 2002). Furthermore, obese women with 
PCOS are more likely indicative of insulin resistance than lean women with or without 
PCOS (P. Acien, et al. 1999). It is well-known that insulin resistance manifests in glucose 
tolerance test (GTT) prior to diabetes mellitus and coronary artery diseases (ML. Traub, 
2011). Based on the recent reports, insulin resistance / hyperinsulinemia correlates with 
implantation disturbances and causes infertility in PCOS women (DJ, Jakubowicz, et al. 
2001). Also, it is reported that the rate of early pregnancy loss is higher in women with 
PCOS than in normal women (DJ. Jakubowicz, et al. 2002). Thereby, insulin resistance / 
hyperinsulinemia is strongly linked to women with PCOS and this correlation has to be 
studied in details. As for obesity and overweight, which also strongly relates with PCOS, 
body mass index (BMI) is suggested to contribute to severity while assessing many 
problems, such as miscarriage, anovulation, infertility and increased prevalence of diabetes 
mellitus (JX. Wang et al. 2002; RJ. Norman, et al. 2002). Also, weight reduction is effective to 
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improve the PCOS symptoms in obese and overweight infertile women, and insulin 
sensitizing drug, such as metformin, ameliorates menstrual cycle and ovulation in PCOS 
women (J. Vrbikova, et al. 2002; B. Baysal, et al. 2001; R. Fleming, et al. 2002). From the 
above-mentioned facts, the adverse effects of insulin resistance / hyperinsulinemia are 
inextricable with infertile women with PCOS and cause ovulatory disturbance, implantation 
failure and early pregnancy loss (in early stage). Yet, the lifestyle changes, such as weight 
reduction and dietary modification, as well as the use of insulin sensitizing agents are 
crucial for the improvement of reproductive functions for PCOS women.  
2. Insulin resistance / hyperinsulinemia and PCOS 
The diagnostic criteria for PCOS followed in most of the studies are in accordance with 
Rotterdam PCOS consensus 2003 (BCJM. Fauser, 2003). Insulin resistance affects 70% of 
PCOS women, while 10% have diabetes mellitus (DM) (R. Freeman, et al. 2010; K. Farrell, et 
al. 2010; F. Ovalle, et al. 2002). Over three years, 25% of PCOS women with normal glucose 
metabolism can become those with abnormal glucose metabolism (MH. Pesant, et al. 2011). 
Therefore, glucose level alone has lack of sensitivity to predict metabolic disorders in 
patients with PCOS. In turn, the assessment of insulin resistance is important to evaluate the 
metabolic conditions in women with PCOS.  
Obese women with PCOS are seen more insulin resistant, hyperandrogenic and 
hypertriglyceridemic although insulin and metabolic indices tend to be similar in lean type 
of women with PCOS and those without PCOS (P. Acien, et al. 1999). Reproductive 
disorders in patients with PCOS may manifest insulin resistance. Irregularity of menstrual 
cycle has been correlated with insulin resistance (T. Strowitzki, et al. 2010). It is reported that 
hyperinsulinemia in PCOS patients with lower pregnancy implantation rate may be 
reflected in the local endometrial level due to impairment of insulin receptor action (R. 
Fornes, et al. 2010). Also, high concentration of insulin in follicular fluid might lead to low 
pregnancy outcomes in patients with PCOS after in vitro fertilization (S. Takikawa, et al. 
2010). Although many areas of PCOS have not been fully understood yet, insulin resistance 
/ hyperinsulinemia plays an important role of pathogenesis and pathophysiology in PCOS.  
3. Assessment of Insulin resistance / hyperinsulinemia 
In order to assess insulin resistance / hyperinsulinemia, the relationship between insulin 
sensitivity and insulin secretion is needed to be understood despite their complicated 
interaction (C. Cobeli, et al. 2007). In general, up-regulation of insulin secretion corresponds 
to the reduction in insulin sensitivity for healthy subjects with normal glucose tolerance (K. 
Færch, et al. 2010). Thus, insulin sensitivity and insulin secretion are inversely related to 
each other and can be seen in a hyperbolic manner. These two variables constantly appear in 
human with the same levels of glucose tolerance, known as the disposition index (K. Faerch, 
et al. 2010). The assessment of the disposition index can be calculated from the measurement 
of insulin sensitivity and insulin secretion by the euglycaemic-hyperinsulinemic clamp 
technique in combination with the intravenous glucose tolerance test (MA. Adbul-Ghani, et 
al. 2006a; K. Færch, et al. 2008; M. Laakso et al. 2008). Additionally, a hepatic insulin 
resistance can be estimated the following multiplication:  
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1 / (endogenous glucose production x basal insulin concentration) 
(C. Brøns et al. 2009; AC. Alibegovic et al. 2009). 
A low disposition index indicates the increase in insulin secretion meaning the dysfunction 
of islet beta-cells; then, resulting in an inadequate hyperinsulinemia (B. Ahre´n, et al. 2002).  
There is no concrete measurement of insulin resistance universally. However, various types 
of methods to measure insulin resistance are proposed, such as hyperinsulinemic 
euglycernic clamp techniques, fasting methods and 75 g of glucose tolerance test (GTT). In 
our studies, hyperinsulinemic euglycernic clamp techniques are not utilized because it 
requires intravenous infusions, extensive time and significant financial resources. With 
combination of fasting methods and 75g of GTT, insulin resistance and hyperinsulinemia 
are assessed in our studies. As an index of insulin resistance, the homeostasis model 
assessment ratio (HOMA-R) is calculated by the formula:  
HOMA-R = Fasting insulin level (μU/ml) x  
Fasting glucose levels (mg/dl) / 405 
 (DR. Mattews, et al. 1985). 
As a result of the assessment for insulin resistance, HOMA-R with greater than 1.6 is 
determined to be insulin resistance (H. Tanaka, et al. 2005). In addition, the amount of 
insulin level with greater than 100 μU/ml at any minutes, or 65 μU/ml at 120 minutes is 
determined to be hyperinsulinemia. HOMA- β estimates steady state of pancreatic β-cell 
function by the measurement of fasting plasma glucose and insulin concentrations. It is 
strongly correlated with high concentration of glycemia as a determinant of its degree. The 
formula is as follows: 
HOMA- β (%) = Fasting plasma insulin (μU/ml) x 360 / 
(Fasting plasma glucose (mmol/L) - 63) 
(DR. Mattews, et al. 1985). 























T ime (minutes)  
Fig. 1. Assessment of insulin secretion after GTT, showing blood glucose concentration 
(mg/dl) on Y axes and time (minutes) on X axes.  
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Therefore, HOMA- β is effective for understanding progressive type 2 DM. Because almost 
all of the subjects in our study show normal range of glucose levels, HOMA- β is not 
analyzed.  
Seventy-five grams of glucose is used for the patients in GTT and blood samples are 
collected at 0, 30, 60 and 120 minutes for circulating blood sugar and insulin levels. As 
shown in Fig. 1, three types of insulin secretions are indicated. In normal type, highest peak 
of insulin is secreted at 30 min. and gradually decreased. In hypersecretion type, the insulin 
level indicates high response at any points – i.e. 0, 30, 60, 120 min. compared with normal. In 
delayed type, the insulin level gradually increases and/or does not return to normal level at 
120 min. Both hypersecretion and delayed secretion indicate insulin abnormalities.  
4. Insulin resistance / hyperinsulinemia and lifestyle intervention 
Lifestyle management may contribute to the improvement of metabolic complication in 
overweight and obese women with PCOS. It also correlates with reproductive function for 
triggering ovulation and maintaining pregnancy by modifying lifestyle as necessary (LJ. 
Moran, et al. 2009). Control in weight for health benefit, instead of weight-loss purpose only, 
helps all women with PCOS and it improves psychological distress, hyperandrogenemia 
and menstrual disturbances that are associated with great food cravings (SS. Lim, et al. 
2009). In fact, approximately 5 to 10% of weight loss is enough to ameliorate psychological 
distress, ovulatory dysfunction, and metabolic disorders (C. Galletly, et al. 1996). Modifying 
both moderate physical activity and dietary management might also support PCOS women 
to result in clinical benefit. Simple cardio exercises, such as walking for at least 30 min. per 
day, are beneficial for PCOS women (ET. Poehlman, et al. 2000).  
Although there is still more research needed to conclude the advantageous dietary approach 
for PCOS women, dietary management may be helpful for improving their reproductive 
and metabolic functions if the strategies are nutritionally balanced and sustainable for them 
(LJ. Moran, et al. 2009).  
From the above-mentioned point of views, the improvement of lifestyle management and its 
disciplinary approach that encourages PCOS patients to have good physical activities and 
dietary strategies may be strongly supportive with targeted medical treatment. In other 
words, medical treatment and lifestyle therapy should be provided in parallel. 
5. Insulin resistance / hyperinsulinemia and ovulatory disorders 
The presence of hyperandrogenism in lean and obese women with PCOS is strongly 
correlated with hyperinsulinemia (RJ. Chang, et al. 1983; A. Dunaif, et al. 1987; A. Dunaif, et 
al. 1989; A. Dunaif, et al. 1992). The hyperandrogenism results from both increased adrenal 
and ovarian androgen production (DA. Ehrmann, et al. 1995; RL. Rosenfield, et al. 1990; E. 
Carmina, et al. 1992; DA. Ehrmann, et al. 1992). Insulin acts via its receptor and appears to 
contribute ovarian and adrenal androgen biosynthesis (RL. Barbieri, et al. 1986; RL. Barbien, 
et al. 1988), which amplifies luteinizing hormone induced androgen production by the theca 
cells and results in hyperandrogenemia (R. Nahum, et al. 1995; DS. Willis, et al. 1998). To 
improve hyperinsulinemia is effective for circulating androgens to decline to normal level 
(RD. Murray, et al. 2000). In addition, the upregulation of insuin-like grouth factor- I (IGF-I) 
receptors may be caused from hyperinsulinemia. IGF-I receptors have the potential to 
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stimulate LH-induced androgen synthesis and suppress IGF-binding protein I (IGF-BPI) 
production by liver (AM. Suikkan, et al. 1988; AM. Suikkan, 1989). Hepatic sex hormone 
binding globulin (SHBG) production may be inhibited by insulin (N. Botwood, et al. 1995) 
and it increases the bioactive androgen that eventually causes virilization. 
In PCOS, many small antral follicles are characteristically recognized by ultra sonography. 
These small antral follicles are due to the arrest of growth after reaching a diameter of 5 to 
8mm. The arrest of small follicles may be caused by premature activation of LH-mediated 
terminal differentiation of granulosa cells (S. Franks, et al. 1996). In the normal menstrual 
cycle, granulosa cells of the dominant follicle become responsive to LH in mid-follicular 
phase at a follicular diameter of 10mm (SG. Hillier 1994). On the other hand, granulose cells 
from follicles as small as 4mm in diameter of anovulatory PCOS are responsive to LH. This 
response to LH is remarkably amplified by insulin. The premature activation of granulosa 
cells to LH induces terminal differentiation, resulting in the arrest of follicle growth (S. 
Franks, et al. 1999).  
In PCOS patients with ovulatory disorders, insulin resistance, hyperinsulinemia, BMI and 
visceral fat are studied. As shown in Table 1, values of BMI, HOMA-R and visceral fat 
accumulation result to be various. However, the results of GTT show abnormal pattern of 
insulin secretion in most of the cases with PCOS. The effects of treatment with insulin 
sensitizing agents are present. If ovulation induction with metformin or pioglitazone is 
failed during one to two cycles, clomiphen citrate is utilized along with one of the insulin 
sensitizing agents. In PCOS, ten out of 11 cases result in ovulation by treating with insulin 
sensitizing agents: 5 cases with metformin and 5 cases with pioglitazone. Based on the 
assessment of GTT including insulin secretion levels, insulin-sensitizing agents are effective 
for treatment of ovulation induction. 
    GTT/   





1 19.4  0.68  none  normal P + CC positive 
2 20.8  1.69  none delayed P + CC positive 
3 23.7  0.65  none delayed P + CC positive 
4 24.8  2.12  none delayed P + CC positive 
5 25.6  1.50  none normal P   positive 
6 25.8  1.42  none delayed M   positive 
7 27.3  4.04  present hypersecrestion M + CC negative 
8 27.6  1.45  present diabetes M   positive 
9 27.8  2.50  present hypersecrestion M  + CC positive 
10 28.0  4.00  none hypersecrestion M   positive 
11 32.0  3.43  none hypersecrestion M   positive 
* P = Pioglitazone  
M = Metformin  
CC= Clomiphene Citrate  
Table 1. BMI, HOMA, obesity with visceral fat, insulin secretion after GTT in 11 cases with 
PCOS, and ovulation results by the treatment of insulin sensitizing agents  
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6. Insulin resistance / hyperinsulinemia and insulin sensitizing agents in 
PCOS 
As shown in Table 2, insulin-sensitizing agents, metformin and pioglitazone, are most effective 
on ovulatory disorder in PCOS with insulin resistance and abnormal insulin secretion. It is 
well known that the functional mechanisms are different in both of the agents. Metformin is an 
oral biguanide, category B drug for pregnant women, which has been approved for treatment 
of type 2 diabetes mellitus. It is thought to affect multiple metabolic pathways, decreasing 
glucose absorption and suppressing hepatic glucose output and gluconeogenesis (F. Mcyer, et 
al. 1967; N. Wollen, et al 1988). Also metformin directly inhibits androgen production in 
human thecal cells (GR. Attia, et al. 2001). Side effects are rare, and gastrointestinal 
disturbances, such as abdominal pain and nausea, rarely cause discontinuation of treatment.  
On the other hand, pioglitazone is a thiazolidinedione derivative to be used for treatment of 
type 2 diabetes mellitus. It is more potent in glucose-lowering effect and favorable effects on 
abdominal lipid levels including the decrease in circulating triglyceride and free fatty acid 
levels. Pioglitazone may affect and differentiate on adipocytes via peroxisome proliferator-
activated receptorγ (PPARγ). As a result, differentiated adipocytes regulate insulin 
sensitivity and improve insulin resistance (T Yamauchi, et al. 2001). Side effects are reported 
as hepatic disturbance and edema but these side effects are tolerable. The main adverse 
effects reported with pioglitazone are those common to the TZD class: weight gain, pedal 
edema, bone loss and precipitation of congestive heart failure in at-risk individuals, without 
any increase in cardiovascular diseases /all-cause mortality. Overall, the safety profile of 
pioglitazone is favorable and remains a useful option for the treatment of insulin resistant 
patients (P. Shah, S Mudallar. 2010). 
For choice of using insulin-sensitizing agents, High Molecular Weight (HMW) adiponectin is 
secreted from adipocytes and acts on increasing insulin sensitivity in target organs (T. 
Kadowaki, et al. 2005). HMW adiponectin is measured in sixty nine cases with non-PCOS and 
we determine normal range to be over 3.5μg/ml. Ovulation induction in PCOS is performed 
based on the property of metformin, pioglitazone and levels of adiponectin. In anovulatory 
PCOS subjects, GTT is first carried out. For positive insulin resistance (IR) with obesity, 
metformin (500~750mg) is chosen. When HMW adiponectin levels are in normal range for 
non-obese patients tested positive for IR, a 500mg dose of metformin is chosen, while a 7.5-
15mg dose of Pioglitazone is chosen for those with low levels of HMW. For individuals with 
negative IR, HMW is measured so as to appropriately select either metformin or pioglitazone. 
Subjects with negative IR have to be abnormal in secretion patterns of insulin and / or glucose 
metabolic pattern by GTT. For the same subjects with normal levels of HMW adiponectin, 
metformin (250mg) is used while pioglitazone (7.5mg) is selected for low levels of HMW 
adiponectin. If ovulation induction with metformin or pioglitazone is failed during three to 
four cycles, clomiphen citrate is utilized along with one of the insulin sensitizing agents. It is 
also significant that improving life-style such as daily exercise and diet is highly recommended 
along with treatment using insulin sensitizing agents.  
Ovulation induction in PCOS subjects is applied to 38 cases shown in Table 2. Ovulation rate 
is very high, 97.3 % (37/38). High pregnancy rate is also observed, 73.0% (27/37). Rate of 
combination use with clomiphen citrate is 36.8% (14/38). Therefore, the proposed 
management protocol satisfies treatment of patients with anovulatory PCOS. 
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Ovulation rate:  97.3% (37 / 38)    
Pregnancy rate: 73.0% (27 / 37)    
Abortion rate: 11.1% (3 / 27)    
Pregnancy rate with metformin:  69.2% (18 / 26)  
Pregnancy rate with pioglitazone:  81.8% ( 9 / 11)  
      
Rate of combination use with clomiphene citrate:  38.8% (14 / 38) 
Table 2. Results of ovulation induction in PCOS subjects based on the properties of insulin 
sensitizing agents and levels of high molecular weight adiponectin. 
7. Insulin resistance / hyperinsulinemia and implantation disorder 
To study how insulin resistance / hyperinsulinemia affects implantation, GTT is carried out 
in seventy-eight subjects who failed implantation by the treatment of freeze-thawing 
embryo transfer method. Although embryos with good quality are transferred at least more 
than one time, pregnancy is not achieved. In this study, good quality embryos are defined as 
over four cells and less than 30% of fragmentation. Thirty five out of 78 cases reveal insulin 
resistance and / or hyperinsulinemia by GTT. Then, 11 out of 35 cases have PCOS. After 
treated with metformin, twenty out of 35 cases become pregnant by freeze-thawing embryo 
transfer. Six cases with PCOS become pregnant; five cases delivered and 1 case aborted. The 
results of this treatment are summarized in Table 3. The result indicates the possible ground 
implantation mechanisms.  
Insulin resistance / hyperinsulinemia 35 cases 
  (PCOS case) (11 cases)
Pregnancy after treatment  20 cases  
  (PCOS case) (16 cases)
  Delivered  16 cases 
  (PCOS case) (5 cases)
 Aborted  4 cases 
  (PCOS case) (1 case ) 
Table 3. Results of implantation outcomes by freeze-thawing embryo transfer after 
treatment by insulin sensitizing agent (metformin). 
According to Jakubowicz et al., glycodelin, insulin-like-growth factor-binding protein 1 
(IGF-BP1), uterine vascularity and blood flow are studied for association with treatment of 
metformin and placebo in PCOS (DJ. Jakubowicz, et al. 2001). Glycodelin is a protein 
synthesized by secretary / decidualized endometrial glands. Circulating glycodelin may 
reflect endometrial function such as endometrial maturation and inhibition of endometrial 
immune response to the embryo (M. Seppala, et al. 1988; M. Julkunen, et al. 1990; AE. 
Bolton, et al. 1987; M. Julkunen, 1986; N. Okamoto, et al. 1991). IGF-BP1 is a protein that 
appears to facilitate adhesion process at the feto-maternal interface and may play an 
important role in the periimplantation period (LC. Giudice, et al. 1998; JI. Jones, et al. 1993). 
In comparison with placebo, metformin treatment increases concentration of glycodelin and 
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IGF-BP1 in luteal phase up to 3 to 4-fold. Besides, it increases in vascular penetration and 
increase in blood flow of spiral arteries that is demonstrated by 20% reduction in the 
resistance index. From this, endometrial function and amelioration of its environment may 
be improved by treatment of hyperinsulinemia, which has a strong correlation with insulin 
resistance and PCOS. 
8. Insulin resistance / hyperinsulinemia and early pregnancy loss 
Women with PCOS are associated with 30 – 50% of early pregnancy loss at a higher risk 
than normal women (L. Regan, et al. 1990; HR. Gray, et al. 2000). They are also involved in 
36 – 82% of the risk for recurrent early pregnancy loss (HS. Liddell, et al. 1997). Treatment of 
insulin sensitizing agents is applied to 38 cases with PCOS that resulted in ovulation of 37 
cases. As shown in Table 3, twenty seven cases became pregnant after the treatment. Then, 
the abortion rate is 11.1% (three out of 27 cases) that is almost as low as that of normal 
women. This explains treatment of insulin sensitizing agents might be effective for 
sustaining early pregnancy periods. This concept can be also emphasized (DJ. Jackbowicz, et 
al. 2002), the rate of early pregnancy loss is 8.8% as compared with 41.9% for control group 
in PCOS. Metformin therapy during pregnancy in women with PCOS is safely associated 
with reduction of spontaneous abortion for the first trimester and is not teratogenic without 
adverse effects on biological and physical conditions of baby. In addition, metformin 
therapy improves the insulin level, HOMA- R and high plasminogen activator inhibitor 
activity (PAI-Fx) (CJ. Glueck, et al. 2002). Therefore, metformin therapy that has insulin-
lowering effect might be accountable for protecting early pregnancy loss. Nevertheless, 
sustaining the pregnancy might be achieved through lifestyle intervention. 
9. Conclusion 
PCOS is a very common complex that occurs in approximately up to 20% of women of 
reproductive age and threatens fertility and metabolic condition as well. And also, it is 
chronic diseases, such as dyslipidemia, type 2 diabetes and cardiovascular diseases, across 
the lifespan. These conditions represent a major health and financial burden. It is mentioned 
that PCOS is the beginning of lifestyle-related diseases. Although it is still challenging to 
fully comprehend and reveal this unknown syndrome for researchers, PCOS has been 
known to be involved in insulin resistance / hyperinsulinemia. It is well-known that insulin 
resistance / hyperinsulinemia is affected by lifestyle factors, such as diet and physical 
activities. As mentioned above, approximately 5 to 10% of weight loss is enough to 
ameliorate ovulatory dysfunction and metabolic disorders. Therefore, the improvement of 
lifestyle is a key to overcoming reproductive and metabolic disorders in women with PCOS. 
Also, the efficacy of insulin sensitizing agents may contribute to the amelioration of insulin 
resistance / hyperinsulinemia and be also effective for the reproductive and metabolic 
functions of PCOS women. Insulin sensitizing agents consequently facilitate ovulation, 
implantation and maintenance of pregnancy. As reiterated, both lifestyle management and 
appropriate medication might be conductive to the improvement of adverse effects for 
reproductive processes by insulin resistance / hyperinsulinemia in PCOS (S. Franks. 2011; T. 
Sakumoto, et al. 2010). Nevertheless, it requires further study for comprehension of PCOS. 
More understanding of the complexity of PCOS might lead to optimal management of 
PCOS for clinicians and patients. 
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The relationship between differentiation of visceral adipocytes and reproductive processes 
is shown in Fig 2 (T. Yamauchi, et al. 2001; T. Sakumoto, et al. 2010). 
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FFA : free fatty acid, PAI-1 : plasminogen activator inhibitor 1, 
PPAR-γ: peroxisome proliferator-activated receptor gamma 
TNF-α: tumor necrosis factor alpha, TZD: thiazolidinedione  
Fig. 2. The relationship between differentiation of visceral adipocytes and reproductive 
processes (T. Sakumoto, et al. 2010) 
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(2009). Impact of nine days of bed rest on hepatic and peripheral insulin action, 
insulin secretion and whole body lipolysis in healthy young male offspring of 
patients with type 2 diabetes. Diabetes. 58, 2749–2756. 
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IGF-BP1 in luteal phase up to 3 to 4-fold. Besides, it increases in vascular penetration and 
increase in blood flow of spiral arteries that is demonstrated by 20% reduction in the 
resistance index. From this, endometrial function and amelioration of its environment may 
be improved by treatment of hyperinsulinemia, which has a strong correlation with insulin 
resistance and PCOS. 
8. Insulin resistance / hyperinsulinemia and early pregnancy loss 
Women with PCOS are associated with 30 – 50% of early pregnancy loss at a higher risk 
than normal women (L. Regan, et al. 1990; HR. Gray, et al. 2000). They are also involved in 
36 – 82% of the risk for recurrent early pregnancy loss (HS. Liddell, et al. 1997). Treatment of 
insulin sensitizing agents is applied to 38 cases with PCOS that resulted in ovulation of 37 
cases. As shown in Table 3, twenty seven cases became pregnant after the treatment. Then, 
the abortion rate is 11.1% (three out of 27 cases) that is almost as low as that of normal 
women. This explains treatment of insulin sensitizing agents might be effective for 
sustaining early pregnancy periods. This concept can be also emphasized (DJ. Jackbowicz, et 
al. 2002), the rate of early pregnancy loss is 8.8% as compared with 41.9% for control group 
in PCOS. Metformin therapy during pregnancy in women with PCOS is safely associated 
with reduction of spontaneous abortion for the first trimester and is not teratogenic without 
adverse effects on biological and physical conditions of baby. In addition, metformin 
therapy improves the insulin level, HOMA- R and high plasminogen activator inhibitor 
activity (PAI-Fx) (CJ. Glueck, et al. 2002). Therefore, metformin therapy that has insulin-
lowering effect might be accountable for protecting early pregnancy loss. Nevertheless, 
sustaining the pregnancy might be achieved through lifestyle intervention. 
9. Conclusion 
PCOS is a very common complex that occurs in approximately up to 20% of women of 
reproductive age and threatens fertility and metabolic condition as well. And also, it is 
chronic diseases, such as dyslipidemia, type 2 diabetes and cardiovascular diseases, across 
the lifespan. These conditions represent a major health and financial burden. It is mentioned 
that PCOS is the beginning of lifestyle-related diseases. Although it is still challenging to 
fully comprehend and reveal this unknown syndrome for researchers, PCOS has been 
known to be involved in insulin resistance / hyperinsulinemia. It is well-known that insulin 
resistance / hyperinsulinemia is affected by lifestyle factors, such as diet and physical 
activities. As mentioned above, approximately 5 to 10% of weight loss is enough to 
ameliorate ovulatory dysfunction and metabolic disorders. Therefore, the improvement of 
lifestyle is a key to overcoming reproductive and metabolic disorders in women with PCOS. 
Also, the efficacy of insulin sensitizing agents may contribute to the amelioration of insulin 
resistance / hyperinsulinemia and be also effective for the reproductive and metabolic 
functions of PCOS women. Insulin sensitizing agents consequently facilitate ovulation, 
implantation and maintenance of pregnancy. As reiterated, both lifestyle management and 
appropriate medication might be conductive to the improvement of adverse effects for 
reproductive processes by insulin resistance / hyperinsulinemia in PCOS (S. Franks. 2011; T. 
Sakumoto, et al. 2010). Nevertheless, it requires further study for comprehension of PCOS. 
More understanding of the complexity of PCOS might lead to optimal management of 
PCOS for clinicians and patients. 
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The relationship between differentiation of visceral adipocytes and reproductive processes 
is shown in Fig 2 (T. Yamauchi, et al. 2001; T. Sakumoto, et al. 2010). 
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Fig. 2. The relationship between differentiation of visceral adipocytes and reproductive 
processes (T. Sakumoto, et al. 2010) 
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Brought into the limelight many decades ago, Polycystic Ovary Syndrome (PCOS) 
is still, to date, surrounded by controversy and mystery. Much attention has been 
attracted to various topics associated with PCOS research and there has been a healthy 
advance towards bettering the understanding of the many implications of this complex 
syndrome. A variety of topics have been dealt with by a panel of authors and compiled 
in this book. They span methods of diagnosis, reproductive anomalies, metabolic 
consequences, psychological mindset and ameliorative effects of various lifestyle 
and medical management options. These books are designed to update all associated 
professionals on the recent developments in this fast-growing field and to encourage 
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